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ABSTRACT 
MIGRATION OF MYELOID-DERIVED SUPPRESSOR CELLS TO TUMOR 
AND TUMOR-DRAINING LYMPH NODE IN A MURINE MODEL OF BREAST 
CANCER 
by 
Vyara Matson 
 
The University of Wisconsin-Milwaukee, 2015 
Under the Supervision of Professor Douglas A. Steeber 
 
 
Myeloid-derived suppressor cells (MDSC) consist of two major subsets, 
monocytic MDSC (M-MDSC) and polymorphonuclear MDSC (PMN-MDSC), both of 
which expand in cancer and suppress the activation of naïve T cells in the tumor-draining 
lymph node (TDLN) and the function of effector T cells in the tumor microenvironment. 
Thus, the ability of MDSC to enter the TDLN and the tumor is likely to be critical for 
suppression of the anti-tumor immune response. L-selectin mediates the homing of 
circulating naïve lymphocytes to lymph nodes and the migration of conventional myeloid 
cells, such as neutrophils and monocytes, to sites of inflammation, but its contribution to 
MDSC migration is unknown. Using the 4T1 murine breast cancer model, we 
demonstrated that MDSC express L-selectin and integrins necessary for migration to 
TDLN and inflammatory sites, such as the tumor. We then demonstrated involvement of 
L-selectin in the migration of PMN-MDSC, but not M-MDSC, to tumors and TDLN. 
This suggests that M-MDSC may utilize L-selectin-independent mechanisms for 
migration. After entry into the tumor, MDSC migrated through the tumor parenchyma 
iii 
 
and associated with MDSC aggregates localized in the immediate vicinity of hypoxic 
areas. BrdU incorporation experiments showed that approximately 20% of tumor-
infiltrating MDSC were undergoing in situ proliferation in the tumor microenvironment. 
Thus, in addition to MDSC recruitment to tumors, intratumoral proliferation of MDSC 
may also contribute to MDSC accumulation. Hypoxia-inducible factor (HIF) is an 
intracellular sensor of hypoxia, which functions to activate the expression of genes 
necessary for adaptation to hypoxic conditions. There are several HIF isoforms with both 
overlapping and opposing roles in various processes, including proliferation. Although 
our preliminary experiments did not confirm a role for HIF in inducing proliferation of 
tumor-infiltrating MDSC, the specific roles of the different HIF isoforms in MDSC 
recruitment, proliferation, and function in the tumor microenvironment requires further 
study. These studies provide insights into the mechanisms of MDSC migration and 
accumulation in the tumor and TDLN. Further studies may create a basis for novel 
immunotherapeutic approaches for the treatment of cancer. 
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CHAPTER 1 
GENERAL INTRODUCTION  
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I. Introduction 
Tumor cells contain mutations or epigenetic abnormalities that result in an altered 
gene expression compared to healthy cells. This altered phenotype can be recognized by 
the adaptive immune system, as tumor-associated antigens (TAA) are presented in the 
tumor-draining lymph node (TDLN). This is of particular relevance to the development 
of immunotherapeutic strategies for the treatment of cancer. The major player in the anti-
tumor immune response are cytotoxic T lymphocytes (CTL), which after their activation 
in the TDLN, can infiltrate the tumor and kill tumor cells upon contact. Various 
promising immunotherapeutic approaches are under investigation with that concept in 
mind. However, in many cancer patients the tumor microenvironment is characterized by 
overpowering immunosuppressive events due to a large extent to the expansion and 
accumulation of myeloid-derived suppressor cells (MDSC). In addition to suppressing 
the function of activated CTL within the tumor, MDSC can also suppress T cell 
activation within the TDLN (1, 2). Importantly, CTL responses are not systemically 
suppressed (3), suggesting that TAA-specific T cell suppression occurs primarily in the 
tumor and the TDLN (4, 5). The mechanisms of MDSC migration to these sites remain 
largely unknown.  
II. Overview of the immune system 
A. Function 
The function of the immune system is, while sparing healthy host tissues and 
cells, to recognize and eliminate pathogenic foreign organisms (including bacteria, fungi, 
and various parasites); virus-infected, neoplastic, and dying host cells; as well as to aid in 
the repair of damaged tissues throughout the body. These functions constitute a complex 
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process called an immune response that is dependent on the ability of leukocytes, 
generated in the bone marrow and released into the bloodstream, to migrate to virtually 
all tissues in the body.  
B. Cells and organs of the immune system 
There are two major lineages of leukocytes, myeloid and lymphoid, which are 
generally responsible for the innate and adaptive branches of the immune response, 
respectively. The myeloid lineage consists of polymorphonuclear cells (including 
neutrophils, eosinophils, and basophils), monocytes, and myeloid dendritic cells (DC). 
Tissue-resident monocytes and basophils become macrophages and mast cells, 
respectively. The lymphoid lineage consists of lymphocytes, including T cells and B 
cells, natural killer (NK) cells, and lymphoid DC. All leukocytes are generated in the 
bone marrow via a process called hematopoiesis and released into the bloodstream. 
Progenitor T cells then migrate to the thymus for an additional process of selection and 
maturation, after which they are once again released into the bloodstream. Because the 
bone marrow and thymus function in the generation and maturation of leukocytes, these 
tissues are also referred to as primary lymphoid organs. In addition, secondary lymphoid 
organs such as spleen, peripheral lymph nodes (PLN) and mucosa-associated lymphoid 
tissues, among others, are the sites where the adaptive immune response is activated. 
These tissues are uniquely positioned for exposure to and surveillance against pathogens 
in the blood, in the peripheral tissues and ingested pathogens, respectively. For instance, 
blood-borne pathogens are filtered through the spleen, while pathogens in the periphery 
are transported with the lymph to the nearest PLN. 
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The spleen is located in the abdominal cavity and is the largest secondary 
lymphoid organ in the body. The spleen is especially equipped for filtering blood and 
surveillance against blood-borne pathogens and is responsible for mounting an immune 
response against systemic infections. It is fed by the splenic artery, which delivers 
substantial amounts of blood to the organ. In addition, the spleen contains networks of 
specialized capillaries, called sinusoids, which are characterized by fenestrated walls 
allowing for easier passage of large molecules and even cells between the blood and the 
spleen parenchyma. The sinusoids are enriched within the red pulp, one of the two major 
compartments of the spleen, which contains myeloid cells, especially macrophages, as 
well as red blood cells. In fact the red pulp is the site of deposition of aged or damaged 
red blood cells, followed by their phagocytic clearance by resident macrophages. The 
other compartment of the spleen, the white pulp, is located around arterioles, which 
branch from the splenic artery to feed all parts of the spleen. The white pulp is the site 
where the immune response to blood-borne pathogens is generated and contains the T 
cell-rich periarteriolar lymphatic sheath (PALS) immediately surrounding the arterioles 
and the B cell-rich follicles and marginal zone located around the PALS. 
PLN are positioned throughout the body and filter lymph, which drains nearby 
tissues and enters the PLN via the afferent lymphatic vessels. The lymph is the major 
vehicle for delivery of antigens to the PLN, thus potentiating immune responses to 
infections in nearby tissues. In addition, the lymph also carries leukocytes from nearby 
tissues to lymph nodes. After its passage through the PLN, the lymph fluid is returned to 
the bloodstream, thus providing a route for leukocyte recirculation between blood and 
PLN. In addition to the lymphatic route, leukocytes primarily enter PLN from the 
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bloodstream, through specialized postcapillary venules called high endothelial venules 
(HEV). Similar to the spleen, the PLN are rich in B cells and T cells. B cells are 
organized in follicles in the cortex, a superficial zone, while T cells are localized deeper, 
in the paracortex. The innermost region in the PLN is the medulla, which contains 
macrophages and specialized antibody-secreting B cells called plasma cells. 
C. Innate immune response 
Neutrophils, macrophages and DC are phagocytic and express pattern recognition 
receptors (PRR) with broad specificity, which recognize classes of molecules commonly 
found in pathogens (pathogen-associated molecular patterns, PAMP) or associated with 
damaged or dying host cells (damage-associated molecular patterns, DAMP) (6). 
Engagement of these receptors at a site of infection or tissue injury, where there is 
abundant presence of PAMP and/or DAMP, initiates signaling resulting in increased 
phagocytic activity and release of inflammatory mediators (cytokines and chemokines) 
that recruit more leukocytes in a process called inflammation. Inflammation involves the 
function of both the innate and the adaptive immune responses. During the initial stages 
of inflammation, activated neutrophils release reactive oxygen and nitrogen species (ROS 
and RNS, respectively), which function locally to destroy the pathogens (along with some 
host cells), thus serving as the first line of defense against the infection. However, 
prolonged activation of the inflammatory process (chronic inflammation) is undesirable, 
because it leads to excessive tissue damage. Therefore, an important trait of the immune 
system are built-in mechanisms for contraction of the immune response and resolution of 
inflammation, followed by tissue remodeling/wound healing, mediated by myeloid cells. 
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D. Adaptive immune response 
While activation of the innate immune response relies on PRR with very broad 
specificities, the receptors necessary for activation of the adaptive immune response 
recognize unique molecules, called antigens. The majority of antigens are peptide 
sequences derived from the processing of larger proteins of endogenous or exogenous 
origin. To be “visible” to the adaptive immune system, antigens must be presented in 
complex with cell surface molecules called major histocompatibility complex (MHC) 
molecules. MHC class II (MHC II) molecules are expressed only by professional antigen-
presenting cells (including DC, macrophages, and B cells) and are used to present 
exogenous antigen processed from phagocytosed material. On the other hand, MHC class 
I (MHC I) molecules are expressed by all host cells and present endogenous antigens 
derived from self components within the cells or from an intracellular pathogen in the 
case of infected host cells. In addition, some DC can use MHC I to present exogenous 
antigens, a process called cross-presentation. Activated DC from the site of infection 
migrate via the lymph to the nearby lymph nodes, where they present antigens derived 
from the phagocytosed pathogens in complex with MHC II and, in some cases, MHC I. 
Antigen-MHC II complexes are recognized by the T cell receptor (TCR) complex of a 
subset of T cells, CD4
+
 T cells, also called T helper cells. These cells do not possess 
cytolytic activity and cannot directly kill target cells, but via secretion of cytokines, can 
activate other leukocytes, as well as endothelial cells. For instance, T helper cells can aid 
in the activation of CD8
+
 T cells. Activated CD8
+
 T cells proliferate and differentiate into 
effector T cells (cytotoxic T cells, CTL) capable of lysing infected host cells that present 
a cognate pathogen-derived antigen in complex with MHC I on their surface. In addition, 
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T helper cells can also activate B cells, which secrete antibodies able to bind to their 
cognate antigen on the surface of pathogenic bacteria, fungi, and parasites, thus 
opsonizing the pathogen. These surface bound antibodies can then be recognized by 
receptors on phagocytic leukocytes which eliminate the pathogen. In addition, especially 
in the case of blood-borne infections, opsonized pathogens can be recognized and lysed 
by the coordinated function of serum proteins, collectively called the complement 
system.  
III. The immune response to cancer 
The immune system can distinguish between self and non-self molecules and 
generate a response that specifically eliminates infections as described above. Tumors, 
except those induced by a viral infection, arise from self rather than non-self cells, and 
thus were long thought to be “invisible” to the immune system. However, it is now 
known that tumors contain multiple genetic and epigenetic alterations, which result in 
TAA that are often immunogenic (7, 8). In fact, the current understanding is that the 
immune system eliminates most tumors before they become clinically detectable. If 
tumors are not completely eliminated, they enter an equilibrium state, in which tumor 
growth is balanced against tumor destruction. This state may last decades, but is 
eventually followed by tumor escape from immune surveillance and manifestation of 
clinically detectable cancer. Both innate and adaptive immune mechanisms are 
implicated in the immune response against cancer; however, the CTL response is the 
major contributor.  
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A. Generation of CTL-mediated anti-tumor response 
In the TDLN, precursors of CTL, via the TCR, recognize TAA presented on 
MHC, which provides the first signal necessary for T cell activation and expansion. The 
second signal is provided by binding of co-stimulatory molecules to cognate receptors on 
the T cell. In response, the T cell starts to express the interleukin-2 (IL-2) receptor, which 
upon binding to its cognate ligand, IL-2, induces the T cell to proliferate and become 
capable of killing target cells, expressing the cognate TAA. 
B. Generation of the NK cell-mediated anti-tumor response 
 Another component of the anti-tumor immune response are the NK cells, which 
also recognize and kill tumor cells, albeit via a different mechanism. Specifically, NK 
cell function is modulated by a balance of inhibiting and activating signals resulting from 
the ligation of inhibitory and activating receptors, respectively. For instance, class I MHC 
molecules, expressed by all healthy nucleated cells in the body, are recognized by 
receptors on NK cells that send a dominant inhibitory signal that prevents NK cell 
activation and cytotoxicity against healthy cells. By contrast, NK cell activating receptors 
bind ligands induced by tumor transformation or cell damage and initiate NK cell-
mediated attack of the target cell. Thus, if a cell lacks or underexpresses MHC I, which is 
often the case with tumor cells, and/or overexpresses activating ligands, NK cells 
eliminate it by releasing cytotoxic substances or inducing apoptotic signals in the target 
cell. 
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IV. Myeloid-derived suppressor cells 
 In order to evade the CTL and NK cell response, tumors utilize a plethora of 
immunosuppressive strategies. One of these involves the induction and accumulation of 
MDSC. 
A. Generation and activation of MDSC 
MDSC, as do all white blood cells, arise in the bone marrow. In a healthy 
individual, immature myeloid cells in the bone marrow differentiate to dendritic cells, 
monocytes, and granulocytes, including neutrophils, basophils, and eosinophils. During 
pathologic conditions such as cancer, infections, traumatic stress, etc., various soluble 
factors drive the expansion of immature myeloid cells and facilitate their activation to 
immunosuppressive MDSC. In the context of cancer progression, MDSC expansion is 
driven by pro-inflammatory cytokines and tumor-derived factors such as vascular 
endothelial growth factor (VEGF) (9), granulocyte/monocyte colony stimulating factor 
(GM-CSF) (10, 11), IL-1β (12), IL-6 (13), stem cell factor (SCF) (14), S100A8/9 
proteins (15), transforming growth factor-β (TGF-β), prostaglandin E2 (PGE2) (16, 17), 
and macrophage colony-stimulating factor (M-CSF) (16), among others. Most of these 
factors affect myelopoiesis and tumor progression via the signal transducer and activator 
of transcription 3 (STAT3) signaling pathway (18-20), and thus MDSC expansion is 
decreased by STAT3 knock-out or inhibition (21-23). Activated STAT3 increases the 
survival and proliferation of immature myeloid cells possibly via upregulation of B-cell 
lymphoma XL (BCL-XL), cyclin D1, c-Myc, and survivin (18, 24). Further activation of 
MDSC is driven by factors secreted by activated T cells and tumor stromal cells, possibly 
in response to tumor cell death (24). Among these factors are interferon γ (IFNγ), toll-like 
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receptor (TLR) ligands, IL-4, IL-13 and TGF-β. These factors trigger signaling via 
STAT1, STAT6, and nuclear factor-kappa B (NF-κB), which induces expression of 
arginase-1, inducible nitric oxide synthase (iNOS), and TGF-β involved in MDSC-
mediated immunosuppression (24). 
B. Mechanisms of MDSC-mediated immunosuppression 
Immunosuppressive functions of myeloid cells were first acknowledged in the late 
1970s and early 1980s and the term “natural suppressor (NS) cells” was initially used for 
them (25-29). These NS cells were implicated in previously observed fetal and neonatal 
immunosuppression in the context of allogeneic graft transplantation experiments in mice 
(30). Importantly, a role for NS cells in the suppression of tumor-specific CTL was also 
recognized at that time (28). Indeed, the heterogeneous cell population that we know 
today as MDSC is no different than the NS cells described several decades ago (29). 
However, it was not until fairly recently that the mechanisms of MDSC-mediated 
immunosuppression became better understood. 
Many of the suppressive functions of MDSC are due to upregulated arginase-1 
and/or iNOS, which control L-arginine metabolism. Arginase-1 metabolizes L-arginine to 
L-ornithine and urea and is induced in myeloid cells by anti-inflammatory cytokines such 
as IL-10, IL-4 and IL-13 (31, 32), as well as TGF-β (33) and GM-CSF (34), and is 
primarily regulated by STAT6 activity (35). iNOS converts L-arginine to L-citrulline and 
nitric oxide (NO) and can be induced by pro-inflammatory cytokines such as IFN-γ, IL-1, 
IFN-α, IFN-β, and tumor necrosis factor (TNF) via NF-κB and STAT1 signaling (36). 
Thus, the expression of these enzymes is differentially regulated. Furthermore, inhibition 
of arginase-1 results in an increase of iNOS function (37), while upregulation of arginase-
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1 depletes L-arginine leading to a decrease in iNOS translation and NO production (38, 
39). However, iNOS function may activate arginase-1 via NO-induced nitrosylation of 
cysteine residues in arginase-1 (40). L-arginine depletion from the tumor 
microenvironment by arginase-1 and/or iNOS causes T cell unresponsiveness by 
decreasing the mRNA stability and/or translation of important factors involved in T cell 
signaling and proliferation. Specifically, lack of L-arginine interferes with TCR signaling 
by downregulating the main signaling component, the CD3 ζ-chain, of the TCR complex, 
as well as inhibiting nuclear translocation of the downstream transcription factor NF-κB 
(41-43). Lack of L-arginine also interferes with IL-2 receptor signaling in T cells by 
inhibiting the upregulation of the tyrosine kinase Jak-3 necessary for activation of 
STAT5-dependent transcription in response to IL-2 (43). In addition, IL-2 receptor 
signaling is also inhibited by exposure to NO, the product of iNOS (44, 45), and NO also 
inhibits the production and release of IL-2 by activated lymphocytes (46, 47) and induces 
T cell apoptosis (48). Importantly, L-arginine depletion also causes proliferative arrest of 
activated T cells by decreasing the mRNA stability and translation of cell cycle regulators 
such as cyclin D3 and cyclin-dependent kinase 4 (49, 50). These effects of L-arginine 
depletion are likely due to decreases in global translation rather than inhibition of the 
translation of specific proteins. 
It has been suggested that arginase-1 and iNOS may cooperatively convert NO to 
ROS and RNS, such as hydrogen peroxide and peroxynitrites, respectively (51), which 
can exert multiple inhibitory effects on T cells. For instance, hydrogen peroxide, an 
electrically neutral and stable molecule that diffuses across membranes, has been 
implicated in the downregulation and functional impairment of the CD3 ζ-chain both in 
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tumor-bearing mice and in cancer patients (52, 53). In addition, peroxynitrite, a highly 
reactive cell-permeable molecule, inhibits T cell function by nitration and nitrosylation of 
cysteine, methionine, tryptophan and tyrosine in multiple protein targets, both extra- and 
intracellular. For instance, antigen-specific T cell unresponsiveness has been linked to 
nitration of the T cell receptor and the CD8 co-receptor molecule, as well as a general 
increase in intracellular nitro-tyrosine levels, while inhibition of arginase-1 and iNOS 
abrogated these effects (1, 54). Furthermore, both hydrogen peroxide and peroxynitrite 
cause apoptosis in antigen-activated T cells, possibly by downregulating the anti-
apoptotic protein B-cell lymphoma 2 (BCL-2) and by upregulating the pro-apoptotic FAS 
ligand (55, 56).  
MDSC also inhibit the function of other components of the anti-tumor immune 
response, such as NK cells and macrophages. For instance, MDSC block the expression 
of the activating receptor NKG2D on NK cells (57) and MDSC depletion in tumor-
bearing mice results in restoration of NK activity (58). MDSC also downregulate IL-12 
production by macrophages, thus skewing the immune response to favor tumor 
progression (59). In addition, MDSC indirectly suppress anti-tumor responses by 
promoting the function of other immunosuppressive populations such as regulatory T 
cells (Treg). Specifically, MDSC activate both the clonal expansion of existing Treg and 
the conversion of naïve CD4
+
 T cell into Treg via various mechanisms, including secretion 
of IL-10 and TGF-β as well as arginase-1 function (60-62). 
In addition to their immunosuppressive functions, MDSC can directly promote 
tumor progression by driving the formation of new blood vessels within the tumor, a 
process called angiogenesis. This process is dependent on MDSC-mediated production of 
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matrix metalloproteinase 9 (MMP9), an enzyme that degrades the extracellular matrix 
and also increases the bioavailability of the pro-angiogenic signal VEGF (63). In 
addition, MDSC can directly incorporate into the tumor endothelium and differentiate 
into endothelial cells (63). 
V. Leukocyte migration 
Leukocyte migration to lymph nodes or sites of inflammation occurs via a multi-
step process, called the adhesion cascade, which involves adhesive and signaling 
interactions between the leukocyte and the endothelium. These interactions are 
sequentially organized into 3 basic stages: 1) leukocyte capture and rolling over the 
endothelium, 2) firm adhesion (arrest), and 3) transendothelial migration (diapedesis) 
(Fig. 1) (64). Each of these stages is characterized by interactions between distinct groups 
of molecules. The adhesion cascade starts with leukocyte margination followed by a 
transient interaction with the endothelium, known as tethering or capture, and further 
transition to leukocyte rolling along the vascular wall. The capture and rolling events are 
dependent on interactions between selectins and their ligands (65, 66). The importance of 
these events is that they allow the leukocyte to slow down and sense chemokines 
displayed on the endothelial surface. The chemokines signal via G protein-coupled 
receptors to induce conformational changes increasing the adhesiveness of leukocyte-
expressed integrins, which, via interactions with endothelial immunoglobulin-like 
superfamily molecules, are involved in decreasing the rolling speed and transitioning to 
the next stage of the adhesion cascade, firm adhesion (64, 67-72). Integrins are also 
involved in the subsequent events in the adhesion cascade including locomotion from the 
site of firm adhesion to a nearby junction between endothelial cells (a process also known 
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as intraluminal crawling) followed by transendothelial migration. In addition, integrins 
participate in leukocyte migration in the extracellular matrix and through epithelial layers 
to reach sites of tissue injury or inflammation (73).  
Leukocyte migration to PLN occurs in specialized post-capillary venules, the 
HEV, morphologically characterized by a plump cuboidal shape of their endothelial cells. 
In addition, HEV differ from other blood vessels by the constitutive expression of HEV-
restricted adhesion molecules, which are especially important for the homing of 
lymphocytes to PLN. On the other hand, the post-capillary venules of peripheral tissues 
do not express sufficient adhesion or signaling molecules to support migration of most 
leukocytes. Thus, in physiologic conditions, peripheral tissues are not readily infiltrated 
by leukocytes, except for some tissue-resident leukocytes. However, activation of these 
tissue resident leukocytes by PAMP and/or DAMP results in the secretion of 
inflammatory mediators, such as TNF-α or IL-1β, which induce the expression of 
adhesion and signaling molecules on the vascular endothelium necessary for additional 
leukocyte recruitment. Thus, lymphocyte homing to PLN is constitutive, while leukocyte 
migration to peripheral non-lymphoid tissues is strongly enhanced only in inflammatory 
conditions. 
A. Selectins mediate leukocyte capture and rolling 
In the initial stages of the adhesion cascade the leukocyte is captured and starts 
rolling over the endothelium. These initial events are carried out via rapid interactions of 
association and release between selectins and their ligands. There are three selectins 
named after their location: P-selectin was initially identified on activated platelets (74, 
75), but is also expressed, as is E-selectin, on activated endothelial cells (76, 77), while 
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L-selectin is expressed on leukocytes. P-selectin is not found on the membrane in resting 
platelets and resting endothelial cells, but is stored in α granule membranes and Weibel-
Palade bodies, respectively, and upon activation, is rapidly distributed to the surface 
membrane. By contrast, expression of E-selectin on the endothelium requires de novo 
synthesis and takes hours (65), while L-selectin expression on leukocytes is constitutive 
(66). L-selectin is localized on the tips of the leukocyte microvilli to improve interactions 
with the endothelium. In addition, there is co-localization of some integrins on the 
leukocyte microvilli promoting synergism between L-selectin and integrins in mediating 
leukocyte adherence to the endothelium (66). The initial capture and fast rolling of the 
leukocyte is mediated by P- and L-selectin, while E-selectin is involved in the subsequent 
slower rolling and the transition to firm adhesion (66). Leukocyte rolling along the 
endothelium consists of rapid association between selectins and their ligands at the 
leading edge and their rapid dissociation at the trailing edge of the leukocyte. The nature 
of the bonds formed between L-selectin and its ligands confers a shear-dependent 
character to L-selectin-mediated rolling, meaning that a minimal hydrodynamic shear 
threshold against the blood vessel wall must be reached for capture and rolling to occur 
(78). 
1. Selectin structure 
The three selectins show some structural similarities and differences. Specifically, 
the N-terminal lectin domain, the epidermal growth factor (EGF)-like domain, and the 
short consensus repeat (SCR) domains (nine SCR in P-selectin, six SCR in E-selectin, 
and two SCR in L-selectin) are well conserved among selectins, while the transmembrane 
and intracellular domains show little sequence identity (66). Ligand binding occurs via 
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the lectin domain and is calcium dependent; however, the EGF-like domain also 
contributes (79-81). The SCR repeats are also thought to promote ligand binding, but 
their major role seems to be increasing the reach of the lectin and EGF-like domains for 
better ligand interactions. With only two SCR domains, L-selectin is the shortest of the 
selectins, but that is compensated by its strategic localization on leukocyte microvilli, 
allowing sufficient reach for ligand interactions. In addition to the above domains, L-
selectin contains an endoproteolytic cleavage site, which upon leukocyte activation is 
targeted by endogenous membrane-bound proteases such as the ADAM metallopeptidase 
domain 17 (ADAM17; also known as TNF-α converting enzyme or TACE) (66). This 
cleavage generates a soluble form of L-selectin (sL-selectin) which is relatively stable 
(t1/2 ~ 20 h) and able to bind ligand. sL-selectin competes with membrane L-selectin for 
endothelial binding partners, thus interfering with L-selectin-dependent leukocyte 
adhesion and migration (79, 82, 83). In addition, studies have also identified soluble 
forms of P- and E-selectin. The levels of sP- and sE-selectin are especially increased in 
inflammatory settings or upon thrombin-mediated platelet activation, likely due to 
cleavage of the membrane-bound forms as a result of these stimuli (65). The function of 
soluble selectins is unclear; however, it has been suggested that they serve as a regulatory 
mechanism to tune down over-activated immune responses by interfering with leukocyte 
migration, or, in the case of sP- and sE-selectin, initiating signaling in leukocytes (65, 
66).  
 2. Selectin ligands 
The selectin ligands comprise a group of glycoproteins expressed on HEV or 
inflamed endothelium, leukocytes, and platelets. A variety of glycoproteins bind selectins 
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in vitro, but confirming their physiologic relevance as selectin ligands is challenging due 
to the nature of the recognition epitope, as well as the redundancy among ligands. In 
general, the ligands consist of various protein scaffolds displaying serine/threonine-rich 
domains that are post-translationally modified by attachment of oligosaccharide chains. 
Specifically, the lectin domain of the selectins recognizes the carbohydrate components 
of the ligand. For instance, binding of all three selectins depends on the presence of sialic 
acid within the carbohydrate moiety of the ligand. In addition, the presence of fucose and 
sulfate are necessary for biologically relevant ligand recognition for P- and L-selectin but 
not for E-selectin (84). Thus, the generation of physiologic selectin ligands requires the 
function of glycosyl- and sulfo-transferases. The spatial and temporal regulation of the 
expression and activity of these groups of enzymes in endothelial cells, leukocytes, or 
platelets is an important determinant of the patterns of leukocyte migration. Consistent 
with the requirement for sialylation, fucosylation and sulfation for selectin binding, the 
tetrasaccharide sialyl Lewis
x
 (sLe
x
) composed of N-acetylglucosamine, galactose, sialic 
acid, and fucose (structure: Siaα2→3Galβ1→4[Fucα1→3]GlcNAc) binds to all selectins, 
but with low affinity (85). For L-selectin, the sulfated form 6-sulfo-sLex confers high 
affinity binding. Studies using anti-sLex blocking antibodies suggest that the 
tetrasaccharide participates in the structure of physiologic L-selectin ligands (86, 87). 
Interestingly, selectin binding occurs even if the required sialic acid, fucose and sulfate 
moieties are not located on the same oligosaccharide. In fact, in some cases the sulfate is 
directly added to tyrosine residues of the protein scaffold, rather than the carbohydrate 
component (84). This discontinuous character of the carbohydrate epitope is reminiscent 
of antibody-binding epitopes composed of amino acids from different parts of the 
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polypeptide chain that are spatially brought together as a result of protein folding. In a 
similar manner, the protein scaffolds may play a vital role in the construction and the 
display of the carbohydrate epitopes. Specifically, the presence and correct localization of 
amino acid residues targeted by appropriate glycosyl- and sulfo-transferases may dictate 
not only the exact types of post-translational modifications, but also the order in which 
these reactions are carried out so as to generate the appropriate carbohydrate epitope. In 
addition, the overall three-dimensional structure of the protein may dictate the correct 
orientation and display of the carbohydrate epitopes. Furthermore, the protein scaffold 
may sequester the carbohydrate epitope on favorable areas of the cell surface for 
enhanced contact with the selectins. The protein scaffolds are likely involved in 
transmitting outside-in signals upon selectin binding.  
Functionally expressed on leukocytes and inflamed endothelium, P-selectin 
glycoprotein ligand-1 (PSGL-1) is the most widely studied selectin ligand and is 
considered to be a major physiologic ligand of P-selectin, although it also binds E- and L-
selectin (88, 89). There are not sufficient in-vivo studies for the identification of a major 
physiologic E-selectin ligand, but some potential partners include E-selectin ligand-1 
(ESL-1) and CD44, the latter of which also binds L-selectin (65). 
The major physiologic L-selectin ligand is also not unequivocally identified due 
to a high degree of redundancy between ligands. Among the protein scaffolds capable of 
displaying appropriate carbohydrate epitopes for L-selectin binding in vitro are CD34, 
glycosylation-dependent cell adhesion molecule-1 (GlyCAM-1), podocalyxin, nepmucin, 
endomucin, Spg200, endoglycan, mucosal vascular addressin cell adhesion molecule-1 
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(MAdCAM-1), PSGL-1, and hematopoietic cell E- and L-selectin ligand (HCELL, a 
glycosylated form of CD44) (65, 66).  
3. Role of selectins in leukocyte migration to PLN 
Expression of L-selectin ligands in PLN drives lymphocyte homing to PLN in the 
steady state as part of the immune surveillance process. L-selectin ligands expressed on 
HEV in PLN are collectively called peripheral node addressins (PNAd), and include 
CD34, GlyCAM-1, podocalyxin, nepmucin, and endomucin (65, 66). L-selectin-
deficiency, or antibody-mediated blockade of L-selectin binding renders lymphocytes 
largely unable to migrate to PLN in vivo (90, 91). Thus, it is not surprising that L-
selectin
-/-
 mice show a 70% decrease in PLN cellularity (92). 
4. Role of selectins in leukocyte migration to sites of inflammation 
L-selectin also plays a role in leukocyte migration to sites of inflammation. As 
described above, inflammation is part of the immune response and involves the 
recruitment of leukocytes to sites of tissue injury or infection where their purpose is to 
eliminate the pathogen and repair the damaged tissue. Various chronic inflammatory 
diseases exhibit blood vessels with enhanced ability to support lymphocyte migration due 
to the upregulation of L-selectin ligands. Inflammatory cytokines, such as TNF-α or IL-
1β, or bacterial components such as lipopolysaccharide (LPS) cause an upregulation of 
adhesion molecules, including L-selectin ligands, on the endothelium in inflamed tissues, 
thus leading to increased leukocyte migration to the inflammatory site (66). Contribution 
of L-selectin in leukocyte migration to sites of inflammation has been documented in 
various conditions (66). For instance, L-selectin is involved in the recruitment of 
neutrophils (93, 94) and T cells (95) to the inflammatory site in ischemia-reperfusion 
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injury, and concanavalin A-induced liver injury, respectively. Furthermore, L-selectin 
plays a role in the recruitment of T cells (96) as well as neutrophils, macrophages, 
lymphocytes and eosinophils (97, 98) to the site of pulmonary inflammation in murine 
and sheep models of asthma, respectively. As another example of pulmonary 
inflammation, mice with pulmonary fibrosis showed an L-selectin-dependent infiltration 
of neutrophils and lymphocytes in the lung (99). 
The major role of P-selectin in platelets appears to be in coagulation (100), but it 
can also mediate interactions between platelets and neutrophils, monocytes, or inflamed 
endothelium, as well as interactions between neutrophils and inflamed endothelium (101-
103). One implication of such interactions is providing for an L-selectin-independent 
mechanism of leukocyte migration to PLN or sites of inflammation. For instance, 
platelet-expressed P-selectin may mediate lymphocyte rolling on HEV through 
interactions with PNAd (104, 105). In addition platelet-expressed P-selectin may be 
involved in the recruitment of leukocytes to sites of inflammation by signaling through 
PSGL-1 binding (106-111). 
B. Integrins are involved in multiple events of the adhesion cascade 
 Integrins are a family of heterodimeric cell adhesion molecules, composed of an α 
and a β chain, which bind immunoglobulin superfamily molecules or molecules of the 
extracellular matrix. Integrins are the major cell adhesion transmembrane receptors and 
can mediate outside-in and inside-out signaling. There are 18 α and 8 β subunits, which 
form 24 known αβ heterodimers, involved in various biologic processes, such as 
development, immune responses, leukocyte migration, and hemostasis. Some leukocyte-
expressed integrins with major roles in migration include αLβ2, αMβ2, α4β1, and α4β7. 
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 The αLβ2 integrin (CD11a/CD18) and αMβ2 integrin (CD11b/CD18) are also 
known as lymphocyte function-associated antigen-1 (LFA-1) and macrophage-1 antigen 
(Mac-1), respectively (112, 113). LFA-1 is expressed on various leukocytes, while Mac-1 
is restricted to myeloid cells and the nonconventional B-1 B cells. These integrins have 
various binding partners with some overlap between the two groups. For instance, both 
bind intercellular adhesion molecule-1 (ICAM-1), a member of the immunoglobulin-like 
gene superfamily (114-117). ICAM-1 is expressed on various cells, including endothelial 
cells, fibroblasts, epithelial cells, monocytes, macrophages, and activated lymphocytes 
among others, and is transcriptionally upregulated in response to inflammatory mediators, 
such as TNF-α, IL-1β, IFN-γ, as well as ROS, and virus or bacterial infections (118). 
LFA-1 or Mac-1 interactions with ICAM-1 play a role in various stages of leukocyte 
migration, including slow rolling, transition to firm adhesion, and diapedesis, as well as 
migration through the extracellular matrix at sites of inflammation (73). LFA-1 and Mac-
1 functions are not restricted to leukocyte migration. For instance, interactions between 
LFA-1, co-localized with TCR on T cells, and ICAM-1, co-localized with MHC on 
antigen-presenting cells, aids in stabilization of cell-cell adhesion and T cell activation 
(119). In addition, Mac-1 is also known as complement receptor type-3, and its 
recognition of the complement protein iC3b on opsonized bacteria aids in phagocytosis 
by neutrophils and macrophages. Furthermore, Mac-1 expressed on activated neutrophils 
also interacts with dendritic cell-specific intracellular adhesion molecule-3-grabbing non-
integrin (DC-SIGN, CD209) on dendritic cells, and this adhesion aids in neutrophil-
induced dendritic cell maturation (120). 
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 The α4β1 and α4β7 integrins are involved in leukocyte migration to sites of 
inflammation and to the gut, respectively. The α4β1 integrin (CD49d/CD29) is also 
known as very late activation-4 (VLA-4) antigen. VLA-4 and α4β7 integrin are expressed 
on hematopoietic stem cells, as well as mature lymphoid and myeloid cells. Specifically, 
both integrins are expressed on naïve lymphocytes, but high levels of α4β7 integrin are 
associated with gut-homing of T and B cells (121, 122). Both VLA-4 and α4β7 integrin 
are also expressed on eosinophils, basophils, NK cells, neutrophils and monocytes, 
although α4β7 integrin expression on monocytes is not constitutive.  Neutrophils express 
lower levels of VLA-4, but sufficient to support migration to inflammatory sites (123). 
Both VLA-4 and α4β7 integrin can bind to fibronectin, as well as to vascular cell adhesion 
molecule-1 (VCAM-1), a member of the immunoglobulin-like gene superfamily, which 
is upregulated on inflamed endothelium, although α4β7 integrin binds with lower affinity 
(124-126). Conversely, MAdCAM-1, constitutively expressed on HEV of mucosa-
associated lymphoid tissues in the gut, is a primary binding partner for α4β7 integrin, 
while VLA-4 binds with very low affinity (127). Interestingly, VLA-4 expressed by some 
tumors suppresses metastasis, possibly by supporting tumor cell adhesion within the 
primary tumor (128). 
VI. Tumor-associated hypoxia 
The rapid proliferation of cancer cells causes tumors to outgrow their existing 
blood vessels, reducing blood flow and consequently oxygen supply, a condition called 
hypoxia. Hypoxia activates the expression of genes that stimulate formation of new blood 
vessels (angiogenesis), growth of existing blood vessels (vasculogenesis), metabolic 
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switch to glycolysis, cell survival, and proliferation, thus helping the tissue to adapt to, 
and counteract, oxygen deficiency.  
A. Hypoxia-inducible factor 
The major transcription factor responsible for sensing and adaptation to hypoxia 
is hypoxia-inducible factor-1 (HIF-1), a heterodimer of HIF-1α and HIF-1β basic helix-
loop-helix-Per-ARNT-Sim (bHLH-PAS) protein subunits, which is regulated by cellular 
oxygen tension (129). HIF-1β is constitutively expressed and was originally identified as 
the aryl hydrocarbon nuclear translocator (ARNT), a binding partner of the aryl 
hydrocarbon receptor (AHR) (130). HIF-1α is ubiquitously and constitutively expressed 
(131), but rapidly degraded (t1/2 ~ 5 min) in well-oxygenated (normoxic; ~21% O2) 
environments via post-translational modifications of an oxygen-dependent degradation 
domain (ODDD) (Fig. 2) (132, 133). Specifically, hydroxylation of proline residues 
Pro402 and Pro564 and acetylation of lysine residue Lys532 favor HIF-1α binding to the 
von Hippel-Lindau (pVHL) protein component of the ubiquitin E3 ligase complex, which 
ubiquinates HIF-1α, thus marking it for degradation by the 26S proteasome (134-137). 
By contrast, hypoxic conditions (~1% O2) result in stabilization of HIF-1α (129, 131, 
138) and its translocation to the nucleus, where it dimerizes with HIF-1β via interactions 
between the HLH motifs and binds to hypoxia response elements (HRE; 5’-RCGTG-3’, 
where R = A or G) of target genes via the basic region of the bHLH domain (139, 140). 
In addition to HIF-1 stabilization, full activation of HIF-1 is achieved by recruitment of 
coactivators such as CBP/p300, SRC-1, and TIF2 to the N-terminal and C-terminal 
transactivation domains (N-TAD and C-TAD, respectively) within the C-terminal region 
of HIF-1α (141, 142). The need for coactivators allows for additional layers of HIF-1 
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regulation. For instance, hydroxylation of the C-TAD asparagine residue Asn803 under 
normoxia inhibits the binding of CBP/p300 (143, 144), while hypoxia reverses this effect 
(145), thus further activating the transcription of target genes.  
Several HIF-1α-related proteins have been identified, including HIF-2α and HIF-
3α, which in humans has at least six splice variants, designated hHIF-3α1, hHIF-3α2 
(also called inhibitory PAS; IPAS), hHIF-3α3, hHIF-3α4, hHIF-3α5, and hHIF-3α6 
(146). HIF-2α and some HIF-3α variants also bind HIF-1β and HRE, but can induce the 
expression of genes distinct from the HIF-1 target genes (147-151), while IPAS binds the 
N-terminal region of HIF-1α and prevents DNA binding, thus acting as a dominant 
negative regulator of HIF-1 function (152). In addition, some HIF-3α variants inhibit 
HIF-1 and HIF-2 function by competing for HIF-1β binding (153, 154). HIF-2α was 
initially found to be expressed in lung and endothelium (147, 148), but later it was 
demonstrated that the isoform is detectable in hypoxic conditions in a wide range of 
tissues and cell types, including myeloid cells (155). HIF-3α is expressed in a variety of 
tissues, and IPAS is expressed in Purkinje cells in the cerebellum and corneal epithelium 
(152), but can also be induced by hypoxia in the heart and lung (156). Similar to HIF-1α, 
in normoxic conditions, both HIF-2α and HIF-3α protein levels are regulated by proline 
hydroxylation within the ODDD, and CBP/p300 coactivator binding to HIF-2α is 
inhibited by asparagine hydroxylation in the C-TAD (134). 
B. Oxygen-dependent regulation of HIF function 
A family of three 2-oxoglutarate- and Fe
2+
-dependent dioxygenases serve as 
oxygen sensors and catalyze the hydroxylation of two proline residues in HIF-α, which 
marks the transcription factor for ubiquitination (157). These proline residues are 
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conserved among all HIF-α isoforms and belong to a consensus sequence LXXLAP, with 
only the second proline of HIF-3α belonging to the sequence LXXLHP (134). The human 
dioxygenases of HIF-α are called prolyl hydroxylase domain (PHD) proteins and there 
are three isoforms: PHD1, PHD2, and PHD3. Of these isoforms, PHD2 has the highest 
activity in vitro and is the limiting enzyme that regulates HIF-1α in vivo (158). All 
isoforms require 2-oxoglutarate and molecular oxygen as substrates and use Fe
2+
 and 
ascorbate (vitamin C) as cofactors. During the reaction, one oxygen atom from O2 is used 
to hydroxylate the proline residue, while the other reacts with 2-oxoglutarate resulting in 
production of succinate and CO2. Dimethyl-oxalyl-glycine (DMOG), a 2-oxoglutarate 
analog, binds all PHD proteins and inhibits their function in a reversible manner, thus 
stabilizing HIF-1α and, in effect, mimicking hypoxia, even when normoxic conditions are 
present (159). In addition, PHD protein function requires binding of Fe
2+
 to two histidine 
and one aspartate residues within the active site. Iron chelators or metal ions, including 
Co
2+
, Ni
2+
, and Mn
2+
, sequester or replace Fe
2+
 at the active site, thus inhibiting PHD 
protein function and stabilizing HIF-1α (160, 161); while ascorbate maintains Fe2+ levels 
in its reduced state and is needed for complete activation of PHD proteins (161, 162). 
Once hydroxylated, HIF-1α binds with high specificity to a conserved 
hydroxyproline-binding pocket in pVHL (163), which together with the transcription 
elongation factors B and C (also called elongin B and elongin C), cullin 2, and the RING 
finger protein RBX1, forms the pVHL-elongin C-elongin B-cullin 2-RBX1 (VCB-CR) 
E3 ubiquitin ligase complex that ubiquinates and targets HIF-1α for degradation (164, 
165).  
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Interestingly, a hereditary disease causing pVHL deficiency is associated with 
cancer development in various tissues, defining VHL as a tumor suppressor gene (165). 
The majority of evidence suggests that the carcinogenic effect of pVHL dysfunction is 
due to HIF-2α stabilization, while there are conflicting reports regarding the role of HIF-
1α in tumor development and progression (166) and insufficient research on the 
contribution of the HIF-α-independent effects of pVHL dysfunction (165). Some of the 
HIF-α-independent functions of pVHL include assembly and regulation of the 
extracellular matrix, microtubule stabilization, maintenance of the primary cilium, 
regulation of apoptosis and cell senescence, and transcriptional regulation via effects on 
RNA polymerase II or modulation of transcription factors other than HIF (165). 
C. Oxygen-independent regulation of HIF function 
There is substantial evidence that ROS, such as superoxide radical and hydrogen 
peroxide, can cause HIF-1α stabilization in normoxia. For example, exogenous hydrogen 
peroxide stabilized HIF-1α and HIF-2α in Hep3B and HEK293 cells in normoxic 
conditions (167). Similar results were observed with the addition of glucose oxidase, 
which generates hydrogen peroxide (167) and this effect was abolished by the addition of 
catalase, which converts hydrogen peroxide to water and O2 (168). Furthermore, 
inhibition of superoxide dismutase (which converts superoxide to O2 and hydrogen 
peroxide) or use of the DMNQ redox cycler (which generates superoxide) also increased 
the HIF-1α levels in normoxic conditions (169, 170). These effects may be due to 
superoxide radical-mediated oxidation of the Fe
2+
 co-factor causing inhibition of PHD 
protein function, and thus, inability of pVHL to bind to HIF-1α and mark it for 
degradation (171). 
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In addition to superoxide, NO produced by iNOS activation also stabilizes HIF-1α 
in normoxia (172). This NO-mediated HIF-1α stabilization may be due to direct 
nitrosation of thiol groups within HIF-1α, an effect that is reversible in the presence of 
antioxidants such as ascorbate (173, 174). In addition, normoxic NO-mediated HIF-1α 
stabilization may be due to PHD protein inhibition (175). 
NO and superoxide are both generated as a result of altered oxygenation states 
and can interact with each other to produce ROS and RNS that nitrate, nitrosate and 
oxidize proteins. In regard to HIF-1α regulation in the presence of NO and superoxide, 
there are conflicting observations: generally, co-incubation with low concentrations of 
NO and superoxide inhibit HIF-1α, while high concentration of these reagents 
synergistically stabilize HIF-1α. To consolidate these observations, it has been suggested 
that superoxide serves as a co-signal for NO-mediated HIF-1α stabilization, but this 
effect is countered by the decrease in NO availability as a result of interaction with 
superoxide. Thus, more NO is needed in the presence of superoxide to achieve HIF-1α 
stabilization (171, 176). In addition to post-translational modification of HIF-1α and PHD 
proteins, NO and superoxide can upregulate HIF-1α transcription and translation via 
activation of ERK and PI3K in normoxia (177, 178). Furthermore, ROS upregulate 
inflammatory mediators such as TNF-α and IL-1β, which in turn induce transcription and 
translation of HIF-1α under normoxia (179, 180). 
VII. Study rationale 
 The major effector cells in the anti-tumor immune response are the CTL. T cell 
priming by antigens from solid tumors occurs in TDLN, as TAA and antigen-presenting 
cells are transported from the tumor and enter these secondary lymphoid structures via 
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the lymph. Thus, for an effective anti-tumor T cell activation to occur, T cells must be 
able to enter the TDLN. The importance of leukocyte migration to lymph nodes in 
mounting an effective immune response extends to most pathologies and constant 
homeostatic lymphocyte recirculation between bloodstream and lymph nodes is a vital 
part of immune surveillance. 
However, in many cancer patients there is stronger tumor-induced 
immunosuppression rather than T cell activation, which is due to a large extent to the 
expansion and accumulation of MDSC. In fact, the accumulation of MDSC limits the 
success of immunotherapy, and correlates with poor prognosis. MDSC accumulate 
primarily in the spleen, liver and blood and to a lesser extent in the tumor and TDLN. 
Despite the less abundant presence of MDSC in tumors and TDLN, it has been shown 
that MDSC-mediated TAA-specific T cell suppression occurs primarily at these two sites 
(4, 5). For instance, tumor-infiltrating MDSC express elevated mRNA and protein levels 
of iNOS and arginase-1 compared to low or undetectable expression of these enzymes in 
splenic MDSC (4, 24, 181, 182). This suggests that MDSC upregulate arginase-1 and 
iNOS production after entering the tumor microenvironment. In addition, MDSC induce 
T cell tolerance in the TDLN (1, 2), suppressing not only the priming of naïve TAA-
specific T cells in the TDLN, but also the secondary response of primed anti-tumor T 
cells (5). Importantly, CTL responses are not systemically suppressed in tumor-bearing 
mice (3), which further supports the notion that T cell suppression may primarily occur in 
situ at the site of tumor growth (3, 183) and within the TDLN (5). Thus MDSC migration 
to the TDLN and tumor may be a limiting factor in MDSC-mediated suppression of the 
anti-tumor T cell response. Because these are considered the sites of MDSC-mediated 
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immunosuppression in vivo, interfering with the ability of MDSC to enter these tissues 
may provide an approach to augment cancer therapy. 
A significant number of studies have been published focused on elucidating the 
mechanisms of MDSC-mediated immunosuppression, as well as on developing strategies 
for MDSC depletion and inhibition of their function. By contrast, there are far fewer 
studies of MDSC migration, most of which focus on the involvement of chemokines in 
MDSC recruitment. However, the involvement of adhesion molecules in MDSC 
migration remains largely unknown. In general, the initial stages of the leukocyte 
migration cascade are largely dependent on L-selectin, but the contribution of this 
molecule to MDSC migration is unknown. We hypothesized that MDSC migration to 
tumor and TDLN depends on L-selectin. 
L-selectin
-/-
 mice have been generated (92) to study various aspects of L-selectin 
biology. Whether L-selectin is involved in MDSC migration can be tested with adoptive 
transfers of cell tracker-labeled wild type or L-selectin
-/-
 MDSC into the circulation of 
tumor-bearing mice, followed by enumeration of the labeled MDSC in the tumor and 
TDLN shortly thereafter. The 4T1 transplantable murine breast cancer model was 
selected for the in vivo study of MDSC migration. The 4T1 cell line was derived from a 
spontaneous mammary tumor in a female BALB/cfC3H mouse (184, 185). BALB/cfC3H 
is a BALB/c subline infected with mouse mammary tumor virus (MMTV), with virion 
transmittance to offspring via the mother’s milk. In mice, this retrovirus has been 
recognized as an etiological agent for breast cancer and BALB/cfC3H mice exhibit 87% 
tumor incidence at 16 months of age, compared to less than 1% in BALB/c mice (186). 
Although the involvement of MMTV or related viruses in the development of human 
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breast cancer remains an issue of much controversy, the murine 4T1 cell line is widely 
used to model human breast cancer, because its metastatic pattern is very similar to that 
of stage IV human breast cancer (187).  
In the preliminary part of the study, we aimed to compare the growth rates of 4T1 
tumors and the kinetics of 4T1 tumor-induced MDSC accumulation after tumor induction 
in wild type vs. L-selectin
-/-
 BALB/c mice. The results from these preliminary 
experiments allowed for the design of further functional studies in which the wild type 
and L-selectin
-/-
 genotypes would be equivalent sources of 4T1 tumor-induced MDSC for 
adoptive transfer experiments. It was of specific interest to determine the involvement of 
L-selectin in MDSC migration to the tumor and TDLN. MDSC are a heterogeneous 
population, but morphologically, functionally, and phenotypically, they can be divided 
into two major subsets, monocytic MDSC (M-MDSC) and polymorphonuclear MDSC 
(PMN-MDSC). These subsets have distinct contributions to immunosuppression and 
tumor growth and it was important to address them as separate populations in the 
migration studies. 
MDSC in the tumor microenvironment upregulate their expression of arginase-1 
and iNOS, possibly due to HIF-1α signaling (181). Therefore, it was of interest to learn 
more about the localization of MDSC relative to hypoxic regions within the tumor 
microenvironment. After observing that MDSC are not uniformly distributed throughout 
the tumor, but aggregate next to hypoxic regions, we followed up by quantifying the 
extent of this co-localization, as well as by addressing aspects of the dynamics of MDSC 
aggregation.  
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FIGURE LEGENDS 
Figure 1. Adhesion cascade 
The adhesion cascade is a process that can occur in post-capillary venules, via 
which circulating leukocytes exit the bloodstream and enter peripheral tissues. 
Specialized post-capillary venules, called high endothelial venules (HEV) in lymph nodes 
and post-capillary venules near sites of inflammation express adhesion molecules and 
display chemokines, which are recognized by adhesion molecules and chemokine 
receptors on the leukocyte, respectively. The interactions between these molecules 
support leukocyte migration. The first stage of the adhesion cascade (1), involves capture 
and rolling events supported by interactions between leukocyte-expressed L-selectin and 
its ligands expressed on the endothelium. In addition, interactions with endothelial P- and 
E-selectins with leukocyte-expressed ligands (not shown) also contribute. The rolling 
process allows the leukocyte to slow down and, via chemokine receptors during the 
activation stage (2), to sense chemokines displayed on the endothelial surface. The 
chemokine signals induce conformational changes in leukocyte-expressed integrins, 
thereby activating them and increasing their binding activity. The activated integrins, via 
interactions with endothelial immunoglobulin-like superfamily molecules, mediate 
leukocyte arrest (3) and diapedesis (4). 
Figure 2. Oxygen-dependent regulation of hypoxia inducible factor-1 alpha 
expression 
Hypoxia inducible factor-1 alpha (HIF-1α) is ubiquitously and constitutively 
expressed. In normoxic cells, HIF-1α is hydroxylated (OH) by dioxygenases, called 
prolyl hydroxylase domain (PHD) enzymes, which consist of three isoforms: PHD1, 
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PHD2, and PHD3. All isoforms require 2-oxoglutarate and molecular O2 as substrates 
and use Fe
2+
 and ascorbate as cofactors. Hydroxylation of HIF-1α is required for binding 
to von Hippel-Lindau (pVHL) protein component of the ubiquitin E3 ligase complex, 
which ubiquinates (Ub) HIF-1α, thus marking it for proteasomal degradation. Acetylation 
(Ac) of HIF-1α also contributes to the binding affinity. PHD proteins do not function in 
hypoxic conditions due to insufficiency of O2 as their substrate and HIF-1α degradation 
does not occur. HIF-1α is translocated to the nucleus where is dimerizes with HIF-1β and 
the dimer binds to hypoxia response elements to induce the expression of target genes. 
Maximal activity of the HIF-1α/ HIF-1β dimer is achieved by recruitment of coactivators 
such as CBP/p300. DMOG, a 2-oxoglutarate analog, binds all PHD protein isoforms and 
inhibits their function in a reversible manner, thus stabilizing HIF-1α and, in effect, 
mimicking hypoxia, even when there is sufficient O2.  
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CHAPTER 2 
ROLE OF L-SELECTIN IN TUMOR PROGRESSION AND ACCUMULATION OF 
MYELOID-DERIVED SUPPRESSOR CELLS 
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ABSTRACT 
Myeloid-derived suppressor cells (MDSC) consist of two major subsets, 
monocytic MDSC (M-MDSC) and polymorphonuclear MDSC (PMN-MDSC), both of 
which expand in cancer and suppress the activation of naïve T cells in the tumor-draining 
lymph node (TDLN) and the function of effector cells in the tumor microenvironment. 
Thus, the ability of MDSC to enter TDLN and the tumor is likely to be critical for 
suppression of the anti-tumor immune response and elucidating the mechanisms of 
MDSC migration to these sites may create a basis for novel immunotherapeutic 
approaches for the treatment of cancer. L-selectin mediates the homing of circulating 
naïve lymphocytes to lymph nodes and the migration of conventional myeloid cells, such 
as neutrophils and monocytes, to sites of inflammation, but its contribution to MDSC 
migration is unknown. In this part of the study we sought to characterize and validate a 
model system for further investigation of L-selectin function in MDSC migration to the 
TDLN and tumor. Using the 4T1 transplantable murine breast cancer model, we observed 
similar tumor growth rates and kinetics of tumor-induced MDSC accumulation in the 
blood of wild type vs. L-selectin
-/-
 mice. In the blood, PMN-MDSC accumulated in 
greater numbers than did M-MDSC, with a M-MDSC/PMN-MDSC ratio of 0.06 in the 
late stages of tumor progression. Quantification of MDSC accumulation in peripheral 
tissues revealed a 26-fold higher M-MDSC/PMN-MDSC ratio in the TDLN of wild type 
mice relative to blood, suggesting preferential accumulation of M-MDSC. In L-selectin
-/-
 
mice, the increase of the M-MDSC/PMN-MDSC ratio was less dramatic, suggesting a 
role of L-selectin in the preferential accumulation of M-MDSC in the TDLN. 
Importantly, MDSC accumulated in large numbers in the spleen of both wild type and L-
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selectin
-/- 
mice and splenic wild type MDSC expressed L-selectin at levels similar to 
those on MDSC in the blood. Therefore, the spleen is a convenient source of MDSC for 
further studies of L-selectin function in MDSC migration. Thus, we herein described 
relevant parameters of 4T1 tumor progression in L-selectin
-/-
 mice and validated their use 
for the study of L-selectin function in MDSC. Additional findings include: 1) presence of 
small numbers of PMN-MDSC in the thymus, which correlated with a decrease in thymic 
cellularity and a tendency for decreased numbers of CD4
+
CD8
+
 double-positive 
thymocytes;  2) preferential aggregation of tumor-infiltrating MDSC in the immediate 
vicinity of hypoxic regions; and 3) expression of the high-affinity folate receptor beta 
(FRβ) on both MDSC subsets, which may provide a potential strategy for the targeted 
elimination of MDSC. Respectively, these additional findings suggest: 1) an inhibitory 
role of MDSC in thymic T cell maturation during cancer; 2) a role of hypoxia in MDSC 
localization in the tumor microenvironment; and 3) a potential use of FRβ for the targeted 
elimination of MDSC in immunotherapy. 
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INTRODUCTION 
The major effector cells in the anti-tumor immune response are the CD8
+
 
cytotoxic T lymphocytes (CTL) (7, 8, 188, 189). The CTL response depends on the 
ability of naïve CD8
+
 T lymphocytes, via their unique T cell receptor (TCR) complexes, 
to recognize tumor-associated antigens (TAA). In the context of additional stimulatory 
signals provided by antigen-presenting cells and other cells of the immune system, TAA 
recognition leads to intracellular signaling causing activation (also referred to as T cell 
priming) and clonal expansion of the primed CD8
+
 T cells. The majority of the resulting 
CD8
+
 T cells further differentiate into highly cytotoxic effector cells capable of lysing 
target tumor cells upon contact, while a minority of CD8
+
 memory T cells acquire 
longevity and the ability to quickly mount a response upon a second encounter of the 
cognate tumor antigen. Because the CTL cytolytic function is contact-dependent, 
activated CTL must infiltrate the tumor and studies with cancer patients show a 
correlation between tumor infiltration by CD8
+
 T cells and a positive prognosis (190-
194). However, the prior stage of the immune response, T cell priming by antigens from 
solid tumors, occurs in peripheral lymph nodes (PLN), that are located in the vicinity of 
the tumor (tumor-draining lymph nodes, TDLN), as antigens are transported from the 
tumor and enter these secondary lymphoid structures via the lymph. Thus, efficient 
homing of naïve T cells to TDLN is required for an effective anti-tumor T cell response. 
Lymphocyte migration to lymph nodes is crucial for the generation of effective immune 
responses in a variety of pathologies and a constant homeostatic lymphocyte recirculation 
between bloodstream and lymph nodes is a vital part of immune surveillance. 
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The ability of circulating lymphocytes to enter lymph nodes is highly dependent 
on their expression of L-selectin (also known as CD62L), an adhesion molecule that 
mediates the initial interactions between the lymphocyte and the endothelium during 
migration to peripheral tissues (195, 196). These initial interactions are followed by a 
cascade of downstream interactions, which potentiate firm adhesion between the 
lymphocyte and the endothelium, ultimately resulting in lymphocyte extravasation into 
the lymph node. Thus, L-selectin-deficient (L-selectin
-/-
) mice show a dramatic reduction 
in lymphocyte migration to PLN (90, 92), decreased PLN cellularity (92) and a blunted 
inflammatory response (64, 197, 198).  L-selectin is expressed by most leukocytes (195, 
199) and interestingly, in addition to its role in leukocyte migration, has a pro-metastatic 
role in cancer progression (200, 201). 
Despite the ability of the immune system to recognize and kill cancer cells, 
tumors constantly adapt and outgrow the immune control. This adaptability is due to the 
high heterogeneity and mutability of tumor cells. In addition, tumors interact with the 
immune system and modulate some of its components. For instance, tumor progression is 
associated with suppression of the immune response in the TDLN (202-204). In addition, 
tumor-derived factors cause hematopoietic abnormalities, resulting in generation and 
release from the bone marrow of underdifferentiated myeloid cells with 
immunosuppressive function. Though historically known as natural suppressor cells, the 
more detailed characterization of these cells in recent years has led to the acceptance and 
wide use of the term myeloid-derived suppressor cells (MDSC) (205). 
MDSC are generated in the bone marrow and accumulate in the spleen in 
response to various pathologic conditions, including cancer, infection, inflammation and 
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traumatic stress, among others (24). MDSC accumulation correlates with chronic 
inflammation in the context of the pathologic conditions, and it is likely that their 
generation constitutes an internal regulatory mechanism used to keep immune responses 
in check and minimize immune-mediated harm to the host.  The MDSC population is 
heterogeneous, but the current view divides it into two major subsets: polymorphonuclear 
and monocytic MDSC, abbreviated PMN-MDSC and M-MDSC, respectively. Both 
subsets express the common myeloid marker CD11b. In addition, murine PMN-MDSC 
show a high expression of Ly-6G and low levels of Ly-6C. On the contrary, murine M-
MDSC express high levels of Ly-6C and stain negative for Ly-6G. Thus PMN-MDSC are 
phenotypically identified as CD11b
+
Ly6G
+
Ly-6C
low/-
, while M-MDSC are identified as 
CD11b
+
Ly-6G
-
Ly-6C
high
 (24, 206). Of these subsets, PMN-MDSC are the more 
predominant population, but M-MDSC have higher immunosuppressive activity on a per-
cell basis (207). The suppressive effects of MDSC result from upregulation of the 
enzymes inducible nitric oxide synthase (iNOS) and arginase-1. Both subsets suppress 
antigen-stimulated T cell proliferation in vitro, albeit via different mechanisms. When 
pre-incubated with T cells, M-MDSC are also able to suppress T cell proliferation 
induced by antibody stimulation of the signaling component of the TCR complex (207). 
Authors refer to these effects on T cell proliferation as antigen-specific and antigen-
nonspecific suppression, respectively. This terminology only refers to the design of the in 
vitro assays used to measure MDSC-mediated suppression and is irrelevant in 
physiologic conditions, where T cell activation can only be induced by appropriately 
displayed antigen. Thus, the term “antigen-nonspecific” T cell suppression does not mean 
that all T cells in vivo are suppressed regardless of their specificity or location. Indeed, T 
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cell function in various tumor models is not systemically suppressed and there is no 
increase in the incidence of opportunistic infections in cancer patients, which would be 
indicative of diminished T cell function (3). This may indicate that although MDSC 
accumulate systemically, their function in suppressing the anti-tumor T cell response may 
be limited to the sites of exposure to TAA. 
It is noteworthy that most studies of MDSC function thus far have used primarily 
MDSC isolated from the spleen and added to ex vivo formats of T cell function assays. 
Most often in these assays T cells are activated to proliferate by co-incubation with a 
cognate antigen, by antibody-induced TCR signaling, or by a general inducer of 
proliferation, such as concanavalin A. Of further note, the suppressive functions of 
MDSC are largely induced by interferon-γ (IFN-γ) signaling and a major source of this 
pro-inflammatory cytokine are activated T cells. Thus, in the context of in vitro T 
cell/MDSC co-culture assays, T cell activation may induce suppressive activities of 
MDSC that have not been in place in vivo at the time of MDSC isolation. This has led 
Haverkamp and colleagues to address the possibility that the in vivo suppressive effects 
of MDSC are only occurring at the sites of ongoing inflammation and T cell activation, 
rather than systemically (4). This study demonstrated that MDSC isolated from the 
inflammatory site in a model of acute prostate inflammation were more suppressive than 
MDSC from the spleen of the same mice in 48-h and 72-h assays of antigen-induced T 
cell proliferation. When IFN-γ signaling was blocked with an anti-IFN-γ antibody in the 
context of this in vitro assay, MDSC from the inflammatory site retained their 
suppressive potential, while MDSC from the spleen exhibited lower suppressive activity.  
In a short-term assay with minimized exposure to IFN-γ, MDSC from the inflamed 
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prostate, but not MDSC from the spleen, exhibited the ability to suppress the proliferation 
of CD8
+
 T cells, pre-activated with cognate antigen. When prostate tumor-bearing mice 
were used, an example of chronic inflammation, the MDSC isolated from the tumor, but 
not those from the spleen, exhibited suppressive function in this short-term assay format. 
Importantly, MDSC depletion in vivo resulted in increased abundance and activation 
potential of T cells in the inflammatory site, but had no effect on the abundance and 
function of T cells in the spleen. The results from the functional characterization of 
MDSC from the inflammatory site and the spleen are in agreement with the observation 
that MDSC from inflamed prostates and prostate tumors express elevated mRNA and 
protein levels of iNOS and arginase-1 (4), a finding that extends to other types of cancer 
(181). The authors concluded that MDSC exhibit immunosuppressive activity only at the 
inflammatory site and further suggest that MDSC function at that site to regulate T cells 
that are already activated, rather than to suppress T cell priming (4). It appears likely that 
in the context of cancer, these considerations would be valid during the earlier stages of 
solid tumor growth, before the establishment of distant metastases and the systemic 
spread of tumor cells and TAA. 
Although the above study did not address a possible role of MDSC in the 
suppression of anti-tumor T cell activation in the TDLN, other in vivo studies 
demonstrate MDSC-mediated T cell tolerization at that site (1, 2). It was further 
demonstrated that MDSC suppress not only the priming of naïve TAA-specific CD4
+
 and 
CD8
+
 T cells in the TDLN, but also the secondary response of primed anti-tumor T cells 
(5). Thus, is appears that MDSC in the tumor microenvironment and in the TDLN 
suppress the T cell response against the tumor. The mechanisms of MDSC-mediated T 
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cell suppression have been well studied but not much is known about the mechanisms of 
MDSC migration to tumors and TDLN. Because these are considered the sites of MDSC-
mediated immunosuppression in vivo, interfering with the ability of MDSC to enter these 
tissues may provide an approach to augment cancer therapy. In general, the initial stages 
of the leukocyte migration cascade are largely dependent on L-selectin, but the 
contribution of this molecule to MDSC migration in particular, is unknown. 
L-selectin
-/-
 mice have been generated (92) to study various aspects of L-selectin 
biology. Whether L-selectin is involved in MDSC migration can be tested with adoptive 
transfers of cell tracker-labeled wild type or L-selectin
-/-
 MDSC into the circulation of 
tumor-bearing mice, followed by enumeration of the labeled MDSC in the tumor and 
TDLN shortly thereafter. In this part of the study, we sought to compare tumor 
progression and MDSC accumulation in wild type and L-selectin
-/-
 mice and to validate a 
model system, in which tumor-bearing wild type and L-selectin
-/-
 mice would be 
equivalent MDSC sources for adoptive transfer experiments, except for the lack of L-
selectin on MDSC from L-selectin
-/-
 mice.  
The 4T1 transplantable murine breast cancer model was selected for the in vivo 
study of MDSC migration. The 4T1 cell line was derived from a spontaneous mammary 
tumor in a female BALB/cfC3H mouse (184, 185). BALB/cfC3H is a BALB/c subline 
infected with mouse mammary tumor virus (MMTV), with virion transmittance to 
offspring via the mother’s milk. In mice, this retrovirus has been recognized as an 
etiological agent for breast cancer. The exogenously introduced viral particles in concert 
with endogenously carried viral DNA integrated in the host genome, cause breast cancer 
in these mice via a complex, but well-characterized process resulting in activation of 
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proto-oncogenes in the mammary tissue (208). As a result, BALB/cfC3H mice exhibit 
87% tumor incidence at 16 months of age, compared to less than 1% in BALB/c mice 
(186). Although the involvement of MMTV or related viruses in the development of 
human breast cancer remains an issue of much controversy, the murine 4T1 breast cancer 
is widely used to model human breast cancer (187). The major advantage to this model in 
modeling human disease is the spontaneous spread of 4T1 metastases to the draining 
lymph nodes, lung, liver, bone, and brain, a metastatic pattern very similar to that of stage 
IV human breast cancer. 
In this part of the study, we demonstrated that 4T1 tumors exhibit similar growth 
rates and similar kinetics of tumor-induced MDSC accumulation when transplanted into 
wild type vs. L-selectin
-/-
 mice. Thus, these genotypes are equivalent sources of 4T1 
tumor-induced MDSC for further functional studies. We also observed a decrease in 
MDSC numbers in the TDLN of L-selectin
-/-
 mice relative to wild type, which could be 
indicative of a role of L-selectin in MDSC migration to the TDLN. In addition, we 
visualized the localization of MDSC relative to B cell and T cell regions within the 
spleen and the TDLN, as well as relative to areas of low oxygenation (hypoxia) in the 
tumor. While we did not observe a particularly strong preference for MDSC co-
localization with either T cell or B cell regions in the spleen and TDLN, we found that in 
the tumor, MDSC were primarily localized in aggregates next to hypoxic regions. Unique 
to the tumor microenvironment, this relationship between hypoxia and MDSC may have 
functional consequences, which require further investigation.  
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MATERIALS AND METHODS 
Cell lines and reagents 
The 4T1 murine mammary carcinoma cell line (ATCC CRL 2539) was purchased 
from ATCC (Manassas, VA). The line was originally derived from a spontaneous 
mammary tumor from a BALB/cfC3H mouse (185, 209). When transplanted ectopically 
into syngeneic BALB/c mice, the 4T1 cell line generates a solid, highly metastatic tumor, 
which spreads to nearby lymph nodes, lungs, bones, brain, and liver, thus resembling 
stage IV metastatic breast cancer in humans.  
Antibodies used in the flow cytometry and fluorescence microscopy experiments 
included: fluorescein isothiocyanate (FITC)-conjugated, allophycocyanin (APC)-
conjugated, or biotinylated anti-CD11b (Clone M1/70, BD Biosciences, San Jose, CA); 
phycoerythrin (PE)-conjugated or FITC-conjugated anti-Ly-6G (Clone 1A8, BD 
Biosciences); peridinin-chlorophyll protein-cyanine 5.5 (PerCP-Cy5.5)-conjugated or  
PE/Cy7-conjugated anti-Ly-6C (Clone HK1.4, BioLegend, San Diego, CA; Clone AL-
21, BD Biosciences); PE-conjugated anti-CD4 (Clone RM4-5, BD Biosciences); APC-
conjugated anti-CD8 (Clone 53-6.7, BD Biosciences); biotinylated anti-Thy1.2 (Clone 
53-2.1, BD Biosciences) and anti-L-selectin (Clone LAM1-116, (210)); rat anti-mouse 
IgD antibody (Clone 11-26, SouthernBiotech, Birmingham, AL); polyclonal rabbit anti-
FRβ antibody (Cat. #PA5-24963, ThermoFisher Scientific, Waltham, MA). Biotinylated 
antibodies were detected with Alexa Fluor
®
 488- or AlexaFluor
®
 350-conjugated avidin 
(Life Technologies, Grand Island, NY), or APC- or tetramethylrhodamine (TRITC)-
conjugated neutralite avidin (SouthernBiotech). The primary rat anti-mouse IgD antibody 
was detected with a secondary TRITC-conjugated goat anti-rat IgG antibody 
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(SouthernBiotech). The primary rabbit anti-FRβ antibody was detected with a secondary 
AlexaFluor
®
 647-conjugated goat anti-rabbit IgG antibody (Jackson Immunoresearch, 
West Grove, PA). Hypoxiprobe™ RedAPC Kit, containing pimonidazole·HCl and APC-
conjugated anti-pimonidazole antibody (Clone 4.3.11.3) was purchased from 
Hypoxiprobe (Burlington, MA) and used to detect hypoxic regions in the tumor 
microenvironment with fluorescence microscopy. 
Mitomycin C (Cayman Chemical, Ann Arbor, MI) was used to inhibit 
proliferation of stimulator cells and Vibrant
®
 carboxy-fluorescein diacetate succinimidyl 
ester (CFDA-SE) cell tracer kit (Life Technologies) was used to detect proliferation of 
responder T cells in a mixed lymphocyte reaction assay. Normal goat serum (Sigma, St. 
Louis, MO) and HyClone
®
 normal horse serum (ThermoFisher Scientific) were used in 
buffers to reduce non-specific binding of antibodies. 5-Bromo-2-deoxyuridine (BrdU), a 
thymidine analog used to measure cell proliferation, was purchased from Sigma. 
Deoxyribonuclease I (DNAse I) from bovine pancreas and collagenase type VIII from 
Clostridium histolyticum used for tissue digestion, were both purchased from Sigma. 
Bovine serum albumin fraction V (also used in the tissue digestion buffer), was 
purchased from ThermoFisher Scientific. 
Animals 
BALB/c (wild type) and C57BL/6 mice were originally purchased from the 
Jackson Laboratories (Bar Harbor, ME) and further housed and bred in a specific 
pathogen-free barrier facility at the University of Wisconsin-Milwaukee and screened 
regularly for pathogens.  L-selectin
-/-
 mice were generated as described (92) and back-
crossed against the BALB/c genetic background for twelve generations. All procedures 
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were approved by the Animal Care and Use Committee of the University of Wisconsin-
Milwaukee. 
Tumor induction 
The 4T1 cells were cultured at 37°C and 5% CO2 in RPMI-1640 medium (Life 
Technologies), supplemented with 10% fetal bovine serum (Atlanta Biological, Forest 
Hills, NY), 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine and 55 μM 
2-mercaptoethanol (all from Life Technologies). At approximately 70% confluency, the 
cells were lifted with Cellstripper purchased from Mediatech (Manassas, VA), and 1x10
4
 
4T1 cells in 50 μl supplement-free RPMI-1640 medium were injected subcutaneously 
into the mammary fat pad of 8-12 week old wild type or L-selectin
-/-
 BALB/c female 
mice. In some of the mice, 50 μl supplement-free RPMI-1640 medium was injected into 
the contralateral mammary fat pad as an internal negative control. Tumor growth was 
monitored by caliper measurements of the major (L, length; mm) and minor (W, width; 
mm) axes and tumor volume (V, volume; mm
3
) was calculated by the formula: V = (L x 
W
2
) / 2. 
Kinetics of MDSC accumulation in blood of 4T1-tumor bearing mice 
At different time points (0, 1, 2, 3, 4 and 5 weeks) after tumor induction, 50-100 
μl of blood per mouse were collected from the retro-orbital sinus using a heparinized 
Pasteur pipette. Leukocyte counts were determined using a hemacytometer after a 10- to 
1000-fold sample dilution in 0.2% glacial acetic acid. Fifty microliters of a 2X optimal 
dilution of anti-CD11b, anti- Ly-6G, and anti-Ly-6C antibodies in PBS containing 2% 
normal horse serum, were added to 50 μl of blood and incubated for 30 min on ice with 
occasional light vortexing. The samples were then washed in PBS, and the red blood cells 
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were lysed in BD FACS Lysis buffer (BD Biosciences) for 10 min at room temperature. 
After two subsequent washes in PBS, the labeled leukocytes were fixed in 1.5% 
formaldehyde in PBS. The frequencies of M-MDSC and PMN-MDSC were determined 
using a FACSCalibur flow cytometer (BD Biosciences) and BD CellQuest™ Pro 
software. Counts of each MDSC subset per 1 ml of blood were calculated from the 
obtained frequencies. 
L-selectin labeling 
To confirm L-selectin expression on MDSC, single-cell suspensions from spleens 
of advanced stage (4-5 weeks) 4T1 tumor-bearing wild type BALB/c mice were 
immunolabeled as above against the MDSC markers CD11b, Ly-6G, and Ly-6C. A 
biotinylated anti-L-selectin antibody was also added to the labeling antibody mix, but 
omitted from negative control samples. The samples were then washed with PBS and 
incubated for an additional 30 min on ice with APC-conjugated neutralite avidin. The 
samples were then washed again in PBS and fixed in 1.5% formaldehyde in PBS. L-
selectin expression was also tested on MDSC in the blood. Whole blood was labeled as 
above and red blood cells were lysed with BD FACS lysis buffer and fixed. Alternatively, 
the whole blood was washed with a 20-fold excess of PBS to remove the plasma 
components, including soluble L-selectin, before labeling. 
Tissue preparation for flow cytometry 
To assess the tissue distribution of MDSC during 4T1 tumor progression, control 
mice without tumors and 4T1 tumor-bearing mice at the 4-week stage were euthanized. 
The following tissues were harvested: bone marrow, thymus, spleen, liver, lung, tumor, 
tumor-draining lymph node (TDLN, the inguinal lymph node next to the primary tumor), 
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and non-draining lymph node (NDLN, the contralateral inguinal lymph node next to the 
site of the vehicle control RPMI-1640 medium injection). Single-cell suspensions were 
prepared as follows: 1) bone marrow was flushed from both femurs with a 27G needle 
and collected in PBS; after centrifugation, red blood cells were lysed in ACK buffer (0.15 
M NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA, pH 7.4), filtered through a 70 μm mesh-
filter and washed three times in PBS; 2) spleen, thymus, and lymph nodes were teased 
apart in a dish filled with PBS as previously described (90), the suspensions were filtered 
through 70 μm mesh and centrifuged; red blood cells from the spleen were lysed in ACK 
buffer, filtered again and washed three times in PBS; 3) liver, lung, and tumor were 
minced with scissors into ~1 mm pieces and incubated for 30-60 min at 37°C and 5% 
CO2 in digestion buffer, containing 562 U/ml collagenase, 20.6 U/ml deoxyribonuclease 
I, and 5 mg/ml bovine serum albumin in PBS. The red blood cells were then lysed in 
ACK buffer, the suspensions were filtered through 70 μm mesh and washed three times 
in PBS.  
Cell counts and viability were determined using a hemacytometer following 
appropriate dilution in trypan blue exclusion dye. The concentrations were adjusted to 
20x10
6 
cells/ml
 
and 1x10
6
 cells of each tissue were immunolabeled for MDSC markers 
and analyzed by flow cytometry as described above. Thymus suspensions were 
additionally labeled with anti-CD4 and anti-CD8 antibodies to determine the frequencies 
of double-negative (CD4
-
CD8
-
), double-positive (CD4
+
CD8
+
), and single-positive CD4
+
 
and CD8
+
 thymocytes. 
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Analysis of MDSC suppressive activity with a mixed lymphocyte reaction assay 
The suppressive activity of MDSC was quantified in the context of a one-way 
mixed lymphocyte reaction. In this assay, stimulator spleen cells from a C57BL/6 mouse 
(haplotype b) were used to activate responder T cells from the spleen of a BALB/c mouse 
(haplotype d). In this combination the responder T cells recognize and react to foreign 
histocompatibility antigens expressed on the allogeneic stimulator cells, and proliferate, 
while the proliferation of any T cells within the stimulator cell population is inhibited by 
pre-treatment with mitomycin C (211). The number of divided responder T cells served 
as a quantitative measure of maximum responder T cell activation. Division of T cells 
was quantified via the carboxy-fluorescein succinimidyl ester (CFSE) dilution method. In 
this approach, the responder cells are incubated with the cell permeable CFDA-SE 
fluorogenic substrate. Intracellular esterases remove the acetate groups converting the 
substrate to a cell impermeable fluorescent CFSE product, which accumulates inside of 
the cell. CFSE via its succinimidyl group attaches covalently to lysine groups within 
intracellular proteins and is retained in the cytoplasm of live cells. Upon cell division, the 
fluorescent product is divided evenly between the two daughter cells, thus halving the 
original fluorescence intensity. This decrease can be detected with flow cytometry and 
the number of CFSE
low
 T cells is a direct measure of T cell proliferation. Addition of 
MDSC sorted from the spleen of a 4T1 tumor-bearing mouse to the stimulator/responder 
cell co-culture should cause a decrease in the number of CFSE
low
 T cells (divided 
responder T cells) and this decrease is a measure of the suppressive activity of MDSC.  
Spleens were harvested from non-tumor-bearing C57BL/6 (for stimulator cells) 
and BALB/c (for responder cells) mice. Single-cell suspensions were prepared as 
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described above and the responder spleen suspension was labeled with antibodies against 
CD4 and CD8 and analyzed by flow cytometry to determine the frequency of responder T 
cells. Fifty million C57BL/6 stimulator spleen cells were treated for 30 min at 37°C with 
50 μg/ml mitomycin C in 1 ml PBS. The cells were then washed three times in PBS and 
added to a 96-well plate at 0.1 x 10
6
 cells/100 μl/well in RPMI-1640 medium, 
supplemented as above. Forty-two million BALB/c responder spleen cells were incubated 
in 0.25 M CFDA-SE in 14 ml PBS at 37°C for 30 min. The cells were then centrifuged 
and resuspended in 10 ml RPMI-1640 medium, supplemented as above, and incubated 
for a further 30 min at 37°C. The cells were then washed and 0.1 x 10
6
 cells/50 μl/well 
were added to the stimulator cells or added to 100 μl of culture medium as a negative 
control for proliferation without stimulation. Spleens were also harvested from BALB/c 
mice bearing 4-week stage 4T1 tumors. The spleen suspension was labeled with MDSC 
markers as described above and the MDSC population, including both M-MDSC and 
PMN-MDSC subsets, was sorted using a FACSAria III cell sorter (BD Biosciences), with 
purity > 95%. The sorted MDSC were seeded into the wells containing stimulator and 
responder cells at various ratios (1:1, 1:2, 1:4, 1:8, 1:16, 1:32 and 1:64) relative to the 
responder T cell number pre-determined with flow cytometry. Each combination was 
seeded in triplicate wells and the cells were co-cultured for 4 days. On the fourth day, the 
triplicate wells were pooled, labeled with antibodies against CD4 and CD8, and the 
number of CFSE
low
CD4
+
 and CFSE
low
CD8
+
 cells (divided CD4
+
 and CD8
+
 T cells, 
respectively) was determined by flow cytometry. Two independent experiments gave 
similar results. 
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Immunofluorescence labeling of frozen tissue sections 
Spleen, tumor and TDLN were harvested from advanced stage 4T1 tumor-bearing 
wild type BALB/c mice. The tissues were then snap-frozen in tissue freezing medium 
(Triangle Biomedical Sciences, Inc, Durham, NC) in liquid nitrogen or on dry ice and 5 
μm thick tissue sections were cut on a cryostat and adhered onto poly-L-lysine-coated 
microscope slides. The sections were fixed in -20°C acetone for 5 min and stored at -
20°C until labeling. The sections were thawed for 5 min and rehydrated in PBS for 10 
min. The sections were then incubated in 5% normal goat serum in PBS to block non-
specific antibody binding. Antibody dilutions were prepared in 2% normal horse serum in 
PBS. The spleen and TDLN sections were immunolabeled against the MDSC markers 
CD11b, Ly-6G, and Ly-6C in a combination with the T cell marker Thy1.2 and the B cell 
marker IgD by incubation with the corresponding antibodies for 30 min at room 
temperature. The slides were then washed twice for 5 min each in 2% normal horse 
serum in PBS and further incubated for 30 min at room temperature with AlexaFluor
®
 
350-conjugated avidin to detect the biotinylated anti-Thy1.2 antibody and with TRITC-
conjugated goat anti-rat IgG antibody to detect the rat anti-mouse IgD antibody. The 
sections were washed twice in PBS for 5 min and mounted in ProLong
®
 Gold antifade 
mounting medium (Life Technologies). The mounting medium was allowed to cure 
overnight before imaging on a Nikon Eclipse TE2000-U epifluorescence microscope 
(Nikon Instruments Inc., Melville, NY) equipped with a Cool Snap ES digital camera 
(Photometrics, Tuscon, AZ). MetaVUE™ software (Universal Imaging Corporation, 
Downington, PA) was used for imaging and analysis.  
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To visualize hypoxic regions within the tumor microenvironment, the tumor-
bearing mice were first injected, 1 h prior to euthanasia, with a single intraperitoneal dose 
of 60 mg/kg body weight pimonidazole·HCl in PBS. This cell permeable reagent binds to 
the thiol groups that result from reduction of protein disulfide bonds in hypoxic 
conditions, and forms stable adducts with intra- and extracellular proteins. Any unbound 
pimonidazole is cleared within 1 h of injection. The tumors were harvested, frozen, 
sectioned, fixed, and stored as above. After thawing, rehydrating and blocking as above, 
the sections were incubated with anti-pimonidazole antibody for 1 h at 37°C in a 
humidified chamber. This step was followed by a 30-min incubation at room temperature 
with antibodies against the MDSC markers CD11b, Ly-6G, and Ly-6C to visualize the 
localization of MDSC relative to hypoxic regions within the primary tumor. All samples 
were imaged as above. 
Folate receptor beta (FRβ) labeling 
Blood and spleen suspensions from mice with advanced stage 4T1 tumors were 
tested for FRβ expression. One hundred microliters of 2X anti-FRβ rabbit polyclonal 
antibody in 2% normal horse serum in PBS were added to 100 μl of blood or 100 μl of 
spleen suspension adjusted to 5x10
6
 cells/100 μl. Negative controls received 100 μl of 
2% normal horse serum in PBS without antibody and all samples were incubated for 30 
min on ice with occasional light vortexing. The samples were then washed with 2% 
normal horse serum in PBS and incubated for 30 min on ice with AlexaFluor
®
 647-
conjugated goat anti-rabbit IgG antibody. The samples were washed again in 2% normal 
horse serum in PBS and blocked for 15 min on ice with 5% normal rabbit serum and 2% 
normal horse serum in PBS, followed by another wash in 2% normal horse serum in PBS. 
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The samples were then incubated for 30 min on ice with antibodies against the MDSC 
markers CD11b, Ly-6G, and Ly-6C, followed by washing in PBS. The spleen samples 
were then fixed in 1.5% formaldehyde in PBS and analyzed by flow cytometry. The red 
blood cells from the blood samples were lysed with BD FACS lysis buffer. The blood 
samples were then washed twice in PBS, fixed in 1.5% formaldehyde in PBS and 
analyzed. 
Statistical analysis 
 Except for the MDSC suppression assays, data are presented as mean ± SEM. 
Significant differences between sample means were determined using a Student’s t test 
with p < 0.05 considered significant.  
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RESULTS 
Accelerated 4T1 tumor growth in L-selectin
-/-
 mice 
Cytotoxic T cell activation in the tumor-draining lymph nodes is necessary for 
anti-tumor immunity and control of tumor growth. Being critical for the homing of naïve 
lymphocytes to PLN, lack of L-selectin may hinder access of naïve CD8
+
 T cells to 
appropriately presented tumor antigens in the presence of relevant co-stimulatory signals. 
Thus, L-selectin deficiency may play an inhibitory role in the generation of anti-tumor 
cytotoxic T cell responses, resulting in accelerated tumor progression. To determine the 
contribution of L-selectin in the control of 4T1 tumor progression, wild type and L-
selectin
-/-
 BALB/c mice were injected subcutaneously into the mammary fat pad with 
1x10
4
 4T1 cells and tumor growth was monitored over a period of 5 weeks. The tumor 
growth curve for both wild type and L-selectin
-/-
 mice was characterized by an initial lag 
phase of 2-3 weeks, followed by an exponential increase in tumor volume during the 
period from 3- to 5-weeks (Fig. 3A). Interestingly, L-selectin deficiency resulted in a 
modest but significant increase in tumor volume (by 14 to 47%) relative to wild type 
control mice during the 2-5 week time period (Table I). Therefore, in this tumor model 
loss of L-selectin expression results in a modest acceleration of tumor growth. 
The kinetics of systemic MDSC accumulation during 4T1 cancer progression in wild 
type and L-selectin
-/-
 mice are equivalent and correlate with tumor growth rate 
Cancer progression drives the generation of MDSC and MDSC accumulation 
corresponds to tumor burden. We asked whether the small increase in tumor growth rate 
in L-selectin
-/-
 mice relative to wild type controls correlated with accelerated systemic 
MDSC accumulation. Blood was collected from tumor-bearing wild type and L-selectin
-/-
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mice at the 1-, 2-, 3-, 4-, and 5-week time points or from mice without tumors. The blood 
samples were immunolabeled against the MDSC markers CD11b, Ly-6G, and Ly-6C, 
and each MDSC subset was quantified by flow cytometry. Figure 3B shows 
representative flow cytometry data plots and gating analysis for quantification of 
CD11b
+
Ly-6G
+
Ly-6C
low
 PMN-MDSC and CD11b
+
Ly-6G
-
Ly-6C
high
 M-MDSC. The 
accumulation kinetic curves (Fig. 3C) of both MDSC subsets resemble the tumor growth 
curve with an initial lag phase of 2-3 weeks, followed by an exponential increase in 
MDSC numbers during the period from 3- to 5-weeks. There was a tendency for 
accelerated accumulation of both PMN-MDSC and M-MDSC in the L-selectin
-/-
 tumor-
bearing mice relative to the corresponding wild type control mice (Table I, Fig. 3C); 
however, these did not reach statistical significance. Therefore, the kinetics of systemic 
MDSC accumulation during 4T1 cancer progression in wild type and L-selectin
-/-
 mice 
were equivalent and correlated with tumor growth rate. 
PMN-MDSC and M-MDSC from spleen and blood of late-stage 4T1 tumor-bearing 
mice express L-selectin 
L-selectin is expressed on all classes of leukocytes, including neutrophils and 
monocytes, the respective conventional counterparts of PMN-MDSC and M-MDSC in 
physiologic conditions. We asked whether L-selectin is also expressed by pathologically 
generated PMN-MDSC and M-MDSC during 4T1 tumor progression. In studies with 
small experimental animals, such as mice, the spleen is the most commonly used source 
in the cases when large numbers of MDSC are needed. Spleen suspensions from wild 
type mice with advanced stage 4T1 tumors were immunolabeled against L-selectin and 
the MDSC markers CD11b, Ly-6G, and Ly-6C, and the expression level of L-selectin by 
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PMN-MDSC and M-MDSC was analyzed by flow cytometry. Both subsets expressed L-
selectin (Fig. 4A). Interestingly, the M-MDSC subset expressed L-selectin at 66% higher 
levels than the PMN-MDSC subset. 
L-selectin is responsible for leukocyte migration from the bloodstream to PLN or 
sites of inflammation and the expression of L-selectin by blood-borne MDSC has 
important biologic relevance. Therefore, in addition to spleen, we also analyzed the L-
selectin expression levels on MDSC in the blood of wild type mice with advanced 
tumors. Various inflammatory conditions are characterized by elevated soluble L-selectin 
(sL-selectin) in the bloodstream as a result of proteolytic cleavage from the surface of 
activated leukocytes (66). Importantly, the presence of sL-selectin in the test samples 
may cause false negative results in immunolabeling experiments, due to competitive 
binding to the anti-L-selectin antibody. Therefore, the test samples included non-washed 
blood, as well as blood that was washed with an excess volume of PBS to remove soluble 
plasma proteins. L-selectin labeling on PMN-MDSC and M-MDSC in non-washed 
samples showed only a small increase in fluorescence intensity compared to the negative 
control (Fig. 4B). By contrast, the removal of soluble plasma proteins dramatically 
improved L-selectin labeling of both subsets, with the fluorescence intensity reaching 
similar levels to those detected in the spleen. Although the splenic PMN-MDSC 
expressed lower levels of L-selectin compared to PMN-MDSC from the blood, the 
difference was not statistically significant. Thus, MDSC from spleen and blood of late-
stage 4T1 tumor-bearing mice expressed similar levels of L-selectin, validating the spleen 
of tumor-bearing mice as an appropriate source of MDSC for functional studies of L-
selectin. 
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Decreased numbers of MDSC in TDLN of L-selectin
-/-
 4T1 tumor-bearing mice 
To determine whether L-selectin deficiency affects the tissue distribution of 
MDSC, advanced stage 4T1 tumor-bearing wild type and L-selectin
-/-
 mice were 
euthanized and bone marrow, thymus, blood, lung, liver, spleen, tumor, TDLN and 
contralateral non-draining lymph node (NDLN) were harvested. Single-cell suspensions 
of these tissues were immunolabeled for the MDSC markers CD11b, Ly-6G, and Ly-6C. 
The frequencies of PMN-MDSC (CD11b
+
Ly-6G
+
Ly-6C
low/-
) and M-MDSC (CD11b
+
Ly-
6G
-
Ly-6C
high
) were quantified by flow cytometry. Non-tumor bearing control wild type 
BALB/c mice were used to quantify the physiologic levels of conventional myeloid cells, 
which have similar expression of CD11b, Ly-6G, and Ly-6C, including CD11b
+
Ly-
6G
+
Ly-6C
low/-
 neutrophils and CD11b
+
Ly-6G
-
Ly-6C
high
 monocytes/macrophages. 
Overall, the presence of advanced stage 4T1 tumors correlated with increased MDSC 
frequencies and counts in all tested tissues from either wild type or L-selectin
-/-
 mice, 
compared to conventional myeloid cells in control healthy mice (Tables II and III, Fig. 
5). Specifically, in the bone marrow of either wild type or L-selectin
-/-
 tumor-bearing 
mice, the frequency of PMN-MDSC showed a modest but significant increase, compared 
to the frequency of polymorphonuclear myeloid cells in the healthy bone marrow, while 
the frequency of the monocytic myeloid subset remained the same (Table II, Fig. 5A). 
However, the total number of both MDSC subsets in bone marrow from tumor-bearing 
mice were increased by an average of 2.2-fold compared to the levels of 
polymorphonuclear and monocytic cells in healthy mice (Table III, Fig. 5B), correlating 
with an overall increase in bone marrow cellularity with tumor progression (Table VI, 
Fig. 5C). Similar to the results from the kinetics study of MDSC accumulation in blood, 
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there was an approximately 7.5-fold increase in PMN-MDSC frequency and a rather 
modest 1.5-fold increase in M-MDSC frequency in the blood of tumor-bearing wild type 
or L-selectin
-/-
 mice compared to the physiologic levels of polymorphonuclear and 
monocytic cells, respectively (Fig. 5A). The lung, a known site of 4T1 tumor metastasis, 
showed an approximately 12-fold increase in PMN-MDSC frequency while relatively 
little change in frequency of M-MDSC was found in either wild type or L-selectin
-/-
 
tumor bearing mice, compared to the corresponding conventional myeloid subsets in the 
healthy lungs (Fig. 5A). However, the number of both PMN-MDSC and M-MDSC were 
increased by approximately 37-fold and 6-fold, respectively (Fig. 5B) with a concomitant 
increase in total lung cellularity (Fig. 5C), likely due to the presence of metastatic burden 
(visual observations). The liver, another typical 4T1 metastatic site, as well as a major 
site of hematopoiesis during fetal development, also exhibited increased myeloid cell 
frequency: ~5.3-fold for PMN-MDSC and 3-fold for M-MDSC of either wild type or L-
selectin
-/-
 tumor-bearing mice. In the spleen, an average 7.7-fold increase in PMN-MDSC 
frequency and an average 3.3-fold increase in M-MDSC frequency was found in wild 
type and L-selectin
-/-
 mice with advanced stage 4T1 cancer (Fig. 5A). This result 
corresponded to dramatic 82-fold and 36-fold increases in cell numbers of PMN-MDSC 
and M-MDSC, respectively (Fig. 5B), that correlated with an ~11-fold increase in splenic 
cellularity during cancer progression (Fig. 5C). Advanced stage 4T1 tumors from either 
wild type or L-selectin
-/-
 mice contained similar frequencies of both PMN-MDSC and M-
MDSC (Fig. 5A) while the total number of each subset was increased by 2-fold and 3.7-
fold, respectively, in the L-selectin
-/-
 mice relative to wild type mice (Fig. 5B). This 
finding may, at least in part, be due to the increased tumor volume and cellularity in L-
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selectin
-/-
 mice at advanced time points after tumor injection (Figs. 3A and 5C). 
Interestingly, during cancer progression, the cellularity of the TDLN in wild type mice 
increased by 2.9-fold, while the contralateral NDLN retained a size typical of the inguinal 
PLN of a healthy control mouse (Fig. 5C). This increase may in part be due to immune 
activation in the TDLN, resulting in increased recruitment of lymphocytes from the 
bloodstream and subsequent proliferation, and/or in part due to the establishment and 
growth of tumor metastases within the TDLN. Importantly, the L-selectin
-/-
 TDLN did 
not significantly increase in cellularity, even in the late stage of 4T1 cancer, and relative 
to the corresponding tissue from wild type tumor-bearing mice, remained 9.9-fold smaller 
(Fig. 5C). In general, differences in numbers of MDSC subsets in the TDLN between 
wild type and L-selectin
-/-
 tumor-bearing mice correlated with tissue cellularity. 
Specifically, numbers of PMN-MDSC and M-MDSC were reduced by 3.3-fold and 6.5-
fold, respectively, in the TDLN of L-selectin
-/-
 tumor-bearing mice relative to wild type 
controls (Fig. 5B). Thus, the 4T1 tumor-driven accumulation of MDSC in the blood, 
spleen, lung, and liver was similar between wild type and L-selectin
-/-
 mice. However, 
advanced stage 4T1 tumors of L-selectin
-/-
 mice were bigger and accumulated more 
MDSC compared to similar stage 4T1 tumors of wild type mice. By contrast, TDLN of 
L-selectin
-/-
 mice were smaller and accumulated fewer MDSC compared to TDLN of 
wild type mice.  
Surprisingly, while the PMN-MDSC were much more abundant than M-MDSC in 
most tested tissues from tumor-bearing wild type or L-selectin
-/-
 mice, both the 
frequencies and numbers of PMN-MDSC and M-MDSC were equivalent in the TDLN 
from these mice (Fig. 5A and 5B). To emphasize this difference, the ratio between the 
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frequencies of M-MDSC and PMN-MDSC (M-MDSC/PMN-MDSC ratio) for each 
tested tissue was plotted and compared to the M-MDSC/PMN-MDSC ratio in the 
circulation (Fig. 6). Relative to blood, there was a small but statistically significant 
increase in the M-MDSC/PMN-MDSC ratio in bone marrow and spleen of both wild type 
and L-selectin
-/-
 tumor-bearing mice. The increase was more prominent in lung and liver, 
though due to greater sample variability, it remained statistically non-significant in the 
lung of L-selectin
-/-
 mice. Importantly, the increase in M-MDSC/PMN-MDSC ratio was 
greatest in the TDLN and NDLN of wild type mice. It is of further importance that 
relative to wild type, this ratio was dramatically decreased, by 6.4-fold, in the NDLN of 
L-selectin
-/-
 mice. However, in the TDLN, the decrease in M-MDSC/PMN-MDSC ratio 
as a result of L-selectin deficiency was more modest, 2.4-fold, and only approached 
significance with a p value of 0.1. 
MDSC from the spleen of 4T1 tumor-bearing mice suppress T cell proliferation in a 
dose-dependent manner 
MDSC were thus far identified based on their phenotypic expression of the 
markers CD11b, Ly-6G, and Ly-6C. To further confirm the suppressive identity of these 
cells, we tested their ability to suppress antigen-induced T cell proliferation in vitro. In a 
mixed lymphocyte reaction, sorted MDSC from spleens of advanced stage tumor-bearing 
mice were added at different ratios relative to the number of responder T cells. The 
proliferation of the responder T cells was quantified with the CFSE dilution method using 
flow cytometry. With this technique, each cell division causes the fluorescence intensity 
of the CFSE-labeled cells to drop by 50% and the CD4
+
 and CD8
+
 subsets of responder T 
cells with decreased CFSE fluorescence can be enumerated. In the absence of antigen 
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stimulation delivered by allogeneic stimulator cells (negative control), there was 
negligent CFSE dilution among the responder T cell populations (Fig. 7). In contrast, the 
addition of stimulator cells (positive control) caused a 66-fold and 14-fold increase in 
divided CD4
+
 and CD8
+
 T cells, respectively. As expected, the addition of MDSC caused 
a dose-dependent decrease in responder T cell proliferation. Specifically, the inhibition of 
proliferation was strongest (by 70 to 93%) when MDSC were half as abundant as the 
responder T cells (MDSC/T cell responders ratio = 1:2) while at a MDSC/T cell ratio of 
1:16, there was virtually no decrease in T cell proliferation. Thus, the combined addition 
of CD11b
+
Ly-6G
+
Ly-6C
low
 PMN-MDSC and CD11b
+
Ly-6G
-
Ly-6C
high
 M-MDSC 
suppressed T cell proliferation in response to alloantigens in a dose-dependent manner, 
functionally confirming the identity of these cells as an immunosuppressive population. 
Splenic MDSC localize in the red pulp, while MDSC in the TDLN localize near 
boundaries between T cell regions and B cell follicles. 
Studies of MDSC biology rarely address the location of these cells within tissues 
of interest. Considering the nature of the immunosuppressive mechanisms of these cells 
and their dependence on target cell proximity, it was of interest to visualize the 
localization of MDSC within the lymphoid tissue architecture of the spleen and TDLN, as 
well as in the tumor microenvironment. Spleen and TDLN sections were labeled with 
antibodies against CD11b, Ly-6G, and Ly-6C to identify the CD11b
+
Ly-6G
+
Ly-6C
low
 
PMN-MDSC and the CD11b
+
Ly-6G
-
Ly-6C
hi
 M-MDSC, and with antibodies against 
Thy1.2 to identify T cell zones and IgD to identify B cell follicles. Consistent with a 
previous observation of MDSC localization in the splenic red pulp (205), we observed a 
profound exclusion of both MDSC subsets from the T cell zones and B cell follicles in 
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the spleen (Fig. 8). Visually, the M-MDSC/PMN-MDSC ratio in the labeled spleen 
sections appeared similar to that determined with flow cytometry. 
MDSC in the TDLN sections were rare events and the abundance of M-MDSC 
was similar to that of PMN-MDSC, thus confirming the flow cytometry results. Relative 
to T cell zones or B cell follicles, there was no clear preference for localization of either 
PMN-MDSC (Fig. 9) or M-MDSC (Fig. 10). Individual PMN-MDSC were occasionally 
found within either T cell or B cell zones, but more often a group of several PMN-MDSC 
together with M-MDSC were found near boundaries between T cell and B cell zones. Of 
note, in addition to CD11b
+
Ly-6G
-
Ly-6C
hi
 M-MDSC, there were other Ly-6C
+
 cells 
detected in the tumor-draining lymph node, and to a lesser extent in the spleen, which 
were localized primarily in the T cell regions. These cells did not express the myeloid 
marker CD11b and were thus not identified as M-MDSC. In addition to myeloid cells, the 
Ly-6C marker is expressed by subsets of memory lymphocytes, as well as some plasma, 
NK, and endothelial cells (212-215). Indeed, the majority of the CD11b
-
Ly-6C
+
 cells also 
expressed Thy1.2, suggesting a memory T lymphocyte identity, and some Ly-6C 
labeling, showed blood vessel morphology. Taken together these results show no strong 
preference for co-localization of MDSC with T cell regions or B cell follicles in the 
spleen and TDLN.  
Tumor-infiltrating MDSC aggregate next to areas of hypoxia. 
Tumors do not have the distinct lymphoid architecture as found in the spleen and 
lymph nodes, but a hallmark of solid tumors are areas of low oxygen tension (hypoxia) 
due to insufficient blood supply. Tissue oxygenation, or lack thereof, is emerging as a 
major regulator of tumor progression, as it generates intracellular signals that modulate 
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tumor cell metabolism, increase the metastatic potential of tumor cells, trigger the 
formation of new blood vessels feeding the tumor, thus leading to a more aggressive 
tumor phenotype (216). We used hypoxia as a marker of tumor tissue architecture in the 
MDSC localization experiments. Low oxygen tension within tumors was indirectly 
detected by binding of the intraperitoneally injected cell permeable chemical 
pimonidazole·HCl to exposed thiol groups in the structure of proteins and peptides. Due 
to the reduction of protein disulfide bonds in hypoxic conditions, regions of low oxygen 
tension contain more thiol groups and retain the bound pimonidazole, which is then 
detected by antibody labeling. The relative abundance of M-MDSC and PMN-MDSC 
confirmed the expectations based on the flow cytometry results. In addition, PMN-
MDSC and M-MDSC were not uniformly distributed within the tumor but rather were 
localized together forming aggregates with only a few individual cells being observed 
around the aggregates. Interestingly these MDSC clusters were often localized 
immediately next to areas of hypoxia. 
PMN-MDSC are detected in the thymus of mice with advanced stage 4T1 tumors 
 MDSC suppress the function of mature T cells after their release from the thymus. 
To the best of our knowledge, there are no reports of MDSC-mediated effects on T cell 
maturation in the thymus. Considering the large accumulation of MDSC in mice with 
advanced stage tumors, we asked whether MDSC are also detectable in the thymus. Of 
the two major MDSC subsets, PMN-MDSC were detected with both flow cytometry and 
fluorescence microscopy, albeit in low numbers, in the thymus of tumor-bearing mice 
(Fig. 12). M-MDSC were also detected with flow cytometry in a quantity statistically 
greater than that of conventional monocytic cells in healthy mice. However, the numbers 
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of M-MDSC were so low that these cells were virtually undetectable in tissue sections, 
and thus are unlikely to have much functional significance in the thymus. In addition to 
the observed PMN-MDSC presence in the thymus, advanced 4T1 tumors also correlated 
with a decrease in overall thymus cellularity and a trending decrease in the number of 
double positive (CD4
+
CD8
+
) thymocytes (p value = 0.16) relative to the healthy controls. 
It remains unclear whether PMN-MDSC in the thymus contribute to these effects or 
interfere in any way with T cell maturation. 
MDSC generated in mice with 4T1 tumors express folate receptor β (FRβ): potential 
use of FR-targeted therapies for MDSC elimination? 
 The high-affinity folate receptor alpha (FRα) has limited expression on healthy 
epithelia, but is overexpressed in a large number of cancers (217, 218). Therefore, FR-
targeting strategies using folate or anti-FR antibody as the targeting ligand have been 
pursued as methods for tumor-specific drug or imaging agent delivery, hyper-thermal or 
mechanical destruction of tumor cells, as well as for visualization of primary and 
metastatic tumors for improved surgical removal (217, 219-224). On the other hand, the 
beta isoform of FR (FRβ) is expressed on some myeloid cells, including myeloid 
leukemias (225-227), but reportedly is only functional on activated macrophages (227, 
228). We asked whether MDSC, as immature myeloid lineage cells, express FRβ, 
providing potential for the therapeutic elimination of these immunosuppressor cells in 
cancer. Blood and spleen cells from late-stage 4T1-bearing mice were immunolabeled 
against FRβ and the MDSC markers CD11b, Ly-6G, and Ly-6C, and analyzed with flow 
cytometry. Both PMN-MDSC and M-MDSC from spleen and blood expressed 
comparable levels of FRβ (Fig. 13). Whether FRβ expressed on MDSC is capable of 
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binding and internalizing folate remains to be determined. It is of further interest to 
determine whether FRβ is also expressed on MDSC in patients with various cancers, thus 
serving as a potential target for the selective elimination of MDSC to alleviate 
immunosuppression and increase the patient’s anti-tumor immune response.  
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DISCUSSION 
CTL can kill tumor cells upon contact and are the most potent effectors in the 
anti-tumor immune response. To acquire tumor cytolytic ability, CTL must be first 
activated by appropriate exposure to tumor antigens in the context of co-stimulation, a 
process that occurs in the TDLN. Thus, the ability of T cells to enter TDLN is vital for 
the efficient generation of an anti-tumor immune response. As evidenced from studies 
with L-selectin
-/-
 mice or blocking antibodies, L-selectin is critical for the homing of 
circulating naïve lymphocytes to PLN. In addition, L-selectin plays an important role in 
the migration of myeloid cells, such as neutrophils and monocytes, to sites of 
inflammation. These effects of leukocyte-expressed L-selectin are mediated via 
interactions with its ligands on the vascular endothelium, which are constitutively 
expressed on HEV in PLN and upregulated in post-capillary venules near inflammatory 
sites. 
Tumor growth is associated with the release of soluble factors that drive the 
generation and accumulation of immunosuppressive MDSC, which enhance tumor 
progression via multiple mechanisms. Importantly, MDSC inhibit CTL activation in the 
TDLN and CTL function in the tumor. Thus the ability of MDSC to enter TDLN and the 
tumor may be critical for suppression of the anti-tumor response. This warrants further 
investigation of the mechanisms of MDSC migration to tumors and TDLN. The role of 
L-selectin in leukocyte migration to PLN and sites of inflammation has been 
characterized for lymphocytes and conventional myeloid cells, but its contribution to 
MDSC migration is unknown. 
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L-selectin
-/-
 mice have been generated to study L-selectin function (92). Hallmark 
characteristics of these mice include inhibition of lymphocyte homing to PLN resulting in 
dramatically decreased PLN cellularity, as well as inhibition of neutrophil recruitment to 
sites of inflammation resulting in the alleviation of inflammation-induced tissue damage. 
In light of these observations, in the context of tumor progression, decreased MDSC 
abundance tumors and TDLN of L-selectin
-/-
 mice relative to wild type may be a sign of 
impaired MDSC migration to these tissues due to lack of L-selectin expression. However, 
contribution of other factors such as differential MDSC survival or egress from these 
tissues cannot be excluded. More direct evidence of the contribution of L-selectin in 
MDSC migration can be gained from adoptive transfer of cell tracker-labeled wild type 
or L-selectin
-/-
 MDSC into the circulation of tumor-bearing mice, followed by 
enumeration of the labeled MDSC in the tumor and TDLN shortly thereafter. This time-
restricted approach minimizes the cumulative possible contribution of differential MDSC 
survival or egress on the abundance of tumor- or TDLN-resident MDSC. Thus any 
differences in the number of tracker-labeled wild type vs. L-selectin
-/-
 MDSC in the 
tumor or TDLN would be primarily the result of altered MDSC migration to these sites. 
With this experimental design in mind, we sought to compare tumor progression 
and MDSC accumulation in wild type and L-selectin
-/-
 mice and to validate a model 
system, in which tumor-bearing wild type and L-selectin
-/-
 mice would be equivalent 
MDSC sources for adoptive transfer experiments, except for the lack of L-selectin on 
MDSC from L-selectin
-/-
 mice. We used the 4T1 transplantable murine breast cancer 
model, which is widely used as a model for stage IV human metastatic breast cancer. We 
observed similar tumor growth rates and kinetics of tumor-induced PMN-MDSC and M-
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MDSC accumulation in wild type vs. L-selectin
-/-
 mice (Fig. 3). We also confirmed the 
expression of L-selectin on PMN-MDSC and M-MDSC (Fig. 4). We further quantified 
the accumulation of these subsets in various tissues in wild type and L-selectin
-/-
 mice 
(Fig. 5) and examined their localization within the spleen (Fig. 8), TDLN (Fig. 9, 10), 
and tumor (Fig. 11). Interestingly, we were able to detect low levels of PMN-MDSC in 
the thymus, which correlated with a decreased thymic cellularity and a tendency for a 
decrease in CD4
+
CD8
+
 double positive thymocytes (Fig. 12). On a different note, we 
showed expression of FRβ on both MDSC subsets (Fig. 13), which may provide a 
potential strategy for the targeted elimination of MDSC. 
Small, but statistically significant acceleration of tumor growth was observed in 
L-selectin
-/-
 mice relative to wild type (Fig. 3A). It can be speculated that a lack of L-
selectin expression, via inhibiting T cell migration to TDLN, would decrease the anti-
tumor T cell activation, ultimately resulting in faster tumor growth. However, this 
putative pro-tumor effect of decreased T cell access to TDLN may have little significance 
in the context of an inherently aggressive cancer such as the 4T1. In addition, this effect 
may be further negated by decreased migration of L-selectin
-/-
  immunosuppressive cells, 
such as regulatory T cells or MDSC to the TDLN or to the tumor, thus alleviating 
immunosuppression at these sites in L-selectin
-/-
 mice. Therefore, the finding that L-
selectin expression has some contribution in the control of tumor growth is not surprising, 
but likely has little functional significance, at least in this model system. 
MDSC generation is driven by tumor-derived soluble factors and MDSC 
accumulation correlates with tumor burden. This well established fact was extended to L-
selectin
-/-
 mice with 4T1 tumors. As expected, both wild type and L-selectin
-/-
 mice 
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exhibited a dramatic increase in circulating MDSC numbers, which correlated with tumor 
burden. In addition, the small increase in tumor growth rate in L-selectin
-/-
 mice was not 
sufficient to cause a statistically significant increase in the rate of MDSC accumulation in 
the blood of L-selectin
-/-
 mice relative to wild type (Fig. 3C).  
MDSC do not only accumulate in the blood. Many studies have shown a dramatic 
accumulation of MDSC in the spleen during tumor progression and other inflammatory 
pathologies. In the spleen of 4T1 tumor-bearing wild type mice, there were 88-fold more 
PMN-MDSC and 35-fold more M-MDSC compared to conventional polymorphonuclear 
and monocytic myeloid cells in healthy mice, respectively (Fig. 5). In the L-selectin
-/-
 
tumor-bearing mice, the increase was 76-fold and 37-fold, respectively, not statistically 
different from that observed in wild type mice. For comparison, the increase in blood 
averaged to 156-fold and 24-fold for PMN-MDSC and M-MDSC, respectively (Fig. 3C). 
The spleen is important for removal of aged or damaged red blood cells from the 
circulation and also plays a role in the immune surveillance against blood-borne 
pathogens. For these functions, the spleen must filter the blood very efficiently and is 
equipped with sinusoids with large fenestrations that allow easier entry of cells into the 
tissue. It is possible that the splenic accumulation of MDSC, paralleling the increase in 
blood-borne MDSC numbers, is merely the result of blood filtration through the spleen. 
Thus, it was not surprising that splenic MDSC localized largely in the red pulp that is rich 
in sinusoids (Fig. 8). In addition, the liver, another organ rich in sinusoids is also a site of 
preferential MDSC homing and accumulation in cancer, irrespective of liver metastasis 
(229). In agreement, we observed an increased frequency of PMN-MDSC and M-MDSC 
in the liver. Interestingly, during cancer progression there are increased numbers of 
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clonogenic myeloid progenitors in the spleen and liver, suggestive of a role of these 
organs in supporting extramedullary hematopoiesis and thus contributing to MDSC 
accumulation (229, 230). 
Regardless of the mechanism of MDSC accumulation in the spleen, the organ is a 
convenient and commonly used experimental source of large numbers of cancer-induced 
MDSC in mice. Its cellularity is dramatically increased in late stages of cancer, it is easily 
dissociated to single cells without the need for enzymatic digestion, and immunolabeling 
gives clean and unambiguous identification of leukocyte subsets with flow cytometry. All 
these factors made it the source of choice for large numbers of MDSC for further sorting 
or adoptive transfer into recipient mice. In addition, our data showed that splenic PMN-
MDSC and M-MDSC expressed similar levels of L-selectin as the corresponding blood-
borne MDSC, further validating this organ as a source of MDSC for the study of L-
selectin function.  
Interestingly, for efficient L-selectin detection in blood samples from mice with 
advanced 4T1 tumors, the blood had to be washed with an excess volume of PBS to 
remove soluble plasma proteins. Various inflammatory conditions are characterized by 
elevated soluble L-selectin (sL-selectin) in the bloodstream, generated by endoproteolytic 
cleavage of membrane-bound L-selectin upon leukocyte activation. High levels of sL-
selectin in the test samples would block antibody labeling of membrane-bound L-selectin 
due to competitive binding to the anti-L-selectin antibody. Thus, the requirement for 
removal of soluble plasma proteins for efficient immunolabeling of L-selectin on 
leukocytes suggests high levels of sL-selectin in the blood of wild type mice with 
advanced 4T1 tumors. A functional significance of sL-selectin during inflammation 
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comes from its ability to compete against membrane-bound L-selectin for endothelial 
binding partners, thus interfering with L-selectin-dependent leukocyte adhesion and 
migration (82, 231). Thus, sL-selectin may serve as a regulatory mechanism to tune down 
over-activated immune responses (66). The protease that cleaves membrane-bound L-
selectin is the cell surface-expressed ADAM17, which functions in a cis manner, cleaving 
L-selectin expressed by the same cell (232, 233). Importantly, ADAM17 is expressed on 
MDSC and it has been suggested that MDSC-expressed ADAM17 cleaves T cell-
expressed L-selectin, thus inhibiting T cell homing to the TDLN and providing yet 
another mechanism of MDSC-mediated suppression of the anti-tumor T cell response 
(234). While such a trans mechanism of action may be controversial, it is likely that 
MDSC-expressed ADAM17 cleaves MDSC-expressed L-selectin in a cis manner and 
contributes to the high circulating sL-selectin levels.  Given this, the relatively high and 
uniform expression of L-selectin observed on the surface of both MDSC subsets is 
unexpected (Fig. 4). Thus, MDSC-expressed ADAM17 may indirectly inhibit T cell 
homing to the TDLN and contribute to the suppression of the anti-tumor T cell response. 
Interestingly, a role of L-selectin in MDSC migration to TDLN was suggested by 
decreased numbers of MDSC in the TDLN of L-selectin
-/-
 mice relative to wild type (Fig. 
5B). On the other hand, the opposite effect was observed in the tumor: at least in part due 
to an increased tumor burden, there were increased MDSC numbers in the tumor of L-
selectin
-/-
 mice, suggesting that L-selectin may not be required for MDSC migration to 
the tumor. Furthermore, L-selectin influenced the ratio between the numbers of M-
MDSC and PMN-MDSC in the lymph nodes (Fig. 6). Specifically, L-selectin expression 
favored a M-MDSC/PMN-MDSC ratio in NDLN that was 17-fold higher than in blood, 
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while loss of L-selectin expression completely eliminated this effect. For TDLN, L-
selectin expression was associated with a 26-fold higher M-MDSC/PMN-MDSC ratio 
relative to the bloodstream, while L-selectin deficiency reduced this effect by greater than 
60%. These results hint at a more efficient migration of M-MDSC from the blood to PLN 
compared to PMN-MDSC, but factors such as enhanced M-MDSC survival or greater 
PMN-MDSC egress from PLN cannot be excluded as contributors to the high M-
MDSC/PMN-MDSC ratio in PLN. In addition, L-selectin may have a greater impact on 
M-MDSC migration to PLN relative to PMN-MDSC. This could be due to higher L-
selectin expression levels on M-MDSC than PMN-MDSC, as indicated by the higher 
fluorescence intensities observed by flow cytometry (Fig. 4). Furthermore, other adhesion 
molecules, preferentially expressed on M-MDSC that synergize with L-selectin could 
also contribute. On the other hand, L-selectin deficiency alters the cellular composition of 
the PLN, thus possibly affecting chemokine production and recruitment of other 
leukocytes. Therefore, to conclusively address the involvement of L-selectin in MDSC 
migration to PLN, a more direct approach is necessary. Here, we validated a model 
system, in which tumor-bearing wild type and L-selectin
-/-
 mice can be used as MDSC 
sources for adoptive transfer experiments for the study of L-selectin involvement in 
MDSC migration.  
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FIGURE LEGENDS 
Figure 3. The kinetics of systemic MDSC accumulation correlate with tumor growth 
rate. 
Wild type and L-selectin
-/-
 mice were injected s.c. in the mammary fat pad with 
10
4
 4T1 cells. Total numbers of each MDSC subset were calculated from the leukocyte 
count. A) At weeks 1, 2, 3, 4, and 5 after 4T1 cell injection, the tumor volumes were 
determined with caliper measurements using the formula V = (L x W
2
)/ 2, where W 
(width) is the short tumor axis and L (length) is the long tumor axis. *p<0.05 vs. wild 
type at each indicated time point. Results are from 22-165 independent experiments per 
genotype per time point. B), C) At weeks 1, 2, 3, 4, and 5 after tumor induction, blood 
was collected from the retro-orbital sinus and the leukocyte concentration was 
determined. The blood was labeled with anti-CD11b, anti-Ly-6G, and anti-Ly-6C 
antibodies and the frequencies of CD11b
+
Ly6G
-
Ly6C
high
 M-MDSC and 
CD11b
+
Ly6G
+
Ly6C
low
 PMN-MDSC were determined with flow cytometry (B), and 
PMN-MDSC and M-MDSC numbers were calculated (C). Results are from 4-11 
independent experiments per genotype per time point. 
Figure 4. PMN-MDSC and M-MDSC from spleen and blood of 4T1 tumor-bearing 
mice express L-selectin. 
A) Spleen cells from advanced stage 4T1 tumor-bearing BALB/c mice were 
labeled with FITC-conjugated anti-CD11b, PE-conjugated anti-Ly-6G, PE/Cy7-
conjugated anti-Ly-6C and biotinylated anti-L-selectin (detected with avidin-APC) 
antibodies. The expression level of L-selectin by CD11b
+
Ly6G
+
Ly-6C
low
 PMN-MDSC 
and CD11b
+
Ly-6G
-
Ly-6C
high
 M-MDSC was determined with flow cytometry using 
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constant voltage settings between experiments. FACS histogram plots (left) are 
representative of 4 experiments with solid lines showing L-selectin expression levels on 
PMN-MDSC or M-MDSC and dashed lines showing isotype control labeling. The bar 
graph (right) represents the mean relative fluorescence intensity of L-selectin-labeled 
PMN-MDSC and M-MDSC. *p<0.05 vs. PMN-MDSC. 
B) Blood was collected from the retro-orbital sinus from advanced stage 4T1 
tumor-bearing mice using a heparinized Pasteur pipette. After a wash in excess PBS or 
without washing, the blood was labeled as above and L-selectin expression was 
determined with flow cytometry. Solid lines represent L-selectin labeling on PMN-
MDSC or M-MDSC in washed blood (bold solid line) or non-washed blood (thin solid 
line); dashed line represents the negative control. Histogram plots (left) are representative 
of a minimum of 3 independent experiments. The bar graph (right) represents the mean 
relative fluorescence intensity of L-selectin-labeled PMN-MDSC and M-MDSC from 
washed blood samples. 
Figure 5. MDSC accumulation in tissues of wild type and L-selectin
-/-
 mice with 
advanced stage 4T1 tumors. 
Wild type (WT) or L-selectin
-/-
 mice were injected s.c. in the mammary fat pad 
with 10
4
 4T1 cells in supplement-free RPMI. Supplement-free RPMI alone was injected 
in the contra-lateral fat pad and served as an internal vehicle control. After 4-5 weeks, 
mice were sacrificed and the indicated tissues collected. TDLN were the inguinal PLN 
next to the site of 4T1 injection, while NDLN were the contralateral inguinal PLN next to 
the vehicle injection site. Single-cell suspensions were immunolabeled against CD11b, 
Ly-6G, and Ly-6C to quantify PMN-MDSC and M-MDSC. Conventional 
 76 
 
polymorphonuclear and monocytic myeloid cells from control WT mice without tumors 
were quantified for comparison. Frequencies (A) and total numbers (B) of 
CD11b
+
Ly6G
+
Ly-6C
low
 polymorphonuclear and CD11b
+
Ly-6G
-
Ly-6C
high
 monocytic 
cells were determined with flow cytometry. Tissue cellularities (C) were determined 
using a hemocytometer. *p<0.05 vs. PMN-MDSC (A and B) or p<0.05 vs. control (C); 
†
p<0.05 vs. WT. Results are from 3-10 independent experiments per genotype per tissue. 
Figure 6. High M-MDSC/PMN-MDSC ratio in PLN of mice with advanced stage 
4T1 tumors is dependent on L-selectin expression. 
The M-MDSC/PMN-MDSC ratio in the blood and various tissues from tumor-
bearing mice was calculated from the data shown in figure 5. Dashed line represents 
equal abundance of M-MDSC and PMN-MDSC; BM, bone marrow; *p<0.05 vs. wild 
type. Results are from 5-14 independent experiments per genotype per tissue. 
Figure 7. MDSC from spleen of 4T1 tumor-bearing mice suppress T cell 
proliferation in a dose-dependent manner. 
MDSC were sorted from the spleens of advanced stage 4T1 tumor-bearing 
BALB/c mice and their ability to suppress T cell proliferation was tested in a mixed 
lymphocyte reaction in a 96-well plate format. The responder cells (10
5
 per well) were 
spleen cells from a non-tumor-bearing BALB/c mouse, labeled with CFSE to detect 
proliferation. Stimulator cells (10
5
 per well) were spleen cells from a C57BL/6 mouse, 
pretreated with mitomycin C to prevent proliferation. The frequency of T cells within the 
responder spleen cell population was determined with flow cytometry and sorted MDSC 
were added to the wells at various ratios relative to the responder T cells. Negative 
control was responders incubated alone and positive control was stimulators co-incubated 
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with responders without added MDSC. Triplicate wells for each combination were 
cultured for 4 days, pooled, and labeled with anti-CD4 and anti-CD8 antibodies. Flow 
cytometric analysis was done by collecting data for the whole sample. A) Events with 
high forward light scatter (FSC) were analyzed to enumerate proliferated CFSE
low
 CD4
+
 
and CFSE
low
 CD8
+
 T cells in each well. Negative control – responder spleen cells 
cultured without stimulator cells or MDSC; positive control – responder cells cultured 
with stimulator cells, but without MDSC; 1:1 through 1:64 – MDSC/T cell responder 
ratios, responder cells were cultured with stimulator cells and decreasing numbers of 
MDSC; CFSE
low
 gate indicates CFSE
low
 CD4
+
 T cell population; numbers next to the 
gate indicate total counts of CFSE
low
 CD4
+
 T cells. B) The total counts of CFSE
low
 CD4
+
 
and CFSE
low
 CD8
+
 T cells were plotted. Data represent the results from one of two 
independent experiments. 
Figure 8. Localization of MDSC in the spleen of advanced stage 4T1 tumor-bearing 
mice. 
Spleens were harvested from advanced stage (4-5 weeks) 4T1 tumor-bearing wild 
type mice. Cryosections were immunolabeled against the pan T cell marker Thy1.2, the 
pan B cell marker IgD, and the MDSC markers CD11b, Ly-6G, and Ly-6C. The sections 
were analyzed with fluorescence microscopy. Digital monochromatic images were 
acquired at a constant exposure, and pseudocolored and overlaid using MetaVue™ 
software. Overlays include Ly-6G (green), Ly-6C (red), Thy1.2 (magenta) and IgD 
(blue). CD11b was expressed by Ly-6G
+
Ly-6C
low/- 
and Ly-6G
-
Ly-6C
high
 cells, but was 
not included in overlays for the sake of clarity. Thus, representative images are of 
CD11b
+
Ly-6G
+
Ly-6C
low/-
 PMN-MDSC (yellow arrowheads in inset) and CD11b
+
Ly-6G
-
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Ly-6C
high
 M-MDSC (white arrows in inset), relative to T cell zones (magenta) and B cell 
follicles (blue). Scale bar (50 μm) is for all images. Images are representative of 3 
independent experiments. 
Figure 9. Localization of PMN-MDSC in the TDLN of advanced stage 4T1 tumor-
bearing mice. 
Spleens were harvested from advanced stage (4-5 weeks) 4T1 tumor-bearing wild 
type mice. Cryosections were immunolabeled against the T cell marker Thy1.2, the B cell 
marker IgD, and the MDSC markers CD11b, Ly-6G, and Ly-6C. The sections were 
analyzed with fluorescence microscopy. Digital monochromatic images were acquired at 
a constant exposure, and pseudocolored and overlaid using MetaVue™ software. 
Representative images are of cells co-expressing Ly-6G (green) and CD11b, but no to 
low levels of Ly-6C, relative to T cell zones (Thy1.2, red) and B cell follicles (IgD, blue). 
CD11b and Ly-6C are not included in overlays for the sake of clarity Arrows point to 
some of the CD11b
+
Ly-6G
+
 Ly-6C
low/-
 cells. Scale bar (50 μm) is for all images. Images 
are representative of 3 independent experiments. 
Figure 10. Localization of M-MDSC in the TDLN of advanced stage 4T1 tumor-
bearing mice. 
TDLN were harvested from advanced stage (4-5 weeks) 4T1 tumor-bearing wild 
type mice. Cryosections were immunolabeled against the T cell marker Thy1.2, the B cell 
marker IgD, and the MDSC markers CD11b, Ly-6G, and Ly-6C. The sections were 
analysed with fluorescence microscopy. Digital monochromatic images were acquired at 
a constant exposure, and pseudocolored and overlaid using MetaVue™ software. 
Representative images are of cells expressing CD11b and high levels of Ly-6C (green), 
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but no Ly-6G, relative to T cell zones (Thy1.2, red) and B cell follicles (IgD, blue). 
CD11b and Ly-6G are not included in overlays for the sake of clarity. Arrows point to 
some of the CD11b
+
Ly-6G
+
 Ly-6C
low/-
 cells. Scale bar (50 μm) is for all images. Images 
are representative of 3 independent experiments. 
Figure 11. Localization of MDSC in advanced stage 4T1 tumors 
To visualize hypoxic regions within the tumor microenvironment, mice with 
advanced stage (4-5 weeks) 4T1 tumors were injected with pimonidazole·HCl 1 h prior 
to euthanasia. Cryosections of tumors were labeled with antibodies against pimonidazole 
and the MDSC markers CD11b, Ly-6G and Ly-6C. The sections were analyzed with 
fluorescence microscopy. Digital monochromatic images were acquired at a constant 
exposure, and pseudocolored and overlaid using MetaVue™ software. Overlays include 
Ly-6G (green), Ly-6C (red), and pimonidazole (blue). CD11b was expressed by Ly-
6G
+
Ly-6C
low/- 
and Ly-6G
-
Ly-6C
high
 cells, but was not included in overlays for the sake of 
clarity. Thus, representative images are of CD11b
+
Ly-6G
+
Ly-6C
low/-
 PMN-MDSC 
(yellow arrowheads in inset) and CD11b
+
Ly-6G
-
Ly-6C
high
 M-MDSC (white arrows in 
inset), relative to hypoxic regions (blue). Scale bar (50 μm) is for all images. Images are 
representative of 3 independent experiments. 
Figure 12. PMN-MDSC are present in the thymus of advanced stage 4T1 tumor-
bearing mice. 
Thymus was collected from healthy or tumor-bearing wild type mice with 
advanced stage 4T1 tumors. A) Single-cell suspensions from thymi were immunolabeled 
against CD11b, Ly-6G, and Ly-6C to quantify polymorphonuclear (PMN) and monocytic 
(M) myeloid cells, or against CD4 and CD8 to quantify CD4
-
CD8
-
 double-negative 
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thymocytes (DN), CD4
+
CD8
+
 double-positive thymocytes (DP) and CD4
+
 and CD8
+
 
single-positive thymocytes with flow cytometry. Thymus cellularity was determined 
using a hemocytometer. *p<0.05 vs. healthy control, 
†
p<0.05 vs. PMN-MDSC. Results 
are from 3-12 independent experiments. B) Cryosections from thymi of wild type mice 
with advanced stage 4T1 tumors were labeled with antibodies against CD11b, Ly-6G, 
Ly-6C, CD4 and CD8. The sections were analyzed with fluorescence microscopy. Digital 
monochromatic images were acquired at a constant exposure, and pseudocolored and 
overlaid using MetaVue™ software. Overlays include Ly-6G (green), CD8 (red) and 
CD4 (blue). Ly-6G
+
 cells expressed CD11b, but no Ly-6C. CD11b and Ly-6C are not 
included in overlays for the sake of clarity. Thus, representative images are of 
CD11b
+
Ly-6G
+
Ly-6C
low/-
 PMN-MDSC (white arrows) relative to CD8
+
 thymocytes 
(red), CD4
+
 thymocytes (blue), and  CD4
+
CD8
+
 double-positive thymocytes (magenta 
resulting from the overlay of CD4 and CD8). Scale bar (50 μm) is for all images. Images 
are representative of 3 independent experiments. 
Figure 13. MDSC from 4T1 tumor-bearing mice express folate receptor β (FRβ). 
Blood and spleen were collected from mice with advanced stage (4-5 weeks) 4T1 
tumors. Spleen single-cell suspensions and blood were labeled with antibodies against 
CD11b, Ly-6G and Ly-6C and a rabbit anti-FRβ antibody, detected with AlexaFluor® 
647-conjugated goat anti-rabbit IgG antibody. The primary rabbit anti-FRβ antibody was 
omitted from the negative control. Solid lines represent FRβ labeling on PMN-MDSC or 
M-MDSC; dashed line is negative control. Histogram plots are representative of a 
minimum of 3 independent experiments. 
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Figure 4 
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Figure 5  
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              A.  FACS analysis of T cell proliferation (4 days MLR) 
 
              B. T cell proliferation (4 days MLR) 
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Table I. Tumor growth rate and kinetics of MDSC accumulation in 4T1 tumor-
bearing wild type and L-selectin
-/-
 mice
a
. 
 
a
Tumors were induced by a s.c. injection of 10
4
 4T1 cells in 50 μl supplement-free RPMI. 
Tumors were measured with calipers and the tumor volume was calculated according to 
the formula: (LxW
2
)/2, where L (length) is the long diameter and W (width) is the short 
Tumor volume (mm
3
)
Genotype Control (no tumor) 1 wk
b
 tumor 2 wk tumor
Wild type N/A 2.78 ± 0.36 41.25 ± 1.86
L-selectin
-/-
N/A 1.48 ± 0.35   53.21 ± 3.25*
Genotype 3 wk tumor 4 wk tumor 5 wk tumor
Wild type 154.68 ± 7.35 434.15 ± 19.37  830.48 ± 53.43
L-selectin
-/-
    227.24 ± 10.76*   493.91 ± 22.21* 1,120.08 ± 58.63*
# of PMN-MDSC (x10
-6
)/ml of blood
Genotype Control (no tumor) 1 wk tumor 2 wk tumor
Wild type 1.4 ± 0.2 1.7 ± 0.3 6.3 ± 0.9
L-selectin
-/-
1.2 ± 0.2 1.6 ± 0.1 4.7 ± 0.6
Genotype 3 wk tumor 4 wk tumor 5 wk tumor
Wild type 25.0 ± 3.9 111.3 ± 16.6 186.7 ± 21.3
L-selectin
-/-
30.0 ± 5.4 133.6 ± 14.5 219.0 ± 18.4
# of M-MDSC (x10
-6
)/ml of blood
Genotype Control (no tumor) 1 wk tumor 2 wk tumor
Wild type 0.53 ± 0.13 0.31 ± 0.04 0.75 ± 0.08
L-selectin
-/-
0.34 ± 0.08 0.24 ± 0.02 0.61 ± 0.05
Genotype 3 wk tumor 4 wk tumor 5 wk tumor
Wild type 1.95 ± 0.32 5.99 ± 0.71   8.84 ± 0.67
L-selectin
-/-
2.65 ± 0.53 7.65 ± 0.59 10.81 ± 0.87
Tumor volume (mm
3
)
Genotype Control (no tumor) 1 wk
b
 tumor 2 wk tumor
Wild type N/A 2.78 ± 0.36 41.25 ± 1.86
L-selectin
-/-
N/A 1.48 ± 0.35   53.21 ± 3.25*
Genotype 3 wk tumor 4 wk tumor 5 wk tumor
Wild type 154.68 ± 7.35 434.15 ± 19.37  8 0.48 ± 53.43
L-selectin
-/-
   227.24 ± 10.76*   493.91 ± 22.21* 1,120.08 ± 58.63*
# of PMN-MDSC (x10
-6
)/ml of blood
Genotype Control (no tumor) 1 wk tumor 2 wk tumor
Wild type 1.4 ± 0.2 1.7 ± 0.3 6.3 ± 0.9
L-selectin
-/-
1.2 ± 0.2 1.6 ± 0.1 4.7 ± 0.6
Genotype 3 wk tumor 4 wk tumor 5 wk tumor
Wild type 25.0 ± 3.9 111.3 ± 16.6 86.7 ± 21.3
L-selectin
-/-
30.0 ± 5.4 133.6 ± 14.5 219.0 ± 18.4
# of M-MDSC (x10
-6
)/ml of blood
Genotype Control (no tumor) 1 wk tumor 2 wk tumor
Wild type 0.53 ± 0.13 0.31 ± 0.04 0.75 ± 0.08
L-selectin
-/-
0.34 ± 0.08 0.24 ± 0.02 0.61 ± 0.05
Genotype 3 wk tumor 4 wk tumor 5 wk tumor
Wild type 1.95 ± 0.32 5.99 ± 0.71   8.84 ± 0.67
L-selectin
-/-
2.65 ± 0.53 7.65 ± 0.59 10.81 ± 0.87
-/-
-/-
-/-
-/-
-/-
-/-
Number
Number
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diameter of the tumor. At the indicated time points after tumor injection, blood was 
collected from the retro-orbital sinus. Leukocyte count was determined using a 
hemocytometer and the blood was labeled with antibodies against CD11b, Ly-6G, and 
Ly-6C. The frequencies of PMN-MDSC and M-MDSC were determined with flow 
cytometry and the counts of PMN-MDSC and M-MDSC per 1 ml of blood were 
calculated. *p<0.05 vs. wild type. Results are from 22-165 mice per genotype per time 
point for tumor growth rate and from 4-11 mice per genotype per time point for MDSC 
accumulation kinetics in the blood. 
b
Abbreviations used: wk, week(s); PMN-MDSC, polymorphonuclear myeloid-derived 
suppressor cell(s); M-MDSC, monocytic myeloid-derived suppressor cell(s). 
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Table II. Frequencies of MDSC subsets in tissues of wild type and L-selectin 
-/-
 mice 
with advanced stage 4T1 tumors
a
. 
 
 
a
Wild type or L-selectin
-/-
 BALB/c mice were injected s.c. in the mammary fat pad with 
10
4
 4T1 cells in supplement-free RPMI. Supplement-free RPMI alone was injected in the 
contra-lateral fat pad and served as an internal vehicle control. After 4-5 weeks, mice 
were sacrificed and the indicated tissues collected. TDLN was represented by the 
inguinal PLN next to the site of 4T1 injection, while NDLN was represented by the 
contralateral inguinal PLN next to the vehicle injection site. Single-cell suspensions were 
MDSC
b
 frequency
Genotype % PMN-MDSC % M-MDSC % PMN-MDSC % M-MDSC
Control 51.54 ± 4.04 6.28 ± 0.60
‡ 10.86 ± 1.91 3.10 ± 0.36
Wild type 63.06 ± 1.82* 7.78 ± 0.60
‡  84.12 ± 1.24*   4.68 ± 0.22*
‡
L-selectin
-/- 61.15 ± 1.96* 7.40 ± 0.29
‡  78.99 ± 4.22*   4.64 ± 0.49*
‡
Genotype % PMN-MDSC % M-MDSC % PMN-MDSC % M-MDSC
Control 3.92 ± 0.41 5.31 ± 2.58 5.41 ± 1.61 4.70 ± 1.88
Wild type 41.91 ± 7,49*  8.88 ± 0.91
‡ 26.84 ± 4.10*  13.68 ± 1.18*
‡
L-selectin
-/- 53.09 ± 9.06*  8.37 ± 1.53
‡ 30.13 ±4.98*  14.11 ± 3.99*
‡
Genotype % PMN-MDSC % M-MDSC % PMN-MDSC % M-MDSC
Control 4.63 ± 1.21 1.37 ± 0.06
‡ N/A N/A
Wild type 36.12 ± 4.30*   4.30 ± 0.63*
‡ 7.46 ± 1.62  0.54 ± 0.20
‡
L-selectin
-/- 35.00 ± 4.73*   4.79 ± 0.67*
‡ 5.90 ± 0.99  0.90 ± 0.21
‡
Genotype % PMN-MDSC % M-MDSC % PMN-MDSC % M-MDSC
Control 0,06 ± 0.02 0.06 ± 0.03 0,06 ± 0.02 0.06 ± 0.03
Wild type   0.59 ± 0.11*   0.56 ± 0.12*   0.70 ± 0.32*  0.35 ± 0.07*
L-selectin
-/-
   1.51 ± 0.45*
†   0.81 ± 0.20*     2.45 ± 0.41*
†
   0.42 ± 0.13*
‡
TDLN NDLN
BONE MARROW
LUNG
SPLEEN
BLOOD
LIVER
TUMOR
*
*
*
. *
*
. .
† †
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immunolabeled against CD11b, Ly-6G, and Ly-6C to quantify PMN-MDSC and M-
MDSC. Conventional polymorphonuclear and monocytic myeloid cells from control wild 
type mice without tumors were also labeled for comparison. Cells suspensions were 
counted using a hemacytometer. Frequencies of CD11b
+
Ly6G
+
Ly-6C
low/-
 
polymorphonuclear and CD11b
+
Ly-6G
-
Ly-6C
high
 monocytic cells were determined with 
flow cytometry. *p<0.05 vs. PMN-MDSC, 
†
p<0.05 vs. tumor-bearing wild type. Results 
are from 3-10 mice per genotype per tissue. 
b
Abbreviations used: MDSC, myeloid-derived suppressor cell(s); PMN-MDSC, 
polymorphonuclear myeloid-derived suppressor cell(s); M-MDSC, monocytic myeloid-
derived suppressor cell(s); TDLN, tumor-draining lymph node(s); NDLN, non-draining 
lymph node(s). 
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Table III. Numbers of MDSC subsets in tissues of wild type and L-selectin 
-/-
 mice 
with advanced stage 4T1 tumors
a
. 
 
a
Tumors were induced in wild type or L-selectin
-/-
 mice and antibody labeling was 
performed as described for Table II. The number of CD11b
+
Ly6G
+
Ly-6C
low/-
 
polymorphonuclear and CD11b
+
Ly-6G
-
Ly-6C
high
 monocytic cells were determined with 
flow cytometry. *p<0.05 vs. PMN-MDSC, 
†
p<0.05 vs. tumor-bearing wild type. Results 
are from 3-10 mice per genotype per tissue. 
b
Abbreviations used: MDSC, myeloid-derived suppressor cell(s); PMN-MDSC, 
polymorphonuclear myeloid-derived suppressor cell(s); M-MDSC, monocytic myeloid-
derived suppressor cell(s); TDLN, tumor-draining lymph node(s); NDLN, non-draining 
lymph node(s).  
MDSC
b
 count (x10
-6
)
Genotype # PMN-MDSC # M-MDSC # PMN-MDSC # M-MDSC
Control 9.2 ± 1.4 1.2 ± 0.2
‡ 0.8 ± 0.2 0.8 ± 0.4
Wild type 17.6 ± 2.0* 2.2 ± 0.3*
‡   28.9 ± 11.7*   5.0 ± 0.7*
L-selectin
-/- 22.7 ± 3.1* 2.5 ± 0.3*
‡ 31.3 ± 6.7*    4.3 ± 0.5*
‡
Genotype # PMN-MDSC # M-MDSC # PMN-MDSC # M-MDSC
Control 3.0 ± 0.8 0.9 ± 0.1
‡
N/A N/A
Wild type 259.9 ± 18.3* 30.7 ± 2.2*
‡
0.53 ± 0.93 0.04 ± 0.02
‡
L-selectin
-/- 
224.4 ± 64.5* 32.7 ± 10.1*
‡
 1.06 ± 0.14
†
0.15 ± 0.03
†‡
Genotype # PMN-MDSC # M-MDSC # PMN-MDSC # M-MDSC
Control 0.001 ± 0.0003 0.001 ± 0.0006 0.001 ± 0.0003 0.001 ± 0.0006
Wild type  0.052 ± 0.0095* 0.061 ± 0.0206*  0.010 ± 0.0025*   0.008 ± 0.0024*
L-selectin
-/- 
 0.015 ± 0.0062*
†
 0.009 ± 0.0039*
†
 0.008 ± 0.0029*    0.002 ± 0.0010*
†
TDLN NDLN
BONE MARROW LUNG
SPLEEN TUMOR
*
*†
† † †
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Table IV. Tissue cellularity of wild type and L-selectin 
-/-
 mice with advanced stage 
4T1 tumors
a
. 
 
 
a
Tumors were induced in wild type or L-selectin
-/-
 mice as described for Table II. Single-
cell suspensions from the indicated tissues were counted using a hemacytometer *p<0.05 
vs. no tumor control, 
†
p<0.05 vs. tumor-bearing wild type. Results are from 3-10 mice per 
genotype per tissue. 
b
Abbreviations used: TDLN, tumor-draining lymph node(s); NDLN, non-draining lymph 
node(s). 
 
  
Tissue cell count (x10
-6
)
Genotype
Control
Wild type
L-selectin
-/- 
Genotype
Control
Wild type
L-selectin
-/- 
Genotype
Control
Wild type
L-selectin
-/- 
  9.2 ± 1.4* 2.0 ± 0.6
   0.9 ± 0.2*
†
   0.3 ± 0.1*
†
TDLN
b NDLN
3.1 ± 0.8 3.1 ± 0.8
BONE MARROW LUNG
18.7 ± 2.8 21.0 ± 4.2
636.0 ± 169.7* 20.8 ± 5.1
†
63.9 ± 4.8 N/A
750.2 ± 81.1*  8.2 ± 1.6
27.9 ± 3.4*  60.2 ± 12.8*
33.4 ± 4.0* 55.2 ± 5.9*
SPLEEN TUMOR
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CHAPTER 3 
INVOLVEMENT OF L-SELECTIN IN MDSC MIGRATION TO TUMOR AND 
TUMOR-DRAINING LYMPH NODES 
  
 99 
 
ABSTRACT 
Myeloid-derived suppressor cells (MDSC) consist of two major subsets, 
monocytic MDSC (M-MDSC) and polymorphonuclear MDSC (PMN-MDSC), both of 
which expand in cancer and suppress the activation of naïve T cells in the tumor-draining 
lymph node (TDLN) and the function of effector cells in the tumor microenvironment. 
Thus, the ability of MDSC to enter TDLN and the tumor is likely to be critical for 
suppression of the anti-tumor immune response and elucidating the mechanisms of 
MDSC migration to these sites may create a basis for novel immunotherapeutic 
approaches for the treatment of cancer. L-selectin mediates the homing of circulating 
naïve lymphocytes to lymph nodes and the migration of conventional myeloid cells, such 
as neutrophils and monocytes, to sites of inflammation, but its contribution to MDSC 
migration is unknown. In this part of the study, we evaluated the expression on MDSC of 
various integrins supporting leukocyte migration to lymph nodes, mucosal lymphoid 
tissues in the gut, and inflammatory sites, such as the tumor. Specifically, both MDSC 
subsets expressed comparable levels of the integrins LFA-1 and Mac-1 known to be 
involved in migration to lymph nodes and inflammatory sites. By contrast, VLA-4, which 
also supports migration to lymph nodes and inflammatory sites, was differentially 
expressed at higher levels on M-MDSC relative to PMN-MDSC. The α4β7 integrin, 
involved in migration to mucosa-associated lymphoid tissues, was virtually absent from 
the surface of most MDSC and was only expressed by a subset of M-MDSC. Together 
with previously demonstrated expression of L-selectin, these observations indicate that 
MDSC are equipped with a set of adhesion molecules necessary for migration to the 
TDLN and tumor. We then evaluated the efficiency of MDSC migration to these sites, as 
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well as the involvement of L-selectin in this process. Specifically, we demonstrated 
involvement of L-selectin in the migration of PMN-MDSC, but not M-MDSC, to tumors 
and TDLN. However, the efficiency of MDSC migration to the TDLN was low. This 
observation is in agreement with previously observed low MDSC numbers in the TDLN 
and questions the functional significance of TDLN-infiltrating MDSC in the suppression 
of the anti-tumor T cell response in this tumor model. 
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INTRODUCTION 
Leukocytes carried with the blood can enter peripheral tissues via a complex, but 
well-regulated process, called the adhesion cascade (see Fig. 1 in Chapter 1). The 
adhesion cascade involves adhesive and signaling interactions between the leukocyte and 
the endothelium. These interactions are sequentially organized in 4 main stages: 1) 
leukocyte capture and rolling over the endothelium, 2) activation, 3) firm adhesion or 
arrest, and 4) transendothelial migration or diapedesis (64). Each of these stages is 
characterized by interactions between distinct groups of molecules. Specifically, the 
capture and rolling events are dependent on interactions between selectins and their 
ligands (65, 66). Via these interactions, the leukocyte slows down and during the 
activation stage senses chemokines displayed on the endothelial surface. Chemokines 
secreted in the inflamed tissue in response to inflammatory mediators are transcytosed by 
endothelial cells and presented on the luminal endothelial surface in association with 
proteoglycans (235). The chemokine signals improve the adhesiveness of leukocyte-
expressed integrins, which, via interactions with endothelial immunoglobulin-like 
superfamily of adhesion molecules, are involved in decreasing the rolling velocity and 
transitioning to the next stage, firm adhesion (64, 68-72, 236). Integrins are also involved 
in all subsequent locomotion events in the adhesion cascade leading to diapedesis, as well 
as leukocyte migration in the extracellular matrix to reach sites of tissue injury or 
inflammation (73). 
Leukocyte migration is essential for the proper function of the immune system in 
both physiologic and pathologic conditions. During physiologic conditions, as part of the 
immunosurveillance process, naïve lymphocytes constantly re-circulate between the 
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blood and the PLN, where they scan for cognate antigens, displayed on antigen-
presenting cells. On the other hand, during pathologic conditions, as part of the immune 
response, activated lymphocytes and myeloid cells such as macrophages and neutrophils 
migrate to damaged or inflamed tissues. In addition, during pathologic conditions, there 
is increased migration of lymphocytes to the PLN draining the inflammatory site, where 
the lymphocytes become activated and enabled to execute an efficient adaptive immune 
response. During both physiologic and pathologic conditions, the migration of 
lymphocytes to the PLN occurs in specialized post-capillary venules, named high 
endothelial venules (HEV) to acknowledge the plump cuboidal shape of their endothelial 
cells. Importantly, in the physiologic steady state, HEV express a diverse group of 
adhesion molecules, collectively termed peripheral node addressins (PNAd), which bind 
to L-selectin (CD62L) expressed on lymphocytes to initiate the adhesion cascade. Among 
the PNAd are glycosylation-dependent cell adhesion molecule-1 (GlyCAM-1), CD34, 
endomucin, podocalyxin, nepmucin, and Spg200 (237, 238). Thus, the tissue-specific 
expression of L-selectin ligands in PLN directs lymphocyte homing to PLN in the steady 
state. Consequently, L-selectin-deficient (L-selectin
-/-
) lymphocytes are largely impaired 
in their ability to migrate to PLN in vivo (66), an effect similar to that of antibody-
mediated blockade of L-selectin binding (91), and L-selectin
-/-
 mice show a 70% decrease 
in PLN cellularity (92). Importantly, during pathologic conditions, inflammatory 
cytokines (e.g. TNF-α, IL-1β), ROS, complement components, immune complexes and 
other factors cause an upregulation of adhesion molecules, including L-selectin ligands, 
on the endothelium in inflamed tissues, thus leading to increased leukocyte migration to 
the inflammatory site (66). Contribution of L-selectin in leukocyte migration to sites of 
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inflammation has been documented in various conditions (66). For instance, L-selectin is 
involved in the recruitment of neutrophils (239, 240) and T cells (95) to the inflammatory 
site in ischemia-reperfusion injury, and concanavalin A-induced liver injury, respectively. 
Furthermore, L-selectin plays a role in the recruitment of T cells (96) as well as 
neutrophils, macrophages, lymphocytes and eosinophils (241, 242) to the site of 
pulmonary inflammation in murine and sheep models of asthma, respectively. As another 
example of pulmonary inflammation, mice with pulmonary fibrosis showed an L-
selectin-dependent infiltration of neutrophils and lymphocytes in the lung (99). Taken 
together these data implicate L-selectin in lymphocyte migration to PLN in steady state 
and disease, as well as in myeloid cell migration to sites of inflammation. 
In addition to selectins, integrins also play a role in determining the destination of 
leukocyte migration. For instance, migration to PLN is dependent on the leukocyte 
expressed αLβ2 integrin (CD11a/CD18), also known as lymphocyte function-associated 
antigen-1 (LFA-1). Migration to sites of inflammation depends on the αMβ2 integrin 
(CD11b/CD18), also known as macrophage-1 antigen (Mac-1), the α4β1 integrin 
(CD49d/CD29), also known as very late activation-4 (VLA-4) antigen, and/or LFA-1. 
The α4β7 integrin is primarily responsible for migration to mucosa-associated lymphoid 
tissue in the gut. The major binding partner of LFA-1 and Mac-1 are the intercellular 
adhesion molecules ICAM-1 and ICAM-2. Both of these molecules are constitutively 
expressed on endothelial cells; however, ICAM-1 is additionally upregulated upon 
endothelial activation by inflammatory mediators (243, 244). VLA-4 primarily binds to 
vascular cell adhesion molecule-1 (VCAM-1) expressed on inflamed endothelium (124). 
An alternative binding partner of α4 is the β7 integrin and the α4β7 integrin dimer, via 
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binding to mucosal vascular addressin cell adhesion molecule-1 (MAdCAM-1), is 
responsible for leukocyte migration to mucosa-associated lymphoid tissues. Thus, the 
combination of adhesion molecules and chemokine receptors expressed by leukocyte 
subsets determines their migratory preferences in the steady state and inflammation. 
Migration of myeloid leukocytes such as neutrophils and monocytes/macrophages 
to sites of inflammation is an important part of the innate immune response and an initial 
line of defense against invading pathogens. Due to the production of reactive oxygen and 
nitrogen species, a process called the respiratory burst, these cells directly kill pathogens 
in the inflammatory site. In addition, they release pro-inflammatory mediators and 
chemokines and thus play a further role in the activation and execution of the adaptive 
immune response. Finally, after the contraction of the immune response, they participate 
in the repair of the tissue damaged during the inflammatory processes. In the context of 
unresolved chronic inflammation; however, there is an abnormal accumulation of 
immature myeloid leukocytes with immunosuppressive functions, called myeloid-derived 
suppressor cells (MDSC). For instance, MDSC accumulate during cancer progression and 
are one of the major mechanisms of tumor-induced immunosuppression. 
Most of the suppressive mechanisms of MDSC are related to the upregulation of 
arginase-1 and inducible nitric oxide synthase (iNOS), which control L-arginine 
metabolism. L-arginine depletion from the tumor microenvironment by these enzymes 
causes T cell unresponsiveness by interfering with signaling from the TCR complex and 
the IL-2 receptor on T cells. In addition, L-arginine deficiency also causes proliferative 
arrest of activated T cells. Furthermore, hydrogen peroxide and peroxynitrites, products 
of the cooperative function of arginase-1 and iNOS, cause apoptosis in antigen-activated 
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T cells (55, 56). Additional pro-tumor effects of MDSC include induction of regulatory T 
cells, as well as participation in the processes of angiogenesis within the tumor 
microenvironments and the establishment of distant site metastases. 
Two major MDSC subsets have been identified morphologically: 
polymorphonuclear (PMN-MDSC) and monocytic (M-MDSC), which differ in 
frequency, immunosuppressive potency and mechanisms of immunosuppression (207, 
245, 246). For instance, in mice, PMN-MDSC are usually more abundant than M-MDSC 
with some dependence of the M-MDSC/PMN-MDSC ratio on the type of tumor. 
However, M-MDSC are more suppressive on a per-cell basis in vitro (207, 245, 246). 
PMN-MDSC-mediated immunosuppression depends primarily on the upregulation of 
arginase-1 and ROS production, while M-MDSC-mediated immunosuppression depends 
on upregulation of both arginase-1 and iNOS and production of reactive nitrogen species 
(206). In light of these differences, it is important to discriminate between the two subsets 
when studying MDSC biology. In addition to their morphological differences, murine 
PMN-MDSC and M-MDSC can be identified by flow cytometry based on their 
expression of the markers CD11b (also known as αM integrin and complement receptor 
type 3) and Gr-1. Specifically, PMN-MDSC and M-MDSC can be distinguished from 
non-myeloid cells by the expression of the myeloid-specific marker CD11b, while 
distinction between PMN-MDSC and M-MDSC is based on the expression levels of Gr-
1: thus PMN-MDSC are identified as CD11b
+
Gr-1
high
, while M-MDSC are identified as 
CD11b
+
Gr-1
low
. However, this labeling combination usually results in a continuum of 
events with various levels of Gr-1 labeling, and a clear distinction between Gr-1
low
 and 
Gr-1
high
 populations remains ambiguous. The anti-Gr-1 antibody (Clone RB6-8C5) binds 
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epitopes present in two different proteins belonging to the Ly-6 superfamily: Ly-6C and 
Ly-6G. The substitution of the RB6-8C5 antibody in MDSC staining protocols with 
antibodies individually specific to Ly-6C and Ly-6G allows unambiguous distinction 
between PMN-MDSC and M-MDSC subsets (206). Thus, the CD11b
+
Gr-1
high
 PMN-
MDSC are identified as CD11b
+
Ly-6G
+
Ly-6C
low/-
, while the CD11b
+
Gr-1
low
 M-MDSC 
are identified as CD11b
+
Ly-6G
-
Ly-6C
high
. 
MDSC are generated in the bone marrow and accumulate in the blood, spleen, 
and tumor. Although MDSC are found in great numbers in the spleen, studies suggest 
that splenic MDSC have limited effect on the immune response to solid tumors compared 
to tumor-resident MDSC. Specifically, tumor-resident MDSC have higher expression of 
arginase-1 and iNOS and higher suppressive activity in assays of T cell function (4, 181). 
In addition, an immunosuppressive role of MDSC in the TDLN has also been 
demonstrated (1, 2, 5). These observations, together with the fact that the suppressive 
function of MDSC against T cells is dependent on cell proximity, highlight the 
importance of TDLN and tumor-resident MDSC in the suppression of anti-tumor T cell 
activation in the TDLN and anti-tumor T cell function within the tumor 
microenvironment. Thus, MDSC migration to TDLN and tumor may be a limiting factor 
in MDSC-mediated suppression of the anti-tumor T cell response. 
Over the last two decades, parallel to a surge in cancer immunotherapy research, 
the study of tumor-induced MDSC has received increasing interest because these cells 
hinder the success of various immunotherapeutic methodologies. As a result, a significant 
number of studies have been published focused on elucidating the mechanisms of 
MDSC-mediated immunosuppression, as well as on developing strategies for MDSC 
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depletion and inhibition of their function. By contrast, there are far fewer studies of 
MDSC migration, most of which focus on the involvement of chemokines in MDSC 
recruitment. Importantly, the involvement of adhesion molecules in regulation of MDSC 
migration remains largely unknown. We previously demonstrated that MDSC from the 
blood and spleen of mice with 4T1 mammary carcinoma expressed L-selectin (see Fig. 4 
in Chapter 2). In this part of the study, we demonstrated that MDSC expressed the 
integrins LFA-1 and Mac-1 involved in migration to PLN and inflammatory sites. In 
addition VLA-4 was differentially expressed at higher levels on M-MDSC relative to 
PMN-MDSC. By contrast, only a subset of M-MDSC expressed the α4β7 integrin, 
involved in migration to mucosa-associated lymphoid tissues. We then evaluated the 
efficiency of MDSC migration, as well as the involvement of L-selectin in MDSC 
migration to secondary lymphoid tissues, such as the lymph nodes, and to inflammatory 
sites, such as the primary tumor. Specifically, using adoptive transfer experiments of L-
selectin-deficient MDSC, we demonstrated involvement of L-selectin in the migration of 
PMN-MDSC, but not M-MDSC, to tumors and TDLN. However, the efficiency of 
MDSC migration to the TDLN was low. This observation is in agreement with the low 
MDSC numbers found in the TDLN (see Fig. 5 in Chapter 2) and questions the functional 
significance of TDLN-resident MDSC in the suppression of the anti-tumor T cell 
response in this tumor model. 
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MATERIALS AND METHODS 
Cell lines and reagents 
The 4T1 murine mammary carcinoma cell line (ATCC CRL 2539) was purchased 
from ATCC (Manassas, VA) and maintained as described in Chapter 2, “Materials and 
Methods.” 
Antibodies used in the flow cytometry and fluorescence microscopy experiments 
included: FITC- or APC-conjugated, or biotinylated anti-CD11b (Clone M1/70, BD 
Biosciences, San Jose, CA); FITC- or PE-conjugated anti-Ly-6G (Clone 1A8, BD 
Biosciences); PerCP-Cy5.5- or PE/Cy7-conjugated anti-Ly-6C (Clone HK1.4, 
BioLegend, San Diego, CA; Clone AL-21, BD Biosciences), FITC-conjugated anti-Gr-1 
(Clone RB6-8C5) and anti-CD11a (Clone M17/4); PE-conjugated anti-CD18 (Clone 
C71/16), anti-β7 integrin (Clone M293), and anti-α4β7 integrin (Clone DATK32); 
PE/Cy7-conjugated anti-CD29 (Clone HMβ1-1); AlexaFluor® 647-conjugated CD49d 
(Clone R1-2); biotinylated anti-CD34 (Clone RAM43, eBioscience, San Diego, CA). 
Biotinylated antibodies were detected with AlexaFluor
®
 350- or AlexaFluor
®
 488-
conjugated avidin (Life Technologies, Grand Island, NY), or TRITC- or APC-conjugated 
neutralite avidin (SouthernBiotech). 
EZ link-sulfo-NHS-biotin (Pierce, Rockford, IL) was used to label the surface of 
cells and subsequently track them in adoptive transfer assays. Normal goat serum (Sigma, 
St. Louis, MO) and HyClone
®
 and normal horse serum (ThermoFisher Scientific, 
Waltham, MA) were used in buffers to reduce non-specific antibody labeling. 
Deoxyribonuclease I (DNAse I) from bovine pancreas and collagenase type VIII from 
Clostridium histolyticum were used for tissue digestion (both from Sigma). Bovine serum 
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albumin fraction V, also used in the tissue digestion buffer, was purchased from 
ThermoFisher Scientific. 
Animals and tumor induction 
BALB/c (wild type) mice were originally purchased from the Jackson 
Laboratories (Bar Harbor, ME) and further housed and bred in a specific pathogen-free 
barrier facility at the University of Wisconsin-Milwaukee and screened regularly for 
pathogens.  L-selectin
-/-
 mice were generated as described (247) and back-crossed against 
the BALB/c genetic background for twelve generations. All procedures were approved by 
the Animal Care and Use Committee of the University of Wisconsin-Milwaukee. Tumors 
were induced as described in Chapter 2, “Materials and Methods.” 
Integrin labeling on MDSC 
Spleens from advanced stage (4-5 weeks) 4T1 tumor-bearing BALB/c mice were 
harvested and single-cell suspensions were prepared as described in Chapter 2 “Materials 
and Methods.” To label for αL integrin (CD11a) expression on MDSC, cells were 
incubated with a combination of APC-conjugated anti-CD11b, FITC-conjugated anti-Ly-
6G, PE/Cy7-conjugated anti-Ly-6C, and PE-conjugated anti-CD11a antibodies. To label 
for β2 integrin (CD18) expression, cells were incubated with a combination of APC-
conjugated anti-CD11b, FITC-conjugated anti-Ly-6G, PE/Cy7-conjugated anti-Ly-6C, 
and PE-conjugated anti-CD18 antibodies. To label for α4 integrin (CD49d) expression, 
cells were incubated with a combination of FITC-conjugated anti-CD11b, PE-conjugated 
anti-Ly-6G, PE/Cy7-conjugated anti-Ly-6C, and AlexaFluor
®
 647-conjugated anti-
CD49d antibodies. To label for β1 integrin (CD29) expression, cells were incubated with 
a combination of biotinylated anti-CD11b, FITC-conjugated anti-Gr-1, and PE/Cy7-
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conjugated anti-CD29 antibodies. To label for β7 or α4β7 integrin expression on MDSC, 
cells were labeled with AlexaFluor
®
 647-conjugated anti-CD11b, FITC-conjugated anti-
Ly-6G, PE/Cy7-conjugated anti-Ly-6C, and PE-conjugated anti-β7 or anti- α4β7 integrin 
antibodies. In the negative control samples, the anti-CD11a, anti-CD18, anti-CD49d, 
anti-CD29, anti-β7 integrin, and anti-α4β7 integrin antibodies were replaced with 
fluorochrome-conjugated isotype control antoibodies. All samples were incubated for 30 
min on ice. The biotinylated anti-CD11b antibody was detected by APC-conjugated 
avidin added for 30 min on ice. Following antibody labeling all cells were washed in 
PBS. All samples were then fixed in 1.5% formaldehyde in PBS and analyzed with a 
FACSCalibur flow cytometer (BD Biosciences) using BD CellQuest™ Pro software. One 
to four experiments were analyzed per labeling combination. 
Adoptive transfer assay 
Spleen single-cell suspensions from advanced stage 4T1 tumor-bearing wild type 
or L-selectin
-/-
 mice were prepared as described in Chapter 2, “Materials and Methods.”  
At a concentration of 12.5x10
6 cells/ml, the spleen cells were labeled with 80 μg/ml EZ 
link-sulfo-NHS-biotin in PBS for 15 min at room temperature with gentle mixing. The 
cells were washed 3 times with PBS, counted on a hemacytometer, and adjusted to 
100x10
6 
cells/ml. Forty million cells were injected i.v. into the lateral tail vein of wild 
type mice bearing mid stage (2-2.5 weeks) 4T1 tumors. In addition, aliquots of the spleen 
cell suspensions were immunolabeled against the MDSC markers CD11b, Ly-6G, and 
Ly-6C, the frequencies of CD11b
+
Ly-6G
+
Ly-6C
low/-
 PMN-MDSC and CD11b
+
Ly-6G
-
Ly-
6C
high
 M-MDSC present in the injected population were determined with flow cytometry, 
and the total number of injected PMN-MDSC and M-MDSC was calculated. Sixteen 
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hours after injection, the recipient mice were euthanized. In some experiments, tumors 
from recipient mice were harvested and cryosectioned for immunofluorescence 
microscopy. Alternatively, blood, bone marrow, spleen, tumor, TDLN, and NDLN were 
collected and used to prepare single-cell suspensions as described in Chapter 2 “Materials 
and Methods.” The single-cell suspensions were labeled with APC-conjugated anti-
CD11b, PE-conjugated anti-Ly-6G, PerCP/Cy5.5-conjugated anti-Ly-6C antibodies and 
AlexaFluor
®
 488-conjugated avidin for 30 min on ice, washed in PBS, fixed with 1.5% 
formaldehyde in PBS, and analyzed with flow cytometry. The number of migrated PMN-
MDSC and M-MDSC in each tissue was determined by multiplying the frequency of 
biotinylated PMN-MDSC or M-MDSC present in each tissue by the total tissue cell 
count. The number of migrated PMN-MDSC or M-MDSC in each tissue was expressed 
as percentage of the total injected PMN-MDSC or M-MDSC, respectively. 
Labeling of tumor cryosections for fluorescence microscopy 
The tumor sections were fixed in -20°C acetone for 5 min and stored at -20°C 
until labeling. The sections were thawed for 5 min and rehydrated in PBS for 10 min. The 
sections were then incubated in 5% normal goat serum in PBS to block non-specific 
antibody binding. Antibody dilutions were prepared in 2% normal horse serum in PBS. 
To visualize the localization of biotinylated (i.e. transferred) MDSC, the tumor sections 
were incubated with fluorochrome-conjugated avidin and antibodies against the MDSC 
markers CD11b, Ly-6G, and Ly-6C for 30 min at room temperature. To visualize the 
localization of MDSC relative to blood vessels, the tumor sections were labeled with 
antibodies against the MDSC markers CD11b, Ly-6G, and Ly-6C, in combination with 
the blood vessel marker CD34. The slides were then washed for 5 min in PBS and 
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mounted in ProLong Gold
®
 antifade mounting medium. The mounting medium was 
allowed to cure overnight and the tumor sections were imaged with a Nikon Eclipse 
TE2000-U epifluorescence microscope (Nikon Instruments Inc., Melville, NY) equipped 
with a Cool Snap ES digital monochromatic camera (Photometrics, Tuscon, AZ). The 
MetaVUE™ software (Universal Imaging Corporation, Downington, PA) was used for 
imaging and analysis. Images are representative of a minimum of 3 independent 
experiments. 
Statistical analysis 
 Data are presented as mean ± SEM. Significant differences between sample 
means were determined using a Student’s t test with p < 0.05 considered to be significant. 
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RESULTS 
PMN-MDSC and M-MDSC from 4T1 tumor-bearing mice exhibit uniform 
expression of LFA-1 and Mac-1, but dufferential expression of VLA-4 and α4β7 
integrin 
 Leukocyte migration to PLN and sites of inflammation requires the orchestrated 
function of various signaling and adhesion molecules. L-selectin and integrins are among 
the leukocyte-expressed adhesion molecules. Using the 4T1 mouse breast cancer model, 
we previously demonstrated with flow cytometry that L-selectin is expressed by both 
PMN-MDSC and M-MDSC, albeit at lower levels on PMN-MDSC compared to M-
MDSC (see Fig. 4 in Chapter 2). In this part of the study, we further examined the 
expression of various integrins on PMN-MDSC and M-MDCS. In these experiments, 
PMN-MDSC were identified as either CD11b
+
Gr-1
high
, or CD11b
+
Ly-6G
+
Ly-6C
low/-
 and 
M-MDSC were identified as either CD11b
+
Gr-1
low
, or CD11b
+
Ly-6G
-
Ly-6C
high
 (Fig. 14). 
CD11b is also known as αM integrin, which combines with β2 integrin (CD18) to form the 
αMβ2 heterodimer, known as Mac-1. The β2 integrin also combines with αL integrin 
(CD11a) to form the αLβ2 heterodimer known as LFA-1. Both LFA-1 and Mac-1 bind 
ICAM-1 expressed on HEV or inflamed endothelium and support migration to PLN and 
inflammatory sites. All myeloid leukocytes, including MDSC, express αM integrin 
(CD11b).  Specifically, in the 4T1 tumor model, PMN-MDCS and M-MDSC expressed 
similar levels of the αM integrin (Fig. 14B). In addition, all 4T1 tumor-induced splenic 
MDSC also expressed αL and β2 integrins and no significant differences in the expression 
levels of these adhesion molecules were detected between PMN-MDSC and M-MDSC 
populations with flow cytometry (Fig. 15). Therefore, PMN-MDSC and M-MDSC 
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express similar levels of LFA-1 and Mac-1, both of which have the potential to support 
MDSC migration to tumors and TDLN via interactions with endothelium-expressed 
ICAM-1. 
 We also tested MDSC for expression of the α4 integrin pairs α4β1 (VLA-4) and 
α4β7. Both VLA-4 and α4β7 integrin bind VCAM-1, which is upregulated on inflamed 
endothelium, and to MAdCAM-1, constitutively expressed on HEV of mucosa-associated 
lymphoid tissues. However, VLA-4 binds with higher affinity to VCAM-1 and α4β7 
integrin binds with higher affinity to MAdCAM-1. Thus VLA-4 primarily supports 
migration to sites of inflammation, while α4β7 integrin primarily supports migration to 
mucosa-associated lymphoid tissues. In the present study, α4 integrin (CD49d) was 
expressed by all PMN-MDSC and M-MDSC from spleens of 4T1 tumor-bearing mice, 
albeit at 2.6-fold higher levels on M-MDSC compared to PMN-MDSC (Fig. 16A). The 
β1 integrin (CD29) was also expressed by both subsets, albeit at 3-fold higher levels on 
M-MDSC (Fig. 16B). In contrast, expression of β7 integrin was limited to a subset of M-
MDSC (Fig. 16C). Similar results were obtained when MDSC were labeled with an 
antibody specific to the α4β7 integrin pair, rather than the monomeric forms of either α4 or 
β7 integrins. Specifically, only a small subset of M-MDSC and none of the PMN-MDSC 
expressed the α4β7 dimer (Fig. 16D). Taken together, these results demonstrate 
differential expression of VLA-4 and α4β7 integrin, which may result in differential 
efficiency of migration to inflammatory sites and mucosa-associated lymphoid tissues. 
MDSC migration to the tumor and TDLN is partially dependent on L-selectin 
 To determine whether L-selectin is involved in MDSC migration to tumors and 
TDLN, we compared in vivo migration of 4T1 tumor-induced MDSC from wild type and 
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L-selectin
-/-
 mice. Specifically, we biotinylated spleen cell suspensions from wild type or 
L-selectin
-/-
 mice with advanced stage 4T1 tumors and transferred the biotinylated cells 
into the circulation of wild type mice bearing medium stage 4T1 tumors. Advanced stage 
4T1 tumor-bearing mice were used as donors because of the higher yield of MDSC, 
while recipients with smaller tumors were used to minimize the amount of endogenous 
circulating MDSC that may compete with the adoptively transferred MDSC for 
interactions with the endothelium within target tissues. In addition, single-cell 
suspensions of smaller tumors show less ambiguity and allow for a clearer subset 
distinction between PMN-MDSC and M-MDSC with flow cytometic analysis compared 
to larger, more advanced, tumors. Leukocytes can migrate to TDLN directly from the 
blood via HEV, as occurs normally during recirculation. Alternatively, leukocytes could 
first enter the tumor or peritumoral tissue, and then carried with the lymph, may enter the 
TDLN via the afferent lymphatics. To allow ample time for maximal leukocyte migration 
to TDLN directly from the bloodstream, but insufficient time for indirect entry via the 
lymphatic route, the transferred cells were allowed to circulate and migrate for 16 h 
before analysis. Following migration, the number of biotinylated PMN-MDSC and M-
MDSC in the tested tissues was determined and expressed as a percentage of all initially 
injected PMN-MDSC and M-MDSC, respectively. The numbers of initially injected 
PMN-MDSC and M-MDSC were 13.1 (± 0.8) x 10
6
 and 0.61 (± 0.09) x 10
6
, respectively.  
Sixteen hours after MDSC transfer, the largest number of recovered PMN-MDSC 
and M-MDSC were from the spleen of the recipient mice (approximately 9.6% of 
injected for either subset), independent of L-selectin expression (Fig.17, Table V). Per 1 
ml of blood, there remained approximately 3.1% of the initially injected PMN-MDSC or 
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M-MDSC regardless of L-selectin expression. Mice have approximately 2 ml of blood 
and thus the extrapolated total number of circulating transferred PMN-MDSC or M-
MDSC (around 6.2% of initially injected) would still be lower than that in the spleen. 
The numbers of biotinylated M-MDSC recovered from the bone marrow from both 
femurs of recipient mice was also independent of L-selectin expression, and comprised 
approximately 1% of the initially injected M-MSDC. By contrast, 2.4% and 1.3% of the 
initially injected wild type and L-selectin
-/-
 PMN-MDSC, respectively, were recovered 
from the bone marrow; however, this difference did not reach statistical significance (p = 
0.09).  
Smaller numbers of biotinylated MDSC were detected in the tumors. Specifically, 
0.28% and 0.08% of the initially injected wild type and L-selectin
-/-
 PMN-MDSC, 
respectively, were recovered from the tumor, which represented a statistically significant 
3.5-fold decrease in migration resulting from the loss of L-selectin expression (see lower 
graphs in Fig. 17, representing the same results as the upper graph, but on a smaller 
scale). By contrast, M-MDSC migration to tumors tended to decrease with the loss of L-
selectin expression, but the decrease did not reach statistical significance (p = 0.16). 
The inguinal PLN in the vicinity of the tumor in recipient mice was used as 
TDLN. The contralateral inguinal PLN from the same recipient mice was used as NDLN 
to show the baseline levels of MDSC migration to PLN in the absence of a nearby tumor. 
The NDLN is located in the vicinity of the mammary fat pad, which instead of 4T1 cell 
injection, received a vehicle control injection and did not develop a tumor. Of note, the 
TDLN was bigger than the NDLN (Table VI), which may in part be due to tumor-
induced immune activation in the TDLN, resulting in increased recruitment and 
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proliferation of lymphocytes. In addition, establishment and growth of tumor metastases 
within the TDLN may also contribute to its increased size. Small numbers of biotinylated 
MDSC were recovered from TDLN and NDLN (Table V), suggesting inefficient 
migration of MDSC from the bloodstream to these secondary lymphoid organs. Loss of 
L-selectin expression on PMN-MDSC resulted in a 3.1-fold and 4.7-fold decrease in 
migration to TDLN and NDLN, respectively (Fig. 17, Table V). By contrast, M-MDSC 
migration to TDLN and NDLN was independent of L-selectin expression. These results 
were surprising in light of previously observed higher expression of L-selectin on splenic 
M-MDSC compared to PMN-MDSC (see Fig. 4A in Chapter 2).  
 Interestingly, M-MDSC migrated more efficiently to TDLN, NDLN and tumors 
compared to PMN-MDSC. Specifically, the percentages of injected wild type M-MDSC 
recovered from TDLN, NDLN and tumor were higher than PMN-MDSC by 38-fold, 9.4-
fold and 2.5-fold, respectively (Fig, 17, Table V). This difference reached statistical 
significance only in the NDLN, while the p values for tumor and TDLN remained at 0.18 
and 0.09, respectively. In the case of L-selectin
-/-
 MDSC, there was a statistically 
significant increase in efficiency of M-MDSC migration to TDLN, NDLN and tumor 
(129-, 62- and 3.5-fold higher, respectively) compared to PMN-MDSC. 
Taken together, in the 4T1 breast cancer model, these results demonstrate that L-
selectin supported PMN-MDSC migration to tumor, TDLN and NDLN. By contrast, M-
MDSC migration to TDLN and NDLN was independent of L-selectin, while a role of L-
selectin in M-MDSC migration to the tumor was not conclusively determined due to 
sample variability. However, the low efficiency of MDSC migration from the 
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bloodstream to lymph nodes suggests that this may not be the primary route of MDSC 
entry into the TDLN. 
Sixteen hours after adoptive transfer of biotinylated spleen cells, tumor-infiltrating 
MDSC are localized outside or in the periphery of endogenous MDSC aggregates 
 To complement the flow cytometry results from the 16-h in vivo migration assays 
described above, we visualized the adoptively transferred biotinylated MDSC within the 
tumor using fluorescence microscopy. We had previously observed that in the 4T1 breast 
cancer model, tumor-infiltrating MDSC were not randomly distributed throughout the 
tumor, but were clustered together in aggregates. Results from the adoptive transfer 
experiments showed that while some of the transferred tumor-infiltrating MDSC were 
found located at the edges of endogenous MDSC aggregates, a similar number were 
found away from the aggregates, and virtually none were found inside the aggregates 
(Fig. 18A). These results suggest that MDSC likely enter tumors from blood vessels 
located outside of the aggregates and then migrate through the parenchyma to associate 
with existing aggregates. To visualize localization of blood vessels relative to the 
endogenous MDSC aggregates, tumor sections were labeled with antibodies against the 
endothelial cell marker CD34 and the MDSC markers CD11b, Ly-6C, and Ly-6G. Blood 
vessels were rarely observed within MDSC clusters, but often there were blood vessel 
networks in the vicinity of larger MDSC clusters (Fig. 18B). Single MDSC were often 
found in the immediate vicinity of the blood vessels and in some cases directly associated 
with the blood vessels, suggesting that these blood vessel networks may be a point of 
entry of MDSC into the tumor. 
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DISCUSSION 
 In leukocyte migration, L-selectin is one of the major adhesion molecules that 
mediates the initial interactions between the leukocyte and the endothelium. Specifically, 
leukocyte-expressed L-selectin interacts with endothelium-expressed ligands via rapid 
catch and release events, which allow the leukocyte to roll along the endothelial layer. 
During the rolling phase, the leukocyte via chemokine receptors senses chemokine 
signals displayed on the endothelium and activates the subsequent phases of migration, 
largely dependent on interactions between leukocyte-expressed integrins and 
endothelium-expressed immunoglobulin-like superfamily molecules. Leukocyte 
migration to PLN is an important part of immunosurveillance against infections and 
activation of adaptive immunity, while migration to inflammatory sites is vital for proper 
execution of the immune response followed by repair of damaged tissue. On the other 
hand, migration of immunosuppressive leukocytes, such as MDSC, to PLN and 
inflammatory sites is potentially critical for the suppression of immune response 
activation and execution, respectively. 
 The destination of a leukocyte during steady state and disease depends on the 
adhesion and signaling molecule profile of the leukocyte.  In this part of the study we 
examined the expression of several integrins on PMN-MDSC and M-MDSC as well as 
the involvement of L-selectin in MDSC migration to TDLN and tumor in the mouse 4T1 
breast cancer model. We demonstrated that all PMN-MDSC and M-MDSC from the 
spleen of tumor-bearing mice expressed the integrins LFA-1 and Mac-1 (Fig. 14 and 15), 
which can support migration to PLN and sites of inflammation. In addition, we 
demonstrated differential expression of the α4 integrin (CD49d) between M-MDSC and 
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PMN-MDSC (Fig. 16). Specifically, all MDSC expressed CD49d, however the M-MDSC 
showed a 2.6-fold higher expression with flow cytometry. These results are in partial 
agreement with a previous report, which demonstrated that M-MDSC but not PMN-
MDSC expressed CD49d in several mouse tumor models (248). The authors further 
proposed the use of CD49d as a marker, alternative to Gr-1 or Ly-6C and Ly-6G, for the 
identification and distinction between the M-MDSC and PMN-MDSC subsets. Based on 
our data, such use is also feasible with the 4T1 tumor model; however, the distinction 
between the two subsets would be based on high vs. low levels of CD49d. It is possible 
that the expression of CD49d on MDSC subsets is dependent on the type of tumor, and 
that unique combinations of tumor-derived factors determine the phenotype of MDSC 
subsets in different types of cancer. 
 CD49d (α4 integrin) combines with the β1 integrin to form VLA-4 or with less 
preference, with the β7 integrin.  VLA-4 and α4β7 integrin have somewhat overlapping 
functions, but VLA-4 is primarily involved in migration to inflammatory sites, while α4β7 
integrin is involved in migration to mucosal lymphoid tissues in the gut. An alternative 
partner for the β7 integrin is the αE integrin and the αEβ7 heterodimer, via interaction with 
its primary ligand E-cadherin, is also involved in leukocyte migration and retention in 
mucosal lymphoid tissues in the gut (249). Similar to CD49d (α4 integrin), the β1 integrin 
was also expressed by both subsets, albeit at higher levels on M-MDSC (Fig. 16). By 
contrast, the β7 integrin and the α4β7 heterodimer were expressed on a small subset of M-
MDSC and absent from PMN-MDSC. Although we did not test for expression of the αE 
integrin, given the limited expression of the β7 integrin, it is likely that efficient migration 
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to mucosal lymphoid tissues in the gut would be possible only for a small subset of M-
MDSC.  
In adoptive transfer experiments, L-selectin was involved in PMN-MDSC 
migration to the TDLN, NDLN, and the tumor; however, the efficiency of PMN-MDSC 
migration, especially to the lymph nodes, was low. On the contrary, M-MDSC migration 
to the TDLN and NDLN was independent of L-selectin expression suggesting a 
compensatory role of other adhesion molecules mediating the capture and fast rolling of 
M-MDSC. For instance, α4 integrins, such as VLA-4, via interactions with VCAM-1 
have been reported to mediate capture and rolling of lymphocytes, myeloid cell lines, and 
hematopoietic progenitor cells both in vitro and in vivo (71, 72, 250-252). Interestingly, 
reports suggest that α4 integrins are constitutively active and have higher binding 
affinities in hematopoietic progenitor cells (253, 254). M-MDSC expressed high levels of 
VLA-4 (Fig. 16) and their close relation to hematopoietic progenitors suggests a 
possibility for constitutive activation and a high binding affinity of this integrin. In 
addition, P-selectin expressed on endothelium in response to inflammatory mediators, 
such as TNF-α, IL-1β, ROS, etc., may also mediate M-MDSC capture and rolling 
independently of L-selectin. That would require expression of P-selectin ligands such as 
PSGL-1 (255, 256) and heat stable antigen (CD24) (257) on M-MDSC. In addition, P-
selectin expressed on activated platelets may support leukocyte migration to PLN or sites 
of inflammation in an L-selectin-independent manner via a process similar to secondary 
tethering. Specifically, activated P-selectin expressing platelets bound to circulating 
leukocytes via interactions with PSGL-1 may serve as a bridge to potentiate tethering and 
rolling interactions over vascular endothelium or HEV that express P-selectin ligands, 
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including PNAd. For instance, this mechanism of L-selectin-independent lymphocyte 
homing to PLN has been implicated in the restoration of lymphocyte homing to PLN by 
injection of activated platelets into the circulation of L-selectin
-/-
 mice (104, 105). 
Furthermore, a similar mechanism has been implicated in the migration of myeloid 
leukocytes to inflamed tissues in models of inflammatory diseases (106, 109, 258). In 
addition to their role in mediating leukocyte capture and rolling, activated platelets are 
also involved in the upregulation of leukocyte and endothelial adhesion molecules, as 
well as in the deposition of inflammatory mediators for leukocyte recruitment to sites of 
inflammation (109, 259, 260). Thus, activated platelets, rather than L-selectin, may play a 
critical role in MDSC migration to tumors or TDLN. Such an assumption is in agreement 
with a well-established relationship between platelet activation and tumor progression. 
Specifically, various types of cancer are associated with increased platelet count 
(thrombocytosis) (261-267) and activation (268-272), resulting from tumor-derived 
factors that drive the generation and differentiation of megakaryocytes, the precursors of 
platelets, in the bone marrow, as well as platelet activation in the bloodstream and in the 
tumor microenvironment (273-278). In turn, activated platelets aid in tumor progression 
via a variety of mechanisms, including the promotion of tumor metastasis, angiogenesis, 
and inflammation, and increased platelet counts correlate with poor prognosis (279, 280). 
In light of these findings, the involvement of activated platelets in MDSC migration to 
tumors and TDLN, as well as other effects of putative MDSC-platelet interactions on 
cancer progression, warrants further investigation. 
Interestingly, Ly-6C expressed at high levels on M-MDSC has been shown to 
enhance the homing of a subset of memory lymphocytes to lymph nodes via interaction 
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with an unknown ligand expressed on HEV (212). Specifically, antibody crosslinking of 
Ly-6C resulted in clustering of LFA-1 on the lymphocyte surface and increased adhesion 
to ICAM-1. Individual blockade of Ly-6C or L-selectin binding resulted in similar 
degrees of inhibition of lymphocyte recruitment to lymph nodes and combined blockade 
of both Ly-6C and L-selectin did not result in further inhibition (212). Therefore, it was 
concluded that Ly-6C may function downstream of L-selectin in a shared PLN homing 
pathway in the tested memory lymphocyte subset, which involves LFA-1. However the 
requirement of Ly-6C for PLN homing is not universal, because naïve lymphocytes, 
which home successfully to PLN, do not express Ly-6C. In addition, whether Ly-6C is 
involved in M-MDSC migration to lymph nodes and tumor is unknown. In the absence of 
L-selectin, Ly-6C expressed on M-MDSC may play a compensatory role in the 
recruitment to lymph nodes and tumor. If that is the case, the differential expression of 
Ly-6C on M-MDSC and PMN-MDSC may in part explain why Ly-6C
low/-
 PMN-MDSC 
migration to PLN and tumor was dependent on L-selectin, while the migration of Ly-
6C
high
 M-MDSC did not depend on L-selectin expression. Furthermore, it is of interest to 
define the role of Ly-6C in M-MDSC migration, because Ly-6C may emerge as a 
candidate for targeted blockade of Ly-6C
high
 M-MDSC migration to PLN and tumor, 
while sparing the homing ability of Ly-6C
- 
lymphocytes to PLN.  
Another interesting finding from the adoptive transfer experiments of MDSC into 
tumor-bearing animals is that M-MDSC migrated more efficiently to tumors and lymph 
nodes compared to PMN-MDSC. A higher efficiency of M-MDSC migration to TDLN 
and NDLN is in agreement with the increased M-MDSC/PMN-MDSC ratio in these 
tissues relative to that in the blood (see Fig. 6 in Chapter 2). However, the M-
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MDSC/PMN-MDSC ratio in the tumor is as low as in the blood, suggesting that the more 
efficient M-MDSC migration to this site is countered by events promoting PMN-MDSC 
accumulation in the tumor. For instance, such events may include M-MDSC egress from 
the tumor or favored survival of PMN-MDSC in the tumor microenvironment compared 
to M-MDSC. In addition, in situ proliferation of PMN-MDSC within the tumor 
microenvironment, or conversion of M-MDSC to PMN-MDSC may in theory lower the 
M-MDSC/PMN-MDSC ratio. Mature myeloid cells do not normally proliferate in 
peripheral tissues and mature monocytic cells do not differentiate into PMN cells. 
However, given the immature nature of MDSC, further differentiation or proliferation 
events outside of the bone marrow may not be fully excluded. For instance, it has been 
suggested that the spleen is a site of extramedullary proliferation of both M-MDSC and 
PMN-MDSC subsets (281) and that M-MDSC can differentiate to PMN-MDSC (282) in 
the tumor-bearing host. Interestingly, the M-MDSC-to-PMN-MDSC transition was the 
result of epigenetic histone deacetylase 2 (HDAC-2)-mediated transcriptional silencing of 
the retinoblastoma 1 gene (282). Inhibition of HDAC-2 activity favored the 
differentiation of M-MDSC to conventional macrophages and dendritic cells in culture. 
These findings provide a fresh perspective on the use of HDAC inhibitors as anti-cancer 
drugs, as restoration of normal myeloid cell differentiation may remove MDSC-mediated 
immunosuppression from the tumor-bearing host and improve immunotherapy. 
It remains unclear why M-MDSC seemed to migrate more efficiently than did 
PMN-MDSC to lymph nodes and tumor. One possibility is a preferential expression of 
appropriate chemokine receptors on M-MDSC. Interestingly, several chemokines and 
chemokine receptors are expressed at higher levels by M-MDSC than by PMN-MDSC in 
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hepatocellular carcinoma (283). For instance, a study using both real-time PCR and flow 
cytometry, demonstrated dramatically higher levels of CC chemokine receptor 2 (CCR2) 
on M-MDSC relative to PMN-MDSC (283). In cancer and other inflammatory 
conditions, CCR2 is involved in the egress of monocytic cells from the bone marrow and 
their migration to the tumor or inflammatory site (284-287). A role of CCR2 in directing 
myeloid cell recruitment to reactive lymph nodes after virus infection has been 
demonstrated (288); however, the significance CCR2 signaling in M-MDSC recruitment 
to the TDLN in cancer remains to be determined. The chemokine receptor CXCR2 was 
also differentially expressed on MDSC subsets in hepatocellular carcinoma, with higher 
levels present on PMN-MDSC than on M-MDSC (283). CXCR2 mediates the release of 
polymorphonuclear cells from the bone marrow to the bloodstream via interactions with 
its ligand CXCL2 expressed by bone marrow endothelial cells in response to 
inflammatory cytokines such as granulocyte colony stimulating factor (G-CSF) (289). In 
addition, production of G-CSF and CXCL2 within the tumor microenvironment is 
implicated in PMN-MDSC accumulation in the tumor (285), suggesting a role of CXCR2 
in PMN-MDSC recruitment to the tumor. Collectively, these studies suggest that M-
MDSC and PMN-MDSC migration to tumors may be differentially regulated by the 
various chemokines present in the tumor microenvironment. 
 
  
 126 
 
FIGURE LEGENDS 
Figure 14. Flow cytometric identification of PMN-MDSC and M-MDSC 
subpopulations. 
 Spleen single-cell suspensions from wild type mice bearing advanced stage 4T1 
tumors were labeled with antibodies against CD11b, Ly-6C, and Ly-6G (A) or CD11b 
and Gr-1 (B) and analyzed with flow cytometry. FACS plots are representative of 5 
independent experiments. Gated regions (C) included live cell gating based on forward 
and side light scatter (R1), followed by gating of M-MDSC (R3) and PMN-MDSC (R4) 
based on expression of CD11b (R2), Ly-6C, and Ly-6G, or CD11b and Gr-1. 
Figure 15. Expression of αL and β2 integrins on PMN-MDSC and M-MDSC. 
 Spleen single-cell suspensions from wild type mice bearing advanced stage 4T1 
tumors were labeled with APC-conjugated anti-CD11b, PE/Cy7-conjugated anti-Ly-6C, 
and PE-conjugated anti-Ly-6G in combination with FITC-conjugated anti-CD11a or 
isotype control antibody (A) or APC-conjugated anti-CD11b, PE/Cy7-conjugated anti-
Ly-6C, and FITC-conjugated anti-Ly-6G in combination with PE-conjugated anti-CD18 
or isotype control antibody (B). The expression levels of CD11a and CD18 on the MDSC 
subsets were determined with flow cytometry using constant voltage settings between 
experiments. FACS histograms are representative of 4 experiments with solid lines 
showing CD11a or CD18 expression levels on PMN-MDSC or M-MDSC and dashed 
lines showing isotype control labeling. Bar graphs represent the mean relative 
fluorescence intensity of CD11a-labeled (A) or CD18-labeled (B) PMN-MDSC and M-
MDSC. 
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Figure 16. Expression of α4, β1, and β7 integrins on PMN-MDSC and M-MDSC. 
 Spleen single-cell suspensions from wild type mice bearing advanced stage 4T1 
tumors were labeled with FITC-conjugated anti-CD11b, PE/Cy7-conjugated anti-Ly-6C, 
and PE-conjugated anti-Ly-6G antibodies in combination with AlexaFluor
®
 647-
conjugated anti-CD49d or isotype control antibody (A) or biotinylated anti-CD11b and 
FITC-conjugated anti-Gr-1 antibodies in combination with PE/Cy7-conjugated anti-
CD29 or isotype control antibody (B) or biotinylated anti-CD11b and FITC-conjugated 
anti-Gr-1 antibodies in combination with PE-conjugated anti-β7 integrin or isotype 
control antibody (C), or biotinylated anti-CD11b and FITC-conjugated anti-Gr-1 
antibodies in combination with PE-conjugated anti-α4β7 integrin or isotype control 
antibody (D). The expression levels of CD49d, CD29, β7 integrin, and α4β7 integrin were 
determined with flow cytometry using constant voltage settings between experiments. 
FACS histograms are representative of 1-4 experiments with solid lines showing CD49d, 
CD29, β7 integrin, or α4β7 integrin labeling levels on PMN-MDSC or M-MDSC and 
dashed lines showing isotype control labeling. Bar graphs represent the mean relative 
fluorescence intensity of CD49d-labeled (A) or CD29-labeled (B) PMN-MDSC and M-
MDSC from 4 experiments. *p<0.05 vs. PMN-MDSC. 
Figure 17. In vivo migration of adoptively transferred 4T1 tumor-induced MDSC. 
Wild type and L-selectin
-/-
 mice were injected s.c. with 10
4
 4T1 cells into the 
mammary fat pad. Four to 5 weeks after tumor induction, the mice were euthanized and 
splenocytes were labeled with biotin. Forty million biotinylated spleen cells were injected 
i.v. into the lateral tail vein of wild type mice bearing mid stage 4T1 tumors, induced as 
above. The frequencies within the donor spleen suspensions of CD11b
+
Ly-6G
+
Ly-6C
low/-
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PMN-MDSC and CD11b
+
Ly-6G
-
Ly-6C
high
 M-MDSC were determined with flow 
cytometry and the total number of injected PMN-MDSC and M-MDSC was calculated. 
Sixteen hours after injection, the mice were euthanized and blood, and single-cell 
suspensions of bone marrow, spleen, tumor, TDLN and NDLN were labeled with 
fluorochrome-conjugated avidin and anti-CD11b, anti-Ly-6G, and anti-Ly-6C antibodies. 
The frequencies of biotinylated PMN-MDSC and M-MDSC in each tissue were 
determined with flow cytometry and the number of migrated PMN-MDSC and M-MDSC 
in each tissue was calculated. The number of migrated PMN-MDSC or M-MDSC in each 
tissue was expressed as percentage of the total number of initially injected PMN-MDSC 
or M-MDSC, respectively. The lower graphs represent the same results for tumor, TDLN 
and NDLN as the upper graph, but with decreased scales to better show the differences. 
Results are from 7-11 independent experiments. *p<0.05 vs. wild type. 
Figure 18. Localization of migrated MDSC relative to blood vessels and endogenous 
MDSC clusters in the tumor microenvironment. 
Biotinylated spleen cells from mice with advanced stage 4T1 tumors were 
injected i.v. into recipient mice bearing mid stage 4T1 tumors and recipients were 
euthanized 16h after the injection. A) Cryosections of tumors were labeled with TRITC-
conjugated avidin and APC-conjugated anti-CD11b, FITC-conjugated anti-Ly-6G and 
PerCP/Cy5.5-conjugated anti-Ly-6C antibodies. The sections were analyzed by 
fluorescence microscopy with digital monochromatic images acquired at a constant 
exposure, and pseudocolored and overlaid using MetaVue™ software. Overlays include 
Ly-6G (green), avidin (red), and Ly-6C (blue). CD11b was not included in overlays for 
the sake of clarity. Tumor cryosections from mice that were not injected with biotinylated 
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donor spleen cells were labeled the same way and used as negative control for avidin 
labeling. Thus, representative images are of biotinylated CD11b
+
Ly-6G
+
Ly-6C
low/-
  
PMN-MDSC associated with MDSC clusters (white arrows) and biotinylated  
CD11b
+
Ly-6G
+
Ly-6C
low/-
 PMN-MDSC localized outside of the MDSC clusters (yellow 
arrows). B) Tumor cryosections from mice with mid stage 4T1 cancer were labeled with 
biotinylated anti-CD34 (blood vessel marker, detected with TRITC-conjugated avidin), 
APC-conjugated anti-CD11b, FITC-conjugated Ly-6G, and PerCP/Cy5.5-conjugated 
anti-Ly-6C antibodies, and analyzed by fluorescence microscopy as above. Overlays 
include Ly-6G (green), Ly-6C (red), and CD34 (blue) labeling. CD11b was not included 
in overlays for the sake of clarity. White arrows indicate CD11b
+
Ly-6G
+
Ly-6C
low/- 
cells 
associated with blood vessels. Images in A and B are representative of 3 independent 
experiments. Scale bar (100 μm) is for all images. 
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Figure 15 
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Figure 16 
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Figure 17 
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Figure 18 
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Table V. Efficiency of MDSC migration quantified as numbers and percent of 
injected PMN-MDSC and M-MDSC recovered 16 h after adoptive transfer
a
  
 
Numbers of recovered MDSC (x10
-3
) 
 
 
Recovered MDSC (% of injected) 
 
 
Donor genotype PMN-MDSC
b M-MDSC PMN-MDSC M-MDSC
Wild type 385 ± 35 20 ± 5 328 ± 93 4 ± 1
L-selectin
-/- 377 ± 81 12 ± 4 177 ± 27 4 ± 1
Donor genotype PMN-MDSC M-MDSC PMN-MDSC M-MDSC
Wild type 1,262 ± 213 49 ± 8 39.9 ± 14.1 2.4 ± 0.7
L-selectin
-/- 1,223 ± 169 38 ± 4 12.3 ± 3.4 1.3 ± 0.4
Donor genotype PMN-MDSC M-MDSC PMN-MDSC M-MDSC
Wild type 0.50 ± 0.14 0.82 ± 0.25 0.16 ± 0.04 0.10 ± 0.03
L-selectin
-/- 0.18 ± 0.06 0.57 ± 0.24  0.04 ± 0.01* 0.06 ± 0.01
Blood (1 ml) Bone marrow
Spleen Tumor
TDLN NDLN
Biotinylated MDSC count (x10
-3
)
Donor genotype PMN-MDSC M-MDSC PMN-MDSC M-MDSC
Wild type 3.1 ± 0.4 3.5 ± 0.8 2.4 ± 0.6 1.0 ± 0.4
L-selectin
-/- 2.6 ± 0.3 3.2 ± 1.1 1.3 ± 0.1 0.9 ± 0.3
Donor genotype PMN-MDSC M-MDSC PMN-MDSC M-MDSC
Wild type 10.2 ± 2.1 9.2 ± 2.4 0.28 ± 0.09 0.71 ± 0.29
L-selectin
-/-   9.1 ± 0.9 9.8 ± 2.4   0.08 ± 0.02*  0.28 ± 0.08
Donor genotype PMN-MDSC M-MDSC PMN-MDSC M-MDSC
Wild type 0.0043 ± 0.0013 0.1632 ± 0.0890 0.0014 ± 0.0004 0.0131 ± 0.0029
L-selectin
-/-   0.0014 ± 0.0004*  0.1789 ± 0.0723   0.0003 ± 0.0001* 0.0184 ± 0.0057
TDLN NDLN
Blood (1ml) Bone marrow
Spleen Tumor
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a
Wild type and L-selectin
-/-
 mice with advanced stage 4T1 tumors were euthanized and 
spleen single-cell suspensions were labeled with EZ link-sulfo-NHS-biotin. Forty million 
biotinylated spleen cells were injected i.v. into the lateral tail vein of wild type mice 
bearing mid stage 4T1 tumors. The frequencies within the donor spleen suspensions of 
CD11b
+
Ly-6G
+
Ly-6C
low/-
 PMN-MDSC and CD11b
+
Ly-6G
-
Ly-6C
high
 M-MDSC were 
determined by flow cytometry and the total number of injected PMN-MDSC and M-
MDSC was calculated. Sixteen hours after injection, the mice were euthanized and blood, 
and single-cell suspensions of bone marrow, spleen, tumor, TDLN and NDLN were 
labeled with fluorochrome-conjugated avidin and anti-CD11b, anti-Ly-6G, and anti-Ly-
6C antibodies. The numbers of migrated PMN-MDSC and M-MDSC were calculated 
from the frequencies of biotinylated PMN-MDSC and M-MDSC present in each tissue, 
determined by flow cytometry. Then, the number of migrated PMN-MDSC or M-MDSC 
in each tissue was expressed as percentage of the total number of initially injected PMN-
MDSC or M-MDSC, respectively. *p<0.05 vs. wild type. Results are from 7-11 mice per 
genotype. 
b
Abbreviations: PMN-MDSC, polymorphonuclear myeloid-derived suppressor cells; M-
MDSC, monocytic myeloid-derived suppressor cells; TDLN, tumor-draining lymph 
node(s); NDLN, non-draining lymph node(s). 
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Table VI. Tissue cellularity of recipient mice bearing mid stage 4T1 tumors
a
. 
 
a
Migration assays were performed as described in Table V. Following migration, blood 
and cells from the indicated tissues were counted on a hemocytometer. Results are from 
15-19 mice per tissue. 
b
Abbreviations used: TDLN, tumor-draining lymph node(s); NDLN, non-draining lymph 
node(s). 
  
Blood (1ml) Bone marrow
17 ± 1 19 ± 2
Spleen Tumor
125 ± 9 4 ± 0.4
TDLN
b NDLN
17 ± 2 4 ± 0.4
Recipient tissue cellularity (x10
-6
)
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Table VII. Numbers of endogenous PMN-MDSC and M-MDSC in wild type 
recipient mice bearing mid stage 4T1 tumors
a
. 
 
a
Migration assays were performed as described in Table V. Following migration, blood 
and cells from the indicated tissues were counted using a hemocytometer and labeled 
with fluorochrome-conjugated avidin and anti-CD11b, anti-Ly-6G, and anti-Ly-6C 
antibodies. The frequencies of resident PMN-MDSC and M-MDSC in each tissue were 
determined by flow cytometry and the total numbers calculated. Results are from 15-19 
mice per tissue. 
b
Abbreviations used: PMN-MDSC, polymorphonuclear myeloid-derived suppressor 
cells; M-MDSC, monocytic myeloid-derived suppressor cells; TDLN, tumor-draining 
lymph node(s); NDLN, non-draining lymph node(s). 
  
PMN-MDSC
b M-MDSC PMN-MDSC M-MDSC
8.2 ± 0.8 0.4 ± 0.04 12.1 ± 1.3 0.5 ± 0.1
PMN-MDSC M-MDSC PMN-MDSC M-MDSC
22.3 ± 1.7 0.7 ± 0.08 0.37 ± 0.06 0.04 ± 0.01
PMN-MDSC M-MDSC PMN-MDSC M-MDSC
0.005 ± 0.001 0.020 ± 0.008 0.002 ± 0.0003 0.002 ± 0.0009
MDSC count (x10
-6
)
Blood (1 ml) Bone marrow
Spleen Tumor
TDLN NDLN
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CHAPTER 4 
TUMOR-INFILTRATING MYELOID-DERIVED SUPPRESSOR CELLS 
AGGREGATE NEAR REGIONS OF HYPOXIA WITHIN THE PRIMARY TUMOR  
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ABSTRACT 
Areas of decreased tissue oxygenation (hypoxia) are a hallmark of the tumor 
microenvironment. Hypoxia-inducible factor (HIF) is an intracellular sensor of hypoxia, 
which functions to activate the expression of genes necessary for adaptation to hypoxia. 
There are several HIF isoforms with both overlapping and opposing roles in various 
processes, but overall hypoxia promotes tumor progression. In addition, it has been 
suggested that HIF activation in the tumor microenvironment increases the 
immunosuppressive activity of myeloid-derived suppressor cells (MDSC). MDSC 
expand in cancer and inhibit the function of anti-tumor effector T cells in the tumor 
microenvironment, thus severely suppressing the immune response. We previously 
observed that in the 4T1 mouse breast cancer model, tumor-infiltrating MDSC 
preferentially aggregated in the immediate vicinity of hypoxic regions. In this part of the 
study we quantified the extent of this co-localization, as well as addressed aspects of the 
dynamics of MDSC aggregate formation. Our results show that an average of 81% of 
MDSC aggregates localized next to areas of hypoxia. In addition, there was substantial 
contact between MDSC aggregates and hypoxic regions, averaging ~60% of total MDSC 
cluster circumference. We further demonstrated that MDSC enter the tumor in areas 
located outside of hypoxic regions and outside of MDSC aggregates, followed by 
migration through the tumor parenchyma to associate with MDSC aggregates. 
Interestingly, BrdU incorporation experiments showed that an average of 19% of tumor-
infiltrating MDSC were undergoing in situ proliferation in the tumor microenvironment. 
Thus, in addition to MDSC recruitment to tumors, intratumoral proliferation of MDSC 
may also contribute to MDSC accumulation. It is of interest to determine the role hypoxia 
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plays in MDSC proliferation. As a preliminary experiment to test whether HIF induces 
proliferation of MDSC in the tumor microenvironment we treated mice with a HIF-
activating drug. Although the treatment did not increase MDSC proliferation, the specific 
roles of the different HIF isoforms in MDSC recruitment, proliferation, and function in 
the tumor microenvironment require further study. 
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INTRODUCTION 
The improperly upregulated proliferation of cancer cells causes tumors to outgrow 
the existing vasculature, reducing blood supply and consequently oxygen tension, a 
condition called hypoxia. Hypoxia is not a condition unique to cancer, but also occurs 
transiently in inflamed tissues due to increased metabolic activity of resident cells or 
recruited inflammatory cells (290, 291). Given the dependence of eukaryotic cells on 
oxygen, the existence of a mechanism for sensing and adaptating to hypoxia is not 
surprising. The central pathway for adaptation to hypoxia is regulated by the transcription 
factor hypoxia-inducible factor-1 (HIF-1), a heterodimer of HIF-1α and HIF-1β subunits 
regulated by cellular oxygen tension (129). Specifically, both subunits are constitutively 
expressed (133), but in well-oxygenated (normoxic) environments, dioxygenase enzymes 
(PHD) hydroxylate an oxygen-dependent degradation domain (ODDD) of HIF-1α thus 
marking the subunit for ubiquitination and proteasomal degradation (132, 133). 
Conversely, hydroxylation of ODDD does not occur in hypoxic conditions, resulting in 
stabilization of HIF-1α (129, 131, 138) and its translocation to the nucleus, where it 
dimerizes with HIF-1β and binds to hypoxia response elements (HREs) of target genes 
(139, 140). Thus HIF-1α is also a sensor of intracellular oxygen levels. HIF-2α is an 
isoform HIF-1α, originally described in lung and endothelium (147, 148), but later it was 
demonstrated that HIF-2α is detectable in hypoxic conditions in a wide range of tissues 
and cell types (155). HIF-2α can bind HIF-1β and HREs, but induces the expression of 
genes distinct from the HIF-1 target genes (147-151). Similar to HIF-1α, in normoxic 
conditions, HIF-2α protein levels are regulated by proline hydroxylation within the 
ODDD, and CBP/p300 coactivator binding to HIF-2α is inhibited by asparagine 
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hydroxylation in the C-terminal transactivation domain (134). Inhibitors of PHD, such as 
dimethyl-oxalyl-glycine (DMOG), prevent the oxygen-induced degradation of HIF-1α 
and HIF-2α, thus activating HIF-1 and HIF-2 target genes in normoxic conditions.  
Among the targets of HIF are genes that stimulate formation of new blood vessels 
(angiogenesis), growth of existing blood vessels (vasculogenesis), metabolic switch to 
anaerobic glycolysis, cell survival and proliferation, which ultimately help the tissue to 
adapt to and counteract oxygen deficiency. Thus, it is not surprising that in various types 
of cancer, intratumoral hypoxia and HIF-1α stabilization aid in tumor growth and 
correlate with a poor prognosis (292). In addition, intratumoral hypoxia in a HIF-
dependent manner promotes tumor metastasis by upregulating genes involved in various 
steps of the metastatic process, including formation of the pre-metastatic niche (216, 293-
295). Furthermore, hypoxia, via HIF-1 and HIF-2, differentially regulates cell cycle 
progression. While HIF-1 stabilization favors cycle arrest (310-312), HIF-2 has been 
shown to induce proliferation (313-315). Importantly, intratumoral hypoxia may 
indirectly enhance tumor progression by increasing the immunosuppressive activity of 
MDSC. Specifically, it has been shown that tumor-infiltrating MDSC are more potent 
inhibitors of T cell function than splenic MDSC, likely due to HIF-1α-mediated 
upregulation of arginase-1 and iNOS (4, 181). 
Interestingly, in the 4T1 mouse breast cancer model, tumor-infiltrating MDSC 
aggregated next to hypoxic regions in the tumor microenvironment (see Fig. 11 in 
Chapter 2). In this part of the study we quantified the extent of this co-localization, as 
well as addressed aspects of the dynamics of MDSC aggregate formation. Our results 
demonstrate that the location of MDSC entry into the tumors is outside of hypoxic 
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regions and outside of the regions of MDSC aggregation. In addition, our results indicate 
that after their entry into tumors, the tumor-infiltrating MDSC migrate through the 
parenchyma to associate with MDSC aggregates. BrdU incorporation experiments further 
showed that in addition to MDSC recruitment to tumors, intratumoral proliferation of 
MDSC may also contribute to MDSC accumulation. A possible role of intratumoral 
hypoxia and HIF in the regulation of MDSC proliferation within the tumor requires 
further study. 
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MATERIALS AND METHODS 
Cell lines and reagents 
The 4T1 murine mammary carcinoma cell line (ATCC CRL 2539) was purchased 
from ATCC (Manassas, VA) and maintained as described in Chapter 2, “Materials and 
Methods.”  
Antibodies used in the flow cytometry and fluorescence microscopy experiments 
include APC-conjugated, or biotinylated anti-CD11b (Clone M1/70, BD Biosciences, San 
Jose, CA), PE- or FITC-conjugated anti-Ly-6G (Clone 1A8, BD Biosciences), 
PerCP/Cy5.5- or PE/Cy7-conjugated anti-Ly-6C (Clone HK1.4, BioLegend, San Diego, 
CA; Clone AL-21, BD Biosciences), and biotinylated anti-CD34 (Clone RAM43, 
eBioscience, San Diego, CA). Biotinylated antibodies were detected with APC- or 
TRITC-conjugated Neutralite avidin (SouthernBiotech, Birmingham, AL). 
Hypoxiprobe™ RedAPC Kit, containing pimonidazole·HCl and APC-conjugated anti-
pimonidazole antibody (Clone 4.3.11.3) or Hypoxiprobe™ 1 Omni Kit, containing 
pimonidazole·HCl and affinity-purified AlexaFluor
®
 647-conjugated anti-pimonidazole 
rabbit antisera (PAb2627AP) were purchased from Hypoxiprobe (Burlington, MA) and 
used to detect hypoxic regions in the tumor microenvironment with fluorescence 
microscopy.  
EZ link-sulfo-NHS-biotin (Pierce, Rockford, IL) was used to track cells in 
adoptive transfer assays. Normal goat serum (Sigma, St. Louis, MO) and HyClone
®
 
normal horse serum (ThermoFisher Scientific, Waltham, MA) were used in buffers to 
reduce non-specific binding of antibodies. 5-Bromo-2-deoxyuridine (BrdU), a thymidine 
analog used to measure cell proliferation was purchased from Sigma. Deoxyribonuclease 
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I (DNAse I) from bovine pancreas and collagenase type VIII from Clostridium 
histolyticum were used for tissue digestion (both from Sigma). Bovine serum albumin 
fraction V, also used in the tissue digestion buffer, was purchased from ThermoFisher 
Scientific. DMOG, a PHD inhibitor used to stabilize HIF-α in vivo, was purchased from 
Cayman Chemical (Ann Arbor, MI).   
Animals and tumor induction 
BALB/c (wild type) mice were originally purchased from the Jackson 
Laboratories (Bar Harbor, ME) and further housed and bred in a specific pathogen-free 
barrier facility at the University of Wisconsin-Milwaukee and screened regularly for 
pathogens. All procedures were approved by the Animal Care and Use Committee of the 
University of Wisconsin-Milwaukee. Tumors were induced as described in Chapter 2, 
“Materials and Methods.” 
Labeling of tumor cryosections for fluorescence microscopy 
4T1 tumor-bearing mice were injected i.p. with 60 mg/kg body weight of 
pimonidazole·HCl dissolved in PBS at a concentration of 5 mg/ml. One hour after the 
injection, the mice were euthanized and tumors were harvested. A middle slice of each 
tumor was snap frozen in tissue freezing medium (Triangle Biomedical Sciences, Inc, 
Durham, NC). Five-μm thick tissue sections were cut on a cryostat, adhered to poly-L-
lysine-coated microscope slides, fixed in -20°C acetone for 5 min and stored at -20°C 
until labeling. The sections were thawed for 5 min and rehydrated in PBS for 10 min. The 
sections were then incubated in 5% normal goat serum in PBS to block non-specific 
antibody binding. Antibody dilutions were prepared in 2% normal horse serum in PBS. 
To visualize the localization of MDSC relative to hypoxic regions within the primary 
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tumor, the sections were incubated with anti-pimonidazole antibody for 1 h at 37°C in a 
humidified chamber, followed by a 30-min incubation at room temperature with 
antibodies against the MDSC markers CD11b, Ly-6G, and Ly-6C. Alternatively, to 
visualize the localization of blood vessels relative to hypoxic regions within the primary 
tumor, the sections were incubated as above with anti-pimonidazole antibody and then 
followed by a 30-min incubation at room temperature with a biotinylated anti-CD34 
antibody. The sections were then washed in PBS and the biotinylated anti-CD34 antibody 
was detected with TRITC-conjugated avidin. All sections were washed in PBS and 
mounted in ProLong Gold
®
 antifade reagent for fluorescence. The samples were imaged 
using a Nikon Eclipse TE2000-U epifluorescence microscope (Nikon Instruments Inc., 
Melville, NY) equipped with a Cool Snap ES digital monochromatic camera 
(Photometrics, Tuscon, AZ). A minimum of 3 sections per tumor were labeled, out of 
which one representative section per tumor was used for further analysis. Successive 
images of tumor sections were taken in a scanning manner to visualize the whole tissue. 
Each image was assigned a number, by which the location of the image within the tissue 
could be determined. The MetaVUE™ software (Universal Imaging Corporation, 
Downington, PA) was used for imaging and analysis. One tumor section per mouse from 
3 mice per labeling combination was analyzed. 
Analysis of MDSC localization relative to hypoxia 
 Images of Ly-6G (representing MDSC aggregates) and hypoxia staining were 
overlaid. For best accuracy, the hypoxic regions were outlined with the Ly-6G overlay 
turned off and the MDSC clusters were outlined with the hypoxic overlay turned off. The 
areas of the MDSC clusters, the hypoxic regions and the remaining part of the tissue were 
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recorded. The circumference of MDSC clusters and hypoxic areas, as well as the length 
of the contact border between the MDSC clusters and the hypoxic areas, were recorded. 
The number of MDSC clusters in contact with hypoxia and the number of MDSC clusters 
located separate from hypoxia were recorded. It was taken into account that some MDSC 
clusters spanned 2 or more images and these clusters were scored only once. 
Analysis of blood vessel localization relative to hypoxia 
 Images of CD34 and hypoxia labeling were overlaid. Three region categories 
were assigned and outlined: hypoxic (HP), corresponding to hypoxia labeling; near-
hypoxic (near-HP), located within 100 μm from the border of the HP regions; and non-
hypoxic (non-HP), located beyond 100 μm from the border of the HP regions. The areas 
of the HP, near-HP and non-HP regions were recorded. The number and lengths of 
CD34
+
 blood vessels in each region were recorded. 
Adoptive transfer assay 
Splenic single-cell suspensions from 4T1 tumor-bearing donor mice were 
prepared, biotinylated and injected into tumor-bearing recipient mice as described in 
Chapter 2, “Materials and Methods.” One or 47 h after injection, the recipients were 
injected with pimonidazole·HCl as described above and euthanized 1 h later. Tumors 
were harvested, cryosectioned, fixed and stored as described above. The sections were 
then labeled to visiualize the localization of biotinylated MDSC relative to hypoxic 
regions and endogenous non-biotinylated MDSC clusters in the tumor environment. 
Specifically, sections were thawed, rehydrated and blocked as described above. Then, the 
sections were incubated with anti-pimonidazole antibody for 1 h at 37°C in a humidified 
chamber, followed by a 30-min incubation at room temperature with TRITC-conjugated 
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avidin, FITC-conjugated Ly-6G, and PerCP/Cy5.5-conjugated anti-Ly-6C antibodies. 
The sections were then washed, mounted and visualized as described above. The 
localization of each detected biotinylated Ly-6G
+
Ly-6C
low/- 
or Ly-6G
-
Ly-6C
high
 cell 
relative to endogenous non-biotinylated MDSC clusters was defined as cluster-associated 
(within cluster) or not associated (outside of cluster) and recorded. 
BrdU labeling 
BrdU was used to quantify in situ MDSC proliferation in the bone marrow, spleen 
and tumor. BrdU is a thymidine analog that incorporates into replicating DNA during the 
S-phase of cell division. In its bound form, it can be detected by anti-BrdU antibody and 
dividing cells can be quantified with flow cytometry. Tumor-bearing mice were injected 
i.p. with a single dose of 100 μg/mg body weight of freshly prepared 10 mg/ml BrdU in 
PBS. The chemical was allowed to circulate for 1 h before mouse euthanasia. Single-cell 
suspensions of bone marrow, spleen and tumor were prepared as described in Chapter 2 
“Materials and Methods.” Five million cells from bone marrow, spleen and tumor were 
labeled in a final volume of 200 μl with biotinylated anti-CD11b, PE/Cy7-conjugated 
anti-Ly-6C, and PE-conjugated anti-Ly-6G antibodies for 30 min on ice. The cells were 
then washed, resuspended in 500 μl of ice-cold 0.15 M NaCl, fixed by the drop-wise 
addition of 1.2 ml of 95% ethanol, and incubated for 30 min on ice. The cells were then 
washed in PBS and incubated in 1% paraformaldehyde and 0.1% Tween-20 in PBS for 
30 min at room temperature to permeabilize cell and nuclear membranes and further fix 
cellular components. The cells were washed in PBS and incubated in 50 U/ml DNAse I in 
DNAse buffer (4.2 mM MgCl2, 0.15M NaCl, pH 5) for 15 min at 37°C. After another 
wash in PBS, 5 μl of FITC-conjugated anti-BrdU or FITC-conjugated isotype-matched 
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irrelevant antibody (negative control), together with 1 μl of APC-conjugated Neutralite 
avidin, was added to the cells and incubated for 30 min on ice. The cells were then 
washed, fixed in 1.5% formaldehyde in PBS, and analyzed with flow cytometry. First, 
live cells were gated based on their forward and side light scatter properties. Of the live 
cells, the CD11b
+
Ly-6G
+
Ly-6C
low/-
 PMN-MDSC and the CD11b
+
Ly-6G
-
Ly-6C
high
 M-
MDSC were gated. Finally, the frequencies of BrdU
+
 cells in the PMN-MDSC or M-
MDSC subsets were determined. Three to four mice were used per tissue. 
DMOG treatment 
The PHD inhibitor DMOG was used to enhance HIF-1α and HIF-2α stabilization 
in tumor-bearing mice. In vivo, maximal HIF-α stabilization is reached at 4 to 6 h after 
i.p. injection of DMOG (296). We tested 2 DMOG treatment regimens, which we termed 
“1-dose” or “2-dose” DMOG treatment. In the “1-dose” regimen, the tumor-bearing mice 
received an i.p. injection of 8 mg of DMOG in 0.5 ml of PBS. After seven hours, the 
mice were injected with BrdU as described above and 1 h after BrdU injection, the mice 
were sacrificed and the tumors were analyzed for BrdU incorporation in PMN-MDSC 
and M-MDSC subsets as described above. In the “2-dose” regimen, tumor-bearing mice 
were first injected i.p. with 8 mg DMOG, followed by a second i.p. injection of 8 mg 
DMOG 8 h after the first one. Thirteen hours after the second DMOG dose, the mice 
were injected with BrdU as described above, and 1 h after BrdU injection the mice were 
sacrificed and the tumors were analyzed for BrdU incorporation as described above. In 
control mice, the DMOG injections were substituted by PBS. Three to six mice were used 
per treatment. 
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Statistical analysis 
 Results are presented as mean ± SEM. Significant differences between sample 
means were determined using a Student’s t test with p < 0.05 considered to be significant. 
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RESULTS 
Tumor-infiltrating MDSC are localized in aggregates of various sizes, most of which 
are found next to areas of hypoxia. 
Tissue oxygenation, or lack thereof, is emerging as a major regulator of tumor 
progression, as it generates intracellular signals that modulate tumor cell metabolism, 
increase the metastatic potential of tumor cells, trigger tumor vascularization, and even 
increase the suppressive function of MDSC, thus leading to a more aggressive cancer 
phenotype. We used the 4T1 mouse breast cancer model to determine the localization of 
tumor-infiltrating MDSC relative to hypoxic regions in the primary tumor. Low oxygen 
tension within tumors was indirectly detected by binding of the intraperitoneally injected 
cell-permeable chemical pimonidazole·HCl to exposed thiol groups in the structures of 
proteins and peptides. Due to the reduction of protein disulfide bonds in hypoxic 
conditions, regions of low oxygen tension contain more thiol groups and retain the bound 
pimonidazole, which is then detected by antibody labeling. MDSC were not uniformly 
distributed within the tumor, but rather were localized together forming aggregates with 
only a few individual cells observed around the aggregates. Interestingly these MDSC 
clusters were often localized immediately next to areas of hypoxia (Fig. 19). 
To quantify MDSC co-localization with hypoxic regions, images of tumor 
sections from 3 mice were collected in a scanning manner using epifluorescence 
microscopy (Fig. 20A). Hypoxic regions and MDSC aggregates were outlined (Fig. 20B), 
and the number of MDSC clusters co-localized next to hypoxic regions, as well as those 
localized separately from hypoxic regions, were counted. Although the total number of 
MDSC aggregates varied, most of the MDCS aggregates (81±8%) were co-localized next 
to hypoxic regions (Fig. 20C). This level of co-localization was unlikely to be random, 
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because the total area of MDSC clusters was only 8±3% of the entire tissue and the total 
hypoxic area was only 13±1% of the whole tissue (Fig. 20D). In addition to the 
percentage of area taken by MDSC clusters and hypoxic regions, the shape of these 
elements should also be considered when quantifying their co-localization, as more 
complex “branching” shapes may increase the chance of random co-localization. In the 
examined tumor sections, the shape of the MDSC aggregates was not complex and more 
often approximated an oval. The shape of the hypoxic regions displayed a minimal 
degree of “branching” in the 2D images without dominating the whole tissue. In most of 
the images, there was substantial contact between the hypoxic regions and MDSC 
clusters, and the MDSC clusters were often partially or entirely surrounded by hypoxia 
(Fig. 19). To quantify this aspect of co-localization, we measured the length of the 
outlines of the MDSC aggregates and hypoxic regions, as well as the length of the contact 
border between the MDSC aggregates and the hypoxic regions (Fig. 21A). Although 
there was some variability in the outline lengths, in all mice, most of the MDSC cluster 
outline (63±6%) was in contact with hypoxia (Fig. 21B). Collectively, these results 
demonstrate that tumor-infiltrating MDSC are predominantly located next to hypoxic 
regions in 4T1 tumors. 
Blood vessels are evenly distributed between hypoxic and non-hypoxic regions 
within the 4T1 tumor microenvironment. 
It was unclear whether the preferential MDSC localization next to hypoxic 
regions in the 4T1 tumors was due to the recruitment of MDSC from other locations 
within the tumor microenvironment or whether the MDSC clusters represented the 
preferential location of MDSC entry into the tumor, possibly due to blood vessel 
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enrichment in areas near hypoxia. To begin addressing this question, we quantified the 
number and length of blood vessels per unit of area in hypoxic regions, in regions near 
hypoxia (within 100 μm, near-hypoxic regions), and in regions farther than 100 μm away 
from hypoxia (non-hypoxic regions; Fig. 22A). There were no significant differences in 
the blood vessel density or the length of blood vessels per unit area between the regions 
defined as hypoxic, near-hypoxic and non-hypoxic (Fig. 22B). These results do not 
exclude the possibility that MDSC primarily enter tumors within near-hypoxic regions. 
However, a possible preferential use of any of the regions defined above as an entry point 
of MDSC into 4T1 tumors would not be due to blood vessel enrichment within the 
preferred region. 
MDSC enter tumors within near- and non-hypoxic regions and migrate toward pre-
existing MDSC aggregates. 
 We previously observed that 16 h after adoptive transfer of biotinylated MDSC 
into the circulation of tumor-bearing recipients, approximately 50% of the tumor-
infiltrating biotinylated MDSC were found outside of endogenous MDSC aggregates and 
the remaining 50% were found in the periphery of the MDSC aggregates (see Fig. 18A in 
Chapter 3). In addition, in the vicinity of MDSC clusters, regions that stained rich in 
blood vessels were also often enriched in individually dispersed MDSC, some of which 
were associated with the blood vessels (see Fig. 18B in Chapter 3). This led us to 
hypothesize that MDSC enter tumors in areas in the vicinity of MDSC clusters, after 
which they migrate through the tumoral extracellular matrix to join clusters. To 
determine the location of initial MDSC entry into the tumor relative to hypoxic regions 
and MDSC clusters, we harvested recipient tumors 2 h after injection of biotinylated 
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MDSC and labeled tumor sections with avidin and antibodies against MDSC and hypoxia 
markers. Two hours after adoptive transfer, 92±6% of tumor-infiltrating biotinylated 
MDSC were localized in near-hypoxic and non-hypoxic regions outside of MDSC 
clusters, while the remaining 8% were found in the periphery of the MDSC aggregates 
and none was found within hypoxic regions (Fig. 23). To determine where the 
biotinylated MDSC accumulated over time, we harvested recipient tumors 48 h after 
injection of biotinylated MDSC and labeled tumor sections as above. Forty-eight hours 
after adoptive transfer, 91±2% of tumor-infiltrating biotinylated MDSC were now 
localized within MDSC clusters, including in the middle of the clusters, while the 
remaining ~9% were found outside of the MDSC aggregates and none was within 
hypoxic regions (Fig. 23). These results demonstrate that after adoptive transfer, MDSC 
are first located outside of MDSC clusters and over time accumulate inside the clusters, 
suggesting that upon their entry into tumors, the tumor-infiltrating MDSC were recruited 
to endogenous MDSC clusters. 
 MDSC proliferate within the 4T1 tumors. 
The accumulation and aggregation of MDSC within 4T1 tumors are due to the 
extravasation of circulating MDSC followed by their migration through the tumoral 
extracellular matrix to the sites of aggregation. Previous studies have demonstrated that 
extramedullary MDSC proliferation occurs in the spleen of tumor-bearing mice (229, 
230). If MDSC proliferation occurs similarly within the tumor, it may also contribute to 
the intratumoral accumulation of MDSC and aggregate formation. We used BrdU 
incorporation to determine whether MDSC proliferated within the tumor 
microenvironment. BrdU is a thymidine analog, which is incorporated within the DNA 
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double helix in the process of DNA replication during the S phase of the cell cycle. BrdU 
was injected i.p. into tumor-bearing mice and the mice were euthanized 1 h later. Thus, 
BrdU marked any cells that were in S phase within the 1-h period. One hour is not 
sufficient time for the completion of MDSC division and exit from the bone marrow or 
spleen and their subsequent extravasation into the tumor tissue. Therefore, the use of this 
time-frame allows the detection of in situ proliferation of MDSC within the tumor-
microenvironment. From flow cytometric analysis of the CD11b
+
Ly-6G
+
Ly-6C
low/- 
PMN-
MDSC and CD11b
+
Ly-6G
-
Ly-6C
high
 M-MDSC populations (Fig. 24A), we determined 
the frequency of BrdU
+
 proliferating cells within each of these subsets in the bone 
marrow, spleen and tumor (Fig. 24B). A higher frequency of M-MDSC, 31±4%, stained 
BrdU
+
 in the bone marrow compared to 7±0.6% of PMN-MDSC, while a difference in 
proliferative rate between the two subsets was not observed in the spleen or tumor. 
Importantly, both subsets of MDSC showed high levels of intratumoral proliferation, 
with an average of 19% being BrdU
+
. Relative to bone marrow, there was a 3-fold higher 
frequency of BrdU
+
 PMN-MDSC in the tumor, suggesting a higher proliferation rate of 
PMN-MDSC in the tumor, or a premature egress of proliferating PMN-MDSC from the 
bone marrow. By contrast, the frequency of tumor-infiltrating BrdU
+
 M-MDSC was 2-
fold lower compared to that in the bone marrow, suggesting a lower proliferation rate of 
M-MDSC in the tumor. Importantly, the finding that the tumor is a site of high levels of 
extramedullary MDSC proliferation suggests that factors characteristic of the tumor 
microenvironment may drive this proliferation. 
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DMOG, an inhibitor of HIF-α degradation, did not increase the frequency of BrdU
+ 
MDSC in the 4T1 tumor microenvironment. 
Both HIF-1α and HIF-2α upregulate genes involved in cell proliferation. 
Generally, HIF-1α and HIF-2α have opposing effects on cell proliferation: HIF-1α targets 
induce cell cycle arrest, while HIF-2α targets induce proliferation. However, crosstalk 
between HIF-1α signaling and inflammatory signaling via STAT3 or NF-κB may 
upregulate genes that induce proliferation. It was of interest to determine whether 
hypoxia was one of the factors that caused the observed proliferation of MDSC in the 
tumor microenvironment. As a preliminary experiment in that direction of research, we 
asked whether additional HIF activation could produce a further increase in MDSC 
proliferation in the tumor microenvironment. We treated tumor-bearing mice with 
DMOG, an inhibitor of the PHD enzymes that mark HIF-1α and HIF-2α for degradation. 
DMOG causes HIF-α stabilization regardless of the cellular oxygenation levels, thus in 
effect mimicking hypoxic conditions and leading to hypoxia-independent upregulation of 
HIF-1 and/or HIF-2 target genes. In vivo, maximal HIF-α stabilization is reached at 4 to 6 
h after i.p. injection of DMOG (296). We tested 2 DMOG treatment regimens, which we 
termed “1-dose” and “2-dose” DMOG treatment (Fig. 25A). In the “1-dose” regimen, 
tumor-bearing mice received 8 mg of DMOG, 7 h after which the mice were injected 
with BrdU and 1 h after BrdU injection, the mice were sacrificed and the tumors were 
analyzed for BrdU incorporation in PMN-MDSC and M-MDSC subsets. In the “2-dose” 
regimen, tumor-bearing mice were injected with 8 mg DMOG, followed by a second 
DMOG injection (also 8 mg) 8 h after the first. Thirteen hours after the second DMOG 
dose, the mice were injected with BrdU; 1 h after BrdU injection the mice were sacrificed 
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and the tumors were analyzed for BrdU incorporation into PMN-MDSC and M-MDSC 
subsets. There was no change in the frequency of BrdU
+
 PMN-MDSC or M-MDSC in 
tumors of mice that received the “1-dose” DMOG treatment relative to mice receiving 
vehicle control (Fig. 25B). In the mice that received the “2-dose” DMOG treatment the 
frequency of BrdU
+
 cells within the PMN-MDSC population decreased by 33% relative 
to control. The frequency of BrdU
+
 cells within the M-MDSC also appeared smaller (by 
23%); however, this decrease did not reach statistical significance. Thus, the experiments 
using DMOG treatment in vivo did not demonstrate involvement of HIF in driving 
MDSC proliferation in the tumor microenvironment.  
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DISCUSSION 
We previously observed that tumor-infiltrating MDSC aggregated next to hypoxic 
regions in the tumor microenvironment. In this part of the study we quantified the extent 
of this co-localization as well as addressed aspects of the dynamics of MDSC aggregate 
formation. In advanced 4T1 tumors, approximately 81% of MDSC aggregates counted 
within fluorescence microscopy images were localized next to areas of hypoxia (Fig. 20). 
The 2-D nature of the images leaves a possibility that some or all of the remaining 19% 
of MDSC aggregates that did not localize next to hypoxia in the observed sections may 
be in contact with hypoxic regions in farther, parallel Z-planes in the 3-D structure of the 
tumor. To quantify the extent of contact between MDSC aggregates and hypoxic regions, 
we determined the percentage of the 2-D MDSC cluster circumference that was in 
contact with hypoxia. There was substantial contact (63% of total MDSC cluster 
circumference) between MDSC aggregates and hypoxic regions (Fig. 21).  
Despite the large extent of contact between MDSC clusters and hypoxic regions, 
the overlapping area between these elements of the tumor microenvironment appeared 
negligible. Interestingly, areas of MDSC clusters were largely non-hypoxic, while 
hypoxic regions contained only sparse numbers of MDSC. This suggests a possibility that 
hypoxic areas in the tumor may actually serve as a barrier to MDSC migration throughout 
the tissue, thus confining and concentrating MDSC within certain locations. Although 
myeloid cells rely primarily on anaerobic glycolysis for ATP production, thus being 
largely equipped to survive low oxygen conditions (297), hypoxic areas are unfavorable 
environments and unless there is a chemotactic gradient originating beyond the hypoxic 
area, it is not surprising that MDSC may not be “inclined” to enter hypoxic regions. 
Myeloid cells consume large amounts of oxygen, necessary for production of ROS. Thus, 
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there is a possibility that the MDSC clusters contribute to the generation of hypoxia, 
resulting in the observed preferential co-localization between MDSC clusters and 
hypoxic regions. However, that would imply that the highest levels of hypoxia should be 
observed within the MDSC aggregates, which, as indicated above, is not the case. Thus, a 
possibility remains that the MDSC aggregate formation, at least in its initial stages, may 
result from MDSC recruitment toward hypoxic tissues. Then, MDSC-derived 
chemotactic factors may drive further recruitment of MDSC. Indeed, adoptively 
transferred biotinylated MDSC initially localized outside of hypoxic regions or MDSC 
clusters and over time accumulated within MDSC clusters. This suggests the presence of 
a chemotactic gradient originating within the MDSC clusters.   
As a major sensor of hypoxia and transcriptional activator of hypoxia-driven 
genes, HIF-1α may play a role in the recruitment of MDSC toward hypoxic regions by 
inducing the secretion of chemotactic factors. For instance, among the products 
upregulated by HIF-1 are vascular endothelial growth factor (VEGF) and stromal cell-
derived factor-1 (SDF-1, also known as CXCL12), a ligand for CXCR4 (298, 299). These 
factors synergistically recruit monocytic cells, pericytes and endothelial progenitor cells, 
which support angiogenesis within the tumor tissue (300-303). Whether these or other 
chemokines induced by HIF participate in the recruitment of MDSC to tumors remains to 
be determined. Interestingly, HIF-1 can also upregulate expression of CXCR4 on tumor 
cells, which has been implicated in tumor metastasis to tissues expressing CXCR4 
ligands (304). A putative induction of CXCR4 expression on tumor-infiltrating MDSC, 
together with the increased SDF-1 levels, may constitute a HIF-1α-dependent mechanism 
for MDSC retention within tumors. 
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In addition to suspected recruitment and retention of MDSC within tumors, 
hypoxia, via HIF-1α, may generate pro-survival signals for MDSC, thus further 
contributing to the observed preferential localization of MDSC clusters near hypoxic 
regions. For instance, HIF-1 has been shown to cooperate with the transcription factors 
NF-κB and STAT3, thus linking hypoxic and inflammatory signaling (305-309). STAT3 
and NF-κB are the major factors involved in MDSC expansion and acquisition of 
suppressive phenotype, respectively (18-22, 24). In addition, synergism between these 
transcription factors and HIF-1 in cancer may result not only in induction of genes 
involved in MDSC expansion and function, but also in the expression of genes favoring 
cell survival (e.g., BCL-XL, BCL-2, CXCR1, CXCR2, survivin) and proliferation (e.g., c-
Myc, cyclin D1) (24, 305-309). Interestingly, using the BrdU incorporation method, we 
determined that an average of 19% of tumor-infiltrating MDSC were undergoing 
proliferation during the 1-h time-frame of BrdU exposure (Fig. 24). This short window of 
BrdU exposure eliminated a possible contribution of BrdU
+
 MDSC recruited from the 
bloodstream to the BrdU
+ 
events detected in the tumor, thus ensuring that the presence of 
BrdU
+
 MDSC within the tumor was due to in situ proliferation. Interestingly, the 
frequency of intratumoral BrdU
+
 PMN-MDSC was 3-fold higher than in the bone 
marrow, suggesting that there may be signals within the tumor microenvironment that are 
stronger stimulators of PMN-MDSC proliferation compared to those in the bone marrow. 
The PMN-MDSC and M-MDSC populations found in extramedullary tissues are 
heterogeneous and likely include progenitor cells with some proliferative potential as 
demonstrated for the spleen and liver (229, 230). Thus, the high levels of intratumoral 
MDSC proliferation may also result from preferential recruitment of myeloid progenitor 
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cells with proliferative potential over myeloid cells at more advanced stages of 
differentiation that are unable to proliferate. 
Hypoxia has been shown to play opposing roles in the regulation of cell 
proliferation. On one end, HIF-1α stabilization in hypoxia may induce cell cycle 
inhibitors such as p21 and p27 resulting in cell cycle arrest (310-312). On the other hand, 
hypoxic stabilization of HIF-2α, a HIF-α isoform homologous to HIF-1α, promotes cell 
proliferation via several mechanisms (313-315). In addition, cross-talk between HIF-1α 
signaling and other signaling pathways, such as STAT3 and NF-κB, may also induce 
genes that activate cell cycle progression, as mentioned above. It remains to be 
determined whether intratumoral hypoxia serves as an inducer of the observed MDSC 
proliferation within the tumor microenvironment. As a preliminary experiment in that 
direction of research, we treated tumor-bearing mice with the PHD inhibitor, DMOG, 
which leads to HIF-α stabilization regardless of the cellular oxygenation levels, thus in 
effect mimicking hypoxic conditions. As is evident from the MDSC/hypoxia co-
localization experiments, only 13±1% of the area of tumor sections labeled positive for 
the hypoxic probe pimonidazole·HCl (Fig. 20D). Therefore, the majority (87%) of the 
tumor microenvironment was not hypoxic. With the DMOG injection we sought to 
maximally stabilize HIF-α throughout the entire tumor and determine whether that results 
in an increase in MDSC proliferation. An 8-h treatment of tumor-bearing mice with a 
single dose of DMOG (“1-dose” regimen) did not affect the frequency of BrdU+ PMN-
MDSC or M-MDSC compared to vehicle control (Fig. 25). A 22-h total treatment of 
tumor-bearing mice with 2 doses of DMOG, the second dose given 8 h after the first dose 
(“2-dose” regimen), resulted in a small decrease in the frequency of cycling PMN-MDSC 
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within the tumor. Notably, neither of the treatment regimens resulted in an increase in 
MDSC proliferation. However, this result does not conclusively exclude a role of HIF in 
driving MDSC proliferation within the tumor microenvironment. Specifically, it is 
possible that HIF-α is maximally activated in tumor-infiltrating MDSC and in this case, 
the DMOG treatment would not show an effect. Although MDSC do not stain as hypoxic, 
they can use hypoxia-independent mechanisms for HIF-α stabilization, allowing for the 
possibility of a more profound HIF activation than the relatively small hypoxic content in 
the tumor. For instance, MDSC produce nitric oxide, which stabilizes HIF-α subunits by 
nitrosylation of cysteine residues within the ODDD (316). Considering the opposing 
effects of HIF-1α and HIF-2α on cell proliferation, it would be of further interest to 
determine the expression levels of these subunits in tumor-infiltrating MDSC, as well as 
to dissect the mechanism via which hypoxia may affect recruitment, function, and 
proliferation of tumor-infiltrating MDSC. 
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FIGURE LEGENDS 
Figure 19. Co-localization of MDSC clusters next to hypoxic regions in 4T1 tumors. 
To visualize hypoxic regions within the tumor microenvironment, 4T1 tumor-
bearing mice were injected with pimonidazole·HCl 1 h prior to euthanasia. Cryosections 
of tumors were labeled with antibodies against pimonidazole and the MDSC markers 
CD11b, Ly-6G and Ly-6C. The sections were analyzed with fluorescence microscopy. 
Digital monochromatic images were acquired at a constant exposure, and pseudocolored 
and overlaid using MetaVue™ software. Overlays include Ly-6G (green), Ly-6C (red), 
and pimonidazole (hypoxia probe, blue). CD11b was expressed by Ly-6G
+
Ly-6C
low/- 
and 
Ly-6G
-
Ly-6C
high
 cells, but was not included in overlays for the sake of clarity. Scale bars 
are 100 μm. Images are from 3 independent experiments and represent examples of 
MDSC clusters localized next to hypoxic regions. 
Figure 20. Quantitation of co-localized MDSC clusters next to hypoxic regions in 
4T1 tumors. 
Three 4T1 tumor-bearing mice were injected with pimonidazole·HCl 1 h prior to 
euthanasia. A) The middle slice of each tumor was frozen. Cryosections of tumors were 
labeled with antibodies against pimonidazole and the MDSC markers CD11b, Ly-6G and 
Ly-6C. One cryosection was analyzed from each tumor with fluorescence microscopy. 
Digital monochromatic images were acquired in a scanning manner covering the entire 
section. B) Images of hypoxia (pimonidazole, blue) and Ly-6G (MDSC clusters, green) 
were pseudocolored and overlaid using MetaVue™ software. CD11b labeling 
corresponded to the Ly-6G-labeled clusters and most of the Ly-6C-labeled cells were 
included within the Ly-6G-labeled clusters. CD11b and Ly-6C labeling was not included 
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in overlays for the sake of clarity. The hypoxic regions and MDSC clusters were outlined 
(dashed line) and the areas of the hypoxic regions and MDSC clusters, as well as the area 
of the remaining tissue, were recorded. The number of co-localized MDSC clusters in 
contact with hypoxia and the number of the separate MDSC clusters not in contact with 
hypoxia were recorded. The scale bar is 100 μm. C) The number of co-localized MDSC 
clusters and the number of the separate MDSC clusters for each of the three analyzed 
tumor sections (1 per mouse; 3 mice used: Mo 1, Mo 2, and Mo 3) were plotted. The 
percentage of co-localized MDSC clusters out of the total number of MDSC clusters in 
each sample was calculated (white numbers in bar graph). D) The total areas of hypoxic 
regions, MDSC clusters and the remaining tissue areas were calculated and plotted for 
each of the 3 mice (Mo 1, Mo 2, and Mo 3). The percentage of hypoxic area out of the 
total tissue area for each mouse was calculated (grey numbers). The percentage of MDSC 
cluster area out of the total tissue area for each mouse was calculated (black bold 
numbers). 
Figure 21. Quantitation of contact between MDSC clusters and hypoxic regions in 
4T1 tumors. 
Tumors were labeled and imaged as described for Fig. 20. A) Images of hypoxia 
(pimonidazole, blue) and Ly-6G (MDSC clusters, green) were pseudocolored and 
overlaid using MetaVue™ software. CD11b labeling corresponded to the Ly-6G-labeled 
clusters and most of the Ly-6C-labeled cells were included within the Ly-6G-labeled 
clusters. CD11b and Ly-6C labeling was not included in overlays for the sake of clarity. 
The hypoxic regions and MDSC clusters were outlined: the dashed line is the portion of 
the outline of hypoxic regions, which is not in contact with MDSC clusters (Hypoxia 
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only); the solid thin line is the portion of the outline of MDSC clusters, which is not in 
contact with hypoxic regions (MDSC only); the solid bold line represents the contact 
borderline between MDSC clusters and hypoxic regions (MDSC/Hypoxia border). The 
length of each line was recorded. Scale bar is 100 μm. B) The total lengths of the 
“Hypoxia only”, “MDSC only” and the “MDSC/Hypoxia border” lines were calculated 
for each of the 3 mice (Mo 1, Mo 2, and Mo 3) and plotted as numbers (left) and 
percentages (right).  
Figure 22. Quantitation of blood vessels in areas of hypoxia, areas near hypoxia, and 
areas far from hypoxia in 4T1 tumors. 
Tumors from pimonidazole-injected mice were sectioned as described for Fig. 20 
and immunolabeled against pimonidazole and the blood vessel marker CD34. A) Images 
of hypoxia (pimonidazole, green) and blood vessels (CD34, red) were pseudocolored and 
overlaid using MetaVue™ software. Three region categories were assigned and outlined: 
hypoxic (HP) corresponding to hypoxia labeling, near-hypoxic (near-HP) located within 
100 μm from the border of the HP regions, and non-hypoxic (non-HP) located beyond 
100 μm from the border of the HP regions. The areas of the HP, near-HP and non-HP 
regions were recorded. The number and lengths of CD34
+
 blood vessels in each region 
were recorded. White arrows indicate examples of blood vessels in HP, near-HP and non-
HP regions. Scale bar is 100 μm. B) The average numbers (left) and lengths (right) per 
unit of area form the three tumors were calculated and plotted for each region (HP, near-
HP, and non-HP). 
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Figure 23. MDSC enter tumors in areas located outside of MDSC clusters and 
accumulate within MDSC clusters over time. 
Spleen single-cell suspensions from 4T1 tumor-bearing donor mice were 
prepared, biotinylated and injected into tumor-bearing recipient mice. One or 47 h after 
injection, the recipients were injected with pimonidazole·HCl and euthanized 1 h later. 
Three tumors (from 3 mice) per time point were harvested, cryosectioned, fixed and 
labeled with avidin and antibodies against pimonidazole, Ly-6G and Ly-6C. Three 
sections per tumor were analyzed. A) Images of hypoxia (pimonidazole, blue), PMN-
MDSC (Ly-6G, green) or M-MDSC (Ly-6C, not shown) and avidin (biotinylated 
migrated cells, red) were pseudocolored and overlaid using MetaVue™ software. The 
localization of each biotinylated MDSC (arrows) relative to endogenous non-biotinylated 
MDSC aggregates was defined as within or outside of the aggregates and the numbers of 
biotinylated MDSC in each of these two categories were recorded for each section. B) 
The total numbers of cluster-associated or not associated biotinylated MDSC from the 
three sections analyzed per tumor were summed and the sums of the three tumors 
analyzed per time point were averaged and plotted. 
Figure 24. Quantitation of MDSC proliferation within bone marrow, spleen and 
tumor from mice with 4T1 breast cancer. 
Tumor-bearing mice were injected i.p. with a single dose of 100 μg/mg body 
weight of freshly prepared 10 mg/ml BrdU in PBS. The BrdU was allowed to circulate 
for 1 h before mouse euthanasia. Single-cell suspensions of bone marrow, spleen and 
tumor were prepared and labeled with antibodies against CD11b, Ly-6C, Ly-6G and 
BrdU. In negative control samples, the anti-BrdU antibody was substituted with an 
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isotype-matched irrelevant antibody. MDSC proliferation was analyzed with flow 
cytometry. A) Live cells were gated based on their forward and side light scatter and the 
CD11b
+
 population of was further analyzed (upper left). The CD11b
+
Ly-6G
+
Ly-6C
low/-
 
PMN-MDSC and the CD11b
+
Ly-6G
-
Ly-6C
high
 M-MDSC were gated (upper right) and 
further analysed for BrdU expression (lower; the dashed line represents negative control 
labeling; the solid line represents BrdU labeling). Plots are representative of tumor 
samples. B) The frequencies of BrdU
+
 cells out of the PMN-MDSC (left) or M-MDSC 
(right) subsets were plotted for each tissue. Three to 4 mice were used per tissue. *p<0.05 
vs. bone marrow (BM). 
Figure 25. Effect of in vivo DMOG treatment on the proliferation of tumor-
infiltrating MDSC. 
Tumor-bearing mice were subjected to 1 of 2 alternative DMOG treatment 
regimens (“1-dose” or “2-dose”) or vehicle control. A) In the “1-dose” regimen, the 
tumor-bearing mice received an i.p. injection 8 mg of DMOG dissolved in 0.5 ml of PBS. 
Seven hours after DMOG administration, the mice were injected i.p. with 100 μg/mg 
body weight of freshly prepared 10 mg/ml BrdU in PBS. In the “2-dose” regimen, tumor-
bearing mice were injected with 8 mg DMOG or vehicle control. Eight hours thereafter, 
the mice were injected with a second dose of DMOG or vehicle control. Thirteen hours 
after the second injection, the mice were injected with BrdU. One hour after BrdU 
injection, all mice were sacrificed and the tumors were analyzed for BrdU incorporation 
in PMN-MDSC and M-MDSC subsets with flow cytometry. B) The frequencies of 
BrdU
+
 cells out of the tumor-infiltrating PMN-MDSC (left) or M-MDSC (right) subsets 
 169 
 
were plotted for each treatment regimen. Three to 6 mice were used per regimen; *p<0.05 
vs. vehicle control. 
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Figure 25 
  
0h 8h7h
DMOG BrdU
Harvest
tumor
1-dose regimen
0h 8h 21h 22h
DMOG DMOG BrdU
Harvest
tumor
2-dose regimen
A.
B.
%
 o
f 
B
r
d
U
+
c
e
ll
s
Control 1-dose 2-dose
DMOG
Tumor
0
5
10
15
20
25
Control 1-dose 2-dose
DMOG
PMN-MDSC M-MDSC
*
 177 
 
 
 
 
 
 
CHAPTER 5 
CONCLUSIONS 
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CONCLUSIONS 
CTL can kill tumor cells upon contact and are the most potent effectors in the 
anti-tumor immune response. Thus, higher numbers of tumor-infiltrating CTL correlate 
with a positive prognosis in cancer patients and various immunotherapeutic strategies 
utilize activated anti-tumor CTL. However, major factors limiting the success of 
immunotherapy are tumor-driven mechanisms of immunosuppression, such as the 
generation of MDSC, which inhibit CTL activation in the TDLN and CTL function in the 
tumor. The mechanisms of MDSC-mediated immunosuppression are dependent on direct 
cell contact or close proximity to target cells. Thus, the ability of MDSC to enter TDLN 
and the tumor is likely to be critical for suppression of the anti-tumor response and 
elucidating the mechanisms of MDSC migration to these sites may create a basis for 
novel immunotherapeutic approaches for the treatment of cancer. For instance, targeted 
MDSC-specific blockade of migration to the tumor would decrease the numbers of 
tumor-infiltrating MDSC, thus relieving some of the suppressive pressure that the tumor 
microenvironment exerts on adoptively transferred engineered or ex vivo activated anti-
tumor CTL. Of note, a decrease in tumor-infiltrating MDSC and enhanced anti-tumor 
immune reactivity can also be achieved by antibody-mediated MDSC depletion (317). 
However, this strategy of MDSC depletion reportedly results in increased production of 
MDSC in the bone marrow, possibly via a mechanism similar to lymphopenia-induced 
homeostatic lymphocyte proliferation (318). Thus the beneficial effect of MDSC 
depletion may not only be short-lived, but may also result in an undesirable increase in 
MDSC accumulation in the long run. On the contrary, immunotherapeutic interference 
with MDSC migration to the tumor and TDLN should eliminate the immunosuppressive 
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activities of MDSC at those sites without increasing the production of MDSC in the bone 
marrow. While the mechanisms of MDSC-mediated immunosuppression are a popular 
area of research, far fewer studies are focused on the mechanisms of MDSC migration to 
the tumor and TDLN. 
The initial capture and rolling stage of the adhesion cascade is largely mediated 
by leukocyte-expressed L-selectin, an adhesion molecule critical for the homing of 
circulating lymphocytes to PLN and the migration of myeloid cells to sites of 
inflammation. These effects of L-selectin are mediated via interactions with its 
endothelial ligands constitutively expressed on HEV in PLN and upregulated in post-
capillary venules in response to inflammatory cytokines. The role of L-selectin in 
leukocyte migration to PLN and sites of inflammation has been characterized for 
lymphocytes and conventional myeloid cells, but its contribution specifically to MDSC 
migration to tumor and TDLN is unknown. Here, we used L-selectin
-/-
 mice to determine 
the involvement of L-selectin in the migration of MDSC subsets to tumor and TDLN in 
the 4T1 murine breast cancer model. Although both the PMN-MDSC and M-MDSC 
subsets expressed L-selectin (see Fig. 4 in Chapter 2), this adhesion molecule was critical 
only for PMN-MDSC migration to tumor and TDLN, while migration of M-MDSC was 
independent of L-selectin expression (see Fig. 17 and Table V in Chapter 3 and Fig. 26). 
This could be due to a possible involvement of VLA-4, expressed at higher levels on M-
MDSC relative to PMN-MDSC (see Fig 16 in Chapter 3), in mediating L-selectin-
independent capture and rolling of M-MDSC on VCAM-1-expressing endothelium. 
Integrin-mediated leukocyte tethering and rolling are not novel concepts, as VLA-4 has 
been reported to mediate capture and rolling of lymphocytes, myeloid cell lines, and 
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hematopoietic progenitor cells both in vitro and in vivo (71, 72, 250-252). It is also 
noteworthy that Ly-6C, expressed at higher levels on M-MDSC relative to PMN-MDSC, 
may play a role in the adhesion cascade by increasing LFA-1-mediated adhesion to 
ICAM-1. Specifically, Ly-6C has been shown to enhance the homing of a subset of 
memory lymphocytes to lymph nodes via its interaction with an unknown ligand 
expressed on HEV (212). Whether Ly-6C or VLA-4 mediate MDSC migration to TDLN 
and tumor is unknown but warrants further investigation, as these molecules may emerge 
as candidates for targeted blockade of M-MDSC migration to TDLN and tumor. 
Another interesting finding described herein is that tumor-infiltrating MDSC 
preferentially localize in aggregates near hypoxic regions and adoptively transferred 
MDSC appeared to actively migrate to endogenous MDSC aggregates after entry into the 
tumor (see Chapter 4). This is likely due to chemotactic gradients generated by the 
MDSC aggregates (Fig. 26). However, it is unclear what signals initiate the de-novo 
formation of intratumoral MDSC aggregates and whether hypoxia is the trigger or the 
result of this event. If homotypic interactions between tumor-infiltrating MDSC during 
aggregation result in the secretion of chemokines for further MDSC recruitment, it would 
be of interest to identify the mechanisms driving the initial events of MDSC aggregation, 
as it may provide a basis for targeted inhibition of MDSC recruitment to tumors.  
As a major sensor of hypoxia and a transcriptional activator of hypoxia-driven 
genes, HIF may play a role in the recruitment of MDSC toward hypoxic regions by 
inducing the secretion of chemotactic factors (Fig. 26). In addition, by upregulating the 
expression of chemokine receptors on MDSC, HIF may play a role in MDSC retention 
within the aggregates. Furthermore, HIF has been shown to synergize with other 
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transcription factors, such as STAT3 and NF-κB, resulting in upregulation of genes 
favoring cell survival and proliferation (24, 305-309). Whether such events occur in 
tumor-infiltrating MDSC is unknown. Interestingly, flow cytometric analysis of BrdU 
incorporation showed proliferation of intratumoral MDSC in the 4T1 model (see Fig 24 
in Chapter 4); however, the mechanisms driving MDSC proliferation in the tumor 
microenvironment require further investigation. Preliminary experiments with a PHD 
inhibitor which results in HIF stabilization did not show evidence of HIF involvement in 
the induction of MDSC proliferation in the tumor. However, HIF may exert pro- or anti-
proliferative effects depending on which isoform of its α subunit is stabilized. For 
instance HIF-1α stabilization leads to suppression of proliferation (310-312), but in 
synergism with STAT3 or NF-κB, it may also induce genes that activate cell cycle 
progression. In contrast, HIF-2α stabilization has pro-proliferative effects (313-315). 
Interestingly, HIF-2α is stabilized by higher oxygen tension compared to HIF-1α, which 
is relevant to the localization of MDSC clusters in the immediate vicinity of hypoxic 
regions, where the oxygen concentration gradient may favor HIF-2α stabilization. In 
addition, both HIF isoforms can also be activated via oxygen-independent mechanisms, 
such as ROS- and RNS-mediated events (167-175), and a hallmark of MDSC function is 
the production of these reactive species. Since the PHD inhibitor used in the preliminary 
experiments described here has the potential to stabilize both HIF-1α and HIF-2α, 
resulting in opposing signals regarding cell proliferation, further studies are required to 
determine whether HIF-1α or HIF-2α is involved in MDSC proliferation in the tumor 
microenvironment. 
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FIGURE LEGENDS 
Figure 26. Roles of L-selectin and hypoxia in MDSC migration to TDLN and tumor 
in the 4T1 breast cancer model.  
 During cancer progression, tumor-derived factors modulate myelopoiesis in the 
bone marrow (BM) resulting in abnormal expansion and accumulation of PMN-MDSC 
and M-MDSC (grey arrows). From the bloodstream, MDSC migrate to the TDLN (thin 
red arrows), where they suppress the activation of the anti-tumor T cell response. PMN-
MDSC migration to the TDLN is L-selectin-dependent, while M-MDSC migration to the 
TDLN does not require L-selectin. In addition, larger numbers of MDSC migrate to the 
tumor (bold red arrows), where they suppress the function of the anti-tumor T cell 
response. Similar to TDLN, PMN-MDSC migration to the tumor is L-selectin-dependent, 
while the involvement of L-selectin in M-MDSC migration to the tumor is unclear. As 
tumors outgrow existing vasculature, hypoxic areas arise characterized by low oxygen 
tension due to insufficient blood supply (blue area). In hypoxic conditions, the 
transcription factor HIF becomes stabilized and activates the expression of genes 
involved in adaptation to hypoxia, cell survival, and proliferation. Importantly, tumor-
infiltrating MDSC preferentially aggregate next to areas of hypoxia. It remains unclear 
whether HIF activates the expression of chemokines, which recruit MDSC to the hypoxic 
site or whether increased oxygen consumption within MDSC aggregates results in the 
generation of hypoxic areas around the aggregates. MDSC enter tumors in areas outside 
of the hypoxic sites and the pre-existing MDSC clusters, after which they migrate 
through the tumor parenchyma and associate with the pre-existing MDSC clusters. It 
remains unclear whether the MDSC within the aggregates secrete chemokines for the 
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recruitment of newly migrated MDSC resulting in expansion of the pre-existing 
aggregates over time. Approximately 20% of tumor-infiltrating MDSC undergo 
proliferation. It remains unclear whether HIF is stabilized in tumor-infiltrating MDSC 
and whether it induces proliferation of these cells. If in place, such a mechanism could 
have a significant contribution to the formation and expansion of MDSC aggregates 
within the tumor. 
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